<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/621E4323-5F3F-488B-A1ED-D31C5A134CD5"><gtr:id>621E4323-5F3F-488B-A1ED-D31C5A134CD5</gtr:id><gtr:name>Puridify</gtr:name><gtr:address><gtr:line1>Basement Flat
93 Camden Street</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>NW1 0HP</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7989ED9B-5D1A-4201-A8BD-AB943285E55A"><gtr:id>7989ED9B-5D1A-4201-A8BD-AB943285E55A</gtr:id><gtr:name>National Physical Laboratory NPL</gtr:name><gtr:address><gtr:line1>National Physical Laboratory</gtr:line1><gtr:line4>Teddington</gtr:line4><gtr:line5>Middlesex</gtr:line5><gtr:postCode>TW11 0LW</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1062CD11-8814-4521-AB20-D85FE05DC353"><gtr:id>1062CD11-8814-4521-AB20-D85FE05DC353</gtr:id><gtr:name>Tissue Growth Technologies</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/645ADF06-01C7-45C1-A485-7102A948B2E5"><gtr:id>645ADF06-01C7-45C1-A485-7102A948B2E5</gtr:id><gtr:name>Smith and Nephew</gtr:name><gtr:address><gtr:line1>York Science Park</gtr:line1><gtr:line2>Heslington</gtr:line2><gtr:line4>York</gtr:line4><gtr:postCode>YO10 5DF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/16819474-44DB-40A9-B322-5977D817BF38"><gtr:id>16819474-44DB-40A9-B322-5977D817BF38</gtr:id><gtr:name>Reneuron</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CF1C5739-6451-4BA1-A48D-FA86E790EA1F"><gtr:id>CF1C5739-6451-4BA1-A48D-FA86E790EA1F</gtr:id><gtr:name>JRI Orthapaedics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E3241676-C5F4-44EA-938D-E6C6EF8C4E50"><gtr:id>E3241676-C5F4-44EA-938D-E6C6EF8C4E50</gtr:id><gtr:name>Unilever R&amp;D Vlaardingen B.V.</gtr:name><gtr:address><gtr:line1>Unilever Research</gtr:line1><gtr:line2>Laboratory</gtr:line2><gtr:line3>Olivier Van Noortlaan 120</gtr:line3><gtr:postCode>NL-3133 AT</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C6722AFF-0817-4DD0-B788-E3A005D84B59"><gtr:id>C6722AFF-0817-4DD0-B788-E3A005D84B59</gtr:id><gtr:name>Anthony Nolan Cell Therapy Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E2385760-DE2E-4D45-A611-DEB951931E81"><gtr:id>E2385760-DE2E-4D45-A611-DEB951931E81</gtr:id><gtr:name>Scottish National Blood Transfusion Service (SNBTS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1EDD7780-33B4-4FC9-BAB6-2D66053C2D1C"><gtr:id>1EDD7780-33B4-4FC9-BAB6-2D66053C2D1C</gtr:id><gtr:name>PA Consulting</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4F1D2F3A-756D-4BC2-9E81-091D0356FECB"><gtr:id>4F1D2F3A-756D-4BC2-9E81-091D0356FECB</gtr:id><gtr:name>TAP Biosystems</gtr:name><gtr:address><gtr:line1>York Way</gtr:line1><gtr:line2>Royston</gtr:line2><gtr:line3>Herts</gtr:line3><gtr:postCode>SG8 5WY</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2F6370BC-EFBC-4526-B1E6-E9FFABC57615"><gtr:id>2F6370BC-EFBC-4526-B1E6-E9FFABC57615</gtr:id><gtr:name>WiCell Research Institute</gtr:name><gtr:address><gtr:line1>505 S. Rosa Rd, Suite 120</gtr:line1><gtr:postCode>53719</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/04BF2ED9-0B45-4C78-91AD-D931C4E2561D"><gtr:id>04BF2ED9-0B45-4C78-91AD-D931C4E2561D</gtr:id><gtr:name>SynbiCITE</gtr:name><gtr:address><gtr:line1>Bessemer Building</gtr:line1><gtr:line2>Imperial College London</gtr:line2><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90F25004-CB74-49D9-BBE8-0ECFBF1D009E"><gtr:id>90F25004-CB74-49D9-BBE8-0ECFBF1D009E</gtr:id><gtr:name>Department for Business, Energy &amp; Industrial Strategy</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BF6E9D7C-AF75-47D4-8EE8-CACFD251EB6C"><gtr:id>BF6E9D7C-AF75-47D4-8EE8-CACFD251EB6C</gtr:id><gtr:name>Waters Corporation / Micromass U K Ltd</gtr:name><gtr:address><gtr:line1>Floats Road</gtr:line1><gtr:line2>Wythenshawe</gtr:line2><gtr:line4>Manchester</gtr:line4><gtr:postCode>M23 9LZ</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7"><gtr:id>4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7</gtr:id><gtr:name>Dana-Farber Cancer Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/25B52D4D-8F62-4194-A826-C35FE2932B53"><gtr:id>25B52D4D-8F62-4194-A826-C35FE2932B53</gtr:id><gtr:name>Terumo BCT</gtr:name><gtr:address><gtr:line1>10811 West Collins Avenue</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6D7EF472-B5A3-4415-9A75-2A188F1805D9"><gtr:id>6D7EF472-B5A3-4415-9A75-2A188F1805D9</gtr:id><gtr:name>Synpromics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5891914B-7E13-456E-A4D8-BCF027E5EC56"><gtr:id>5891914B-7E13-456E-A4D8-BCF027E5EC56</gtr:id><gtr:name>Technology Strategy Board (TSB)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D499B952-83B1-4A9C-B565-56C2C8E5EA6A"><gtr:id>D499B952-83B1-4A9C-B565-56C2C8E5EA6A</gtr:id><gtr:name>Cool Logistics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/266A21DC-1B69-4C44-8284-C0F19275769B"><gtr:id>266A21DC-1B69-4C44-8284-C0F19275769B</gtr:id><gtr:name>Haemostatix</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BF9ACCD7-5AF4-49DE-9F89-3FB101F65D11"><gtr:id>BF9ACCD7-5AF4-49DE-9F89-3FB101F65D11</gtr:id><gtr:name>Intercytex</gtr:name><gtr:address><gtr:line1>Innovation House</gtr:line1><gtr:line2>Crewe Road</gtr:line2><gtr:postCode>M23 9QR</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/17C3EBC3-C791-4A07-B606-28B17862590B"><gtr:id>17C3EBC3-C791-4A07-B606-28B17862590B</gtr:id><gtr:name>Grimsby Institute of Further and Higher Education</gtr:name><gtr:address><gtr:line1>Nuns Corner</gtr:line1><gtr:city>Grimsby</gtr:city><gtr:postCode>DN34 5BQ</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5A8E328E-8A10-45F8-9C51-6BD66C215CC0"><gtr:id>5A8E328E-8A10-45F8-9C51-6BD66C215CC0</gtr:id><gtr:name>Nottingham University Hospital NHS Trust</gtr:name><gtr:address><gtr:line1>Nottingham University HospitalMedical Physics and clinical engineeringQMC Campus</gtr:line1><gtr:city>Nottingham</gtr:city><gtr:postCode>NG7 2UH</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2982B127-2288-4653-AD41-52579705E79C"><gtr:id>2982B127-2288-4653-AD41-52579705E79C</gtr:id><gtr:name>Synthace</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/252189B3-135F-4D99-BFB7-0799A34A409C"><gtr:id>252189B3-135F-4D99-BFB7-0799A34A409C</gtr:id><gtr:name>Loughborough University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1EE8CD7-CD19-45E5-BBD3-203DB6940C50"><gtr:id>A1EE8CD7-CD19-45E5-BBD3-203DB6940C50</gtr:id><gtr:name>Oswestry Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/216D191F-5CE8-47C1-91A9-2A5392E83A8A"><gtr:id>216D191F-5CE8-47C1-91A9-2A5392E83A8A</gtr:id><gtr:name>Ludwig Boltzmann Society</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A67238CB-2373-4605-B999-E1499B873021"><gtr:id>A67238CB-2373-4605-B999-E1499B873021</gtr:id><gtr:name>Athersys Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5DDCCDE6-59AD-4755-85D5-7A124AFAEF1D"><gtr:id>5DDCCDE6-59AD-4755-85D5-7A124AFAEF1D</gtr:id><gtr:name>Roslin Cells Ltd</gtr:name><gtr:address><gtr:line1>Roslin Biocentre</gtr:line1><gtr:postCode>EH25 9PP</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0518C2CF-1198-483C-9D01-D6ACE512823A"><gtr:id>0518C2CF-1198-483C-9D01-D6ACE512823A</gtr:id><gtr:name>nanoTherics Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0D6753B-F36B-42FC-AE69-F190D5500334"><gtr:id>A0D6753B-F36B-42FC-AE69-F190D5500334</gtr:id><gtr:name>Future Health Technologies</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CB90AF84-0C45-4AE3-A91A-5F9EDBE89398"><gtr:id>CB90AF84-0C45-4AE3-A91A-5F9EDBE89398</gtr:id><gtr:name>Cell Therapy Catapult</gtr:name><gtr:address><gtr:line1>12th Floor Tower Wing, Guys Hospital, 
Great Maze Pond,</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 9RT</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BB5D13FA-B0C2-46DD-B6BC-C7ACF4460406"><gtr:id>BB5D13FA-B0C2-46DD-B6BC-C7ACF4460406</gtr:id><gtr:name>British Mass Spectrometry Society</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7008F77D-D7F3-4558-AEE7-9195B7890A2D"><gtr:id>7008F77D-D7F3-4558-AEE7-9195B7890A2D</gtr:id><gtr:name>Moorfields Eye Hospital NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9D53091E-603E-4B64-B5EC-6430D28827FD"><gtr:id>9D53091E-603E-4B64-B5EC-6430D28827FD</gtr:id><gtr:name>Syngenta</gtr:name><gtr:address><gtr:line1>WRO-1004.1.51</gtr:line1><gtr:line2>Schwarzwaldallee 215</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0D187167-7469-4B9D-87CB-05FF35A2F5ED"><gtr:id>0D187167-7469-4B9D-87CB-05FF35A2F5ED</gtr:id><gtr:name>Fondazione Filarete</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/07A4DD96-333A-43AF-B267-C561D699DD89"><gtr:id>07A4DD96-333A-43AF-B267-C561D699DD89</gtr:id><gtr:name>Lucideon</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2CC7FDF4-8B09-4C9F-8291-B964EA78CF79"><gtr:id>2CC7FDF4-8B09-4C9F-8291-B964EA78CF79</gtr:id><gtr:name>Lonza Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8B397931-E408-4411-9815-5BECA5DCEFFA"><gtr:id>8B397931-E408-4411-9815-5BECA5DCEFFA</gtr:id><gtr:name>LGC Limited</gtr:name><gtr:address><gtr:line1>Queens Road</gtr:line1><gtr:postCode>TW11 0LY</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/88A06326-4F7D-42CA-A844-E480B443F052"><gtr:id>88A06326-4F7D-42CA-A844-E480B443F052</gtr:id><gtr:name>The Orthopaedic Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/01677AAD-3DF1-4035-9801-81583641AB1E"><gtr:id>01677AAD-3DF1-4035-9801-81583641AB1E</gtr:id><gtr:name>Bose</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A38855B8-20F0-4C36-8BD0-014FDCBE9DDB"><gtr:id>A38855B8-20F0-4C36-8BD0-014FDCBE9DDB</gtr:id><gtr:name>Knowledge Transfer Network</gtr:name><gtr:address><gtr:line1>FIRST FLOOR, ST. JAMES' HOUSE
ST. JAMES' SQUARE</gtr:line1><gtr:city>Cheltenham</gtr:city><gtr:postCode>GL50 3PR</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6A813AFF-50EC-4A1D-8E9A-7765A8E199D5"><gtr:id>6A813AFF-50EC-4A1D-8E9A-7765A8E199D5</gtr:id><gtr:name>SRG</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD21B8FC-26A6-4A3A-9A23-207B6667CB41"><gtr:id>DD21B8FC-26A6-4A3A-9A23-207B6667CB41</gtr:id><gtr:name>University of Pittsburgh</gtr:name><gtr:address><gtr:line1>University of Pittsburgh</gtr:line1><gtr:line4>Pittsburgh</gtr:line4><gtr:line5>Pennsylvania</gtr:line5><gtr:postCode>PA 15260</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83420A4C-4809-40D9-BDB0-48EF6EA1089E"><gtr:id>83420A4C-4809-40D9-BDB0-48EF6EA1089E</gtr:id><gtr:name>Ruskinn Technology Ltd</gtr:name><gtr:address><gtr:line1>Sony Technology Centre</gtr:line1><gtr:line2>Pencoed</gtr:line2><gtr:postCode>CF35 5HZ</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AABC93A2-D58A-43E8-BF82-BF126EA1BD93"><gtr:id>AABC93A2-D58A-43E8-BF82-BF126EA1BD93</gtr:id><gtr:name>MIca Biosystems</gtr:name><gtr:address><gtr:line1>23 Arley Road</gtr:line1><gtr:city>Solihull</gtr:city><gtr:postCode>B91 1NJ</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B7A730C8-5B91-4DCE-B71A-1E59E3D94C1A"><gtr:id>B7A730C8-5B91-4DCE-B71A-1E59E3D94C1A</gtr:id><gtr:name>MCR Media Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EA19B049-C415-4846-B97E-7079D67E9973"><gtr:id>EA19B049-C415-4846-B97E-7079D67E9973</gtr:id><gtr:name>Regentec</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AC164095-49BC-4450-8225-CC32DB237D60"><gtr:id>AC164095-49BC-4450-8225-CC32DB237D60</gtr:id><gtr:name>Asymptote</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D50BF543-96B5-424B-AD6B-810107B13112"><gtr:id>D50BF543-96B5-424B-AD6B-810107B13112</gtr:id><gtr:name>World Courier</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/CAA9A40D-0226-4A4F-AC0D-D8299E30A1EF"><gtr:id>CAA9A40D-0226-4A4F-AC0D-D8299E30A1EF</gtr:id><gtr:name>Loughborough University</gtr:name><gtr:department>Sch of Mechanical and Manufacturing Eng</gtr:department><gtr:address><gtr:line1>Loughborough University</gtr:line1><gtr:line4>Loughborough</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE11 3TU</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CAA9A40D-0226-4A4F-AC0D-D8299E30A1EF"><gtr:id>CAA9A40D-0226-4A4F-AC0D-D8299E30A1EF</gtr:id><gtr:name>Loughborough University</gtr:name><gtr:address><gtr:line1>Loughborough University</gtr:line1><gtr:line4>Loughborough</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE11 3TU</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/621E4323-5F3F-488B-A1ED-D31C5A134CD5"><gtr:id>621E4323-5F3F-488B-A1ED-D31C5A134CD5</gtr:id><gtr:name>Puridify</gtr:name><gtr:address><gtr:line1>Basement Flat
93 Camden Street</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>NW1 0HP</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7989ED9B-5D1A-4201-A8BD-AB943285E55A"><gtr:id>7989ED9B-5D1A-4201-A8BD-AB943285E55A</gtr:id><gtr:name>National Physical Laboratory NPL</gtr:name><gtr:address><gtr:line1>National Physical Laboratory</gtr:line1><gtr:line4>Teddington</gtr:line4><gtr:line5>Middlesex</gtr:line5><gtr:postCode>TW11 0LW</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1062CD11-8814-4521-AB20-D85FE05DC353"><gtr:id>1062CD11-8814-4521-AB20-D85FE05DC353</gtr:id><gtr:name>Tissue Growth Technologies</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/645ADF06-01C7-45C1-A485-7102A948B2E5"><gtr:id>645ADF06-01C7-45C1-A485-7102A948B2E5</gtr:id><gtr:name>Smith and Nephew</gtr:name><gtr:address><gtr:line1>York Science Park</gtr:line1><gtr:line2>Heslington</gtr:line2><gtr:line4>York</gtr:line4><gtr:postCode>YO10 5DF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/16819474-44DB-40A9-B322-5977D817BF38"><gtr:id>16819474-44DB-40A9-B322-5977D817BF38</gtr:id><gtr:name>Reneuron</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CF1C5739-6451-4BA1-A48D-FA86E790EA1F"><gtr:id>CF1C5739-6451-4BA1-A48D-FA86E790EA1F</gtr:id><gtr:name>JRI Orthapaedics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E3241676-C5F4-44EA-938D-E6C6EF8C4E50"><gtr:id>E3241676-C5F4-44EA-938D-E6C6EF8C4E50</gtr:id><gtr:name>Unilever R&amp;D Vlaardingen B.V.</gtr:name><gtr:address><gtr:line1>Unilever Research</gtr:line1><gtr:line2>Laboratory</gtr:line2><gtr:line3>Olivier Van Noortlaan 120</gtr:line3><gtr:postCode>NL-3133 AT</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C6722AFF-0817-4DD0-B788-E3A005D84B59"><gtr:id>C6722AFF-0817-4DD0-B788-E3A005D84B59</gtr:id><gtr:name>Anthony Nolan Cell Therapy Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E2385760-DE2E-4D45-A611-DEB951931E81"><gtr:id>E2385760-DE2E-4D45-A611-DEB951931E81</gtr:id><gtr:name>Scottish National Blood Transfusion Service (SNBTS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1EDD7780-33B4-4FC9-BAB6-2D66053C2D1C"><gtr:id>1EDD7780-33B4-4FC9-BAB6-2D66053C2D1C</gtr:id><gtr:name>PA Consulting</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4F1D2F3A-756D-4BC2-9E81-091D0356FECB"><gtr:id>4F1D2F3A-756D-4BC2-9E81-091D0356FECB</gtr:id><gtr:name>TAP Biosystems</gtr:name><gtr:address><gtr:line1>York Way</gtr:line1><gtr:line2>Royston</gtr:line2><gtr:line3>Herts</gtr:line3><gtr:postCode>SG8 5WY</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2F6370BC-EFBC-4526-B1E6-E9FFABC57615"><gtr:id>2F6370BC-EFBC-4526-B1E6-E9FFABC57615</gtr:id><gtr:name>WiCell Research Institute</gtr:name><gtr:address><gtr:line1>505 S. Rosa Rd, Suite 120</gtr:line1><gtr:postCode>53719</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/04BF2ED9-0B45-4C78-91AD-D931C4E2561D"><gtr:id>04BF2ED9-0B45-4C78-91AD-D931C4E2561D</gtr:id><gtr:name>SynbiCITE</gtr:name><gtr:address><gtr:line1>Bessemer Building</gtr:line1><gtr:line2>Imperial College London</gtr:line2><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90F25004-CB74-49D9-BBE8-0ECFBF1D009E"><gtr:id>90F25004-CB74-49D9-BBE8-0ECFBF1D009E</gtr:id><gtr:name>Department for Business, Energy &amp; Industrial Strategy</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BF6E9D7C-AF75-47D4-8EE8-CACFD251EB6C"><gtr:id>BF6E9D7C-AF75-47D4-8EE8-CACFD251EB6C</gtr:id><gtr:name>Waters Corporation / Micromass U K Ltd</gtr:name><gtr:address><gtr:line1>Floats Road</gtr:line1><gtr:line2>Wythenshawe</gtr:line2><gtr:line4>Manchester</gtr:line4><gtr:postCode>M23 9LZ</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7"><gtr:id>4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7</gtr:id><gtr:name>Dana-Farber Cancer Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/25B52D4D-8F62-4194-A826-C35FE2932B53"><gtr:id>25B52D4D-8F62-4194-A826-C35FE2932B53</gtr:id><gtr:name>Terumo BCT</gtr:name><gtr:address><gtr:line1>10811 West Collins Avenue</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6D7EF472-B5A3-4415-9A75-2A188F1805D9"><gtr:id>6D7EF472-B5A3-4415-9A75-2A188F1805D9</gtr:id><gtr:name>Synpromics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5891914B-7E13-456E-A4D8-BCF027E5EC56"><gtr:id>5891914B-7E13-456E-A4D8-BCF027E5EC56</gtr:id><gtr:name>Technology Strategy Board (TSB)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D499B952-83B1-4A9C-B565-56C2C8E5EA6A"><gtr:id>D499B952-83B1-4A9C-B565-56C2C8E5EA6A</gtr:id><gtr:name>Cool Logistics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/266A21DC-1B69-4C44-8284-C0F19275769B"><gtr:id>266A21DC-1B69-4C44-8284-C0F19275769B</gtr:id><gtr:name>Haemostatix</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BF9ACCD7-5AF4-49DE-9F89-3FB101F65D11"><gtr:id>BF9ACCD7-5AF4-49DE-9F89-3FB101F65D11</gtr:id><gtr:name>Intercytex</gtr:name><gtr:address><gtr:line1>Innovation House</gtr:line1><gtr:line2>Crewe Road</gtr:line2><gtr:postCode>M23 9QR</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/17C3EBC3-C791-4A07-B606-28B17862590B"><gtr:id>17C3EBC3-C791-4A07-B606-28B17862590B</gtr:id><gtr:name>Grimsby Institute of Further and Higher Education</gtr:name><gtr:address><gtr:line1>Nuns Corner</gtr:line1><gtr:city>Grimsby</gtr:city><gtr:postCode>DN34 5BQ</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5A8E328E-8A10-45F8-9C51-6BD66C215CC0"><gtr:id>5A8E328E-8A10-45F8-9C51-6BD66C215CC0</gtr:id><gtr:name>Nottingham University Hospital NHS Trust</gtr:name><gtr:address><gtr:line1>Nottingham University HospitalMedical Physics and clinical engineeringQMC Campus</gtr:line1><gtr:city>Nottingham</gtr:city><gtr:postCode>NG7 2UH</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2982B127-2288-4653-AD41-52579705E79C"><gtr:id>2982B127-2288-4653-AD41-52579705E79C</gtr:id><gtr:name>Synthace</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/252189B3-135F-4D99-BFB7-0799A34A409C"><gtr:id>252189B3-135F-4D99-BFB7-0799A34A409C</gtr:id><gtr:name>Loughborough University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1EE8CD7-CD19-45E5-BBD3-203DB6940C50"><gtr:id>A1EE8CD7-CD19-45E5-BBD3-203DB6940C50</gtr:id><gtr:name>Oswestry Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/216D191F-5CE8-47C1-91A9-2A5392E83A8A"><gtr:id>216D191F-5CE8-47C1-91A9-2A5392E83A8A</gtr:id><gtr:name>Ludwig Boltzmann Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A67238CB-2373-4605-B999-E1499B873021"><gtr:id>A67238CB-2373-4605-B999-E1499B873021</gtr:id><gtr:name>Athersys Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5DDCCDE6-59AD-4755-85D5-7A124AFAEF1D"><gtr:id>5DDCCDE6-59AD-4755-85D5-7A124AFAEF1D</gtr:id><gtr:name>Roslin Cells Ltd</gtr:name><gtr:address><gtr:line1>Roslin Biocentre</gtr:line1><gtr:postCode>EH25 9PP</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0518C2CF-1198-483C-9D01-D6ACE512823A"><gtr:id>0518C2CF-1198-483C-9D01-D6ACE512823A</gtr:id><gtr:name>nanoTherics Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0D6753B-F36B-42FC-AE69-F190D5500334"><gtr:id>A0D6753B-F36B-42FC-AE69-F190D5500334</gtr:id><gtr:name>Future Health Technologies</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CB90AF84-0C45-4AE3-A91A-5F9EDBE89398"><gtr:id>CB90AF84-0C45-4AE3-A91A-5F9EDBE89398</gtr:id><gtr:name>Cell Therapy Catapult</gtr:name><gtr:address><gtr:line1>12th Floor Tower Wing, Guys Hospital, 
Great Maze Pond,</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 9RT</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BB5D13FA-B0C2-46DD-B6BC-C7ACF4460406"><gtr:id>BB5D13FA-B0C2-46DD-B6BC-C7ACF4460406</gtr:id><gtr:name>British Mass Spectrometry Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7008F77D-D7F3-4558-AEE7-9195B7890A2D"><gtr:id>7008F77D-D7F3-4558-AEE7-9195B7890A2D</gtr:id><gtr:name>Moorfields Eye Hospital NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9D53091E-603E-4B64-B5EC-6430D28827FD"><gtr:id>9D53091E-603E-4B64-B5EC-6430D28827FD</gtr:id><gtr:name>Syngenta</gtr:name><gtr:address><gtr:line1>WRO-1004.1.51</gtr:line1><gtr:line2>Schwarzwaldallee 215</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0D187167-7469-4B9D-87CB-05FF35A2F5ED"><gtr:id>0D187167-7469-4B9D-87CB-05FF35A2F5ED</gtr:id><gtr:name>Fondazione Filarete</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/07A4DD96-333A-43AF-B267-C561D699DD89"><gtr:id>07A4DD96-333A-43AF-B267-C561D699DD89</gtr:id><gtr:name>Lucideon</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2CC7FDF4-8B09-4C9F-8291-B964EA78CF79"><gtr:id>2CC7FDF4-8B09-4C9F-8291-B964EA78CF79</gtr:id><gtr:name>Lonza Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8B397931-E408-4411-9815-5BECA5DCEFFA"><gtr:id>8B397931-E408-4411-9815-5BECA5DCEFFA</gtr:id><gtr:name>LGC Limited</gtr:name><gtr:address><gtr:line1>Queens Road</gtr:line1><gtr:postCode>TW11 0LY</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/88A06326-4F7D-42CA-A844-E480B443F052"><gtr:id>88A06326-4F7D-42CA-A844-E480B443F052</gtr:id><gtr:name>The Orthopaedic Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/01677AAD-3DF1-4035-9801-81583641AB1E"><gtr:id>01677AAD-3DF1-4035-9801-81583641AB1E</gtr:id><gtr:name>Bose</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A38855B8-20F0-4C36-8BD0-014FDCBE9DDB"><gtr:id>A38855B8-20F0-4C36-8BD0-014FDCBE9DDB</gtr:id><gtr:name>Knowledge Transfer Network</gtr:name><gtr:address><gtr:line1>FIRST FLOOR, ST. JAMES' HOUSE
ST. JAMES' SQUARE</gtr:line1><gtr:city>Cheltenham</gtr:city><gtr:postCode>GL50 3PR</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6A813AFF-50EC-4A1D-8E9A-7765A8E199D5"><gtr:id>6A813AFF-50EC-4A1D-8E9A-7765A8E199D5</gtr:id><gtr:name>SRG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD21B8FC-26A6-4A3A-9A23-207B6667CB41"><gtr:id>DD21B8FC-26A6-4A3A-9A23-207B6667CB41</gtr:id><gtr:name>University of Pittsburgh</gtr:name><gtr:address><gtr:line1>University of Pittsburgh</gtr:line1><gtr:line4>Pittsburgh</gtr:line4><gtr:line5>Pennsylvania</gtr:line5><gtr:postCode>PA 15260</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83420A4C-4809-40D9-BDB0-48EF6EA1089E"><gtr:id>83420A4C-4809-40D9-BDB0-48EF6EA1089E</gtr:id><gtr:name>Ruskinn Technology Ltd</gtr:name><gtr:address><gtr:line1>Sony Technology Centre</gtr:line1><gtr:line2>Pencoed</gtr:line2><gtr:postCode>CF35 5HZ</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AABC93A2-D58A-43E8-BF82-BF126EA1BD93"><gtr:id>AABC93A2-D58A-43E8-BF82-BF126EA1BD93</gtr:id><gtr:name>MIca Biosystems</gtr:name><gtr:address><gtr:line1>23 Arley Road</gtr:line1><gtr:city>Solihull</gtr:city><gtr:postCode>B91 1NJ</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B7A730C8-5B91-4DCE-B71A-1E59E3D94C1A"><gtr:id>B7A730C8-5B91-4DCE-B71A-1E59E3D94C1A</gtr:id><gtr:name>MCR Media Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EA19B049-C415-4846-B97E-7079D67E9973"><gtr:id>EA19B049-C415-4846-B97E-7079D67E9973</gtr:id><gtr:name>Regentec</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AC164095-49BC-4450-8225-CC32DB237D60"><gtr:id>AC164095-49BC-4450-8225-CC32DB237D60</gtr:id><gtr:name>Asymptote</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D50BF543-96B5-424B-AD6B-810107B13112"><gtr:id>D50BF543-96B5-424B-AD6B-810107B13112</gtr:id><gtr:name>World Courier</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/022F39AC-7EAF-4736-9045-0EDFF9F24B96"><gtr:id>022F39AC-7EAF-4736-9045-0EDFF9F24B96</gtr:id><gtr:name>East Midlands Strategic Health Authority</gtr:name><gtr:address><gtr:line1>Octavia House</gtr:line1><gtr:line2>Interchange Business Park</gtr:line2><gtr:line3>Bostock's Lane</gtr:line3><gtr:postCode>NG10 5QG</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A3118865-52B5-4587-B957-3E0BB585A3FD"><gtr:id>A3118865-52B5-4587-B957-3E0BB585A3FD</gtr:id><gtr:name>MHRA Medicines &amp; Health Care Products Re</gtr:name><gtr:address><gtr:line1>Department of Health - Whitehall</gtr:line1><gtr:line2>10-2 Market Towers</gtr:line2><gtr:line3>1 Nine Elms Road</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SW8 5NQ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0B34FB68-7594-485B-AF0F-C951AB6783F7"><gtr:id>0B34FB68-7594-485B-AF0F-C951AB6783F7</gtr:id><gtr:name>Inst for Surface and Boundary Layers</gtr:name><gtr:address><gtr:line1>Fraunhofer IGB</gtr:line1><gtr:line4>Nobelstrasse 12</gtr:line4><gtr:line5>Stuttgart</gtr:line5><gtr:postCode>70569</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/32AE43DA-808D-4DF2-9894-0542D85633FB"><gtr:id>32AE43DA-808D-4DF2-9894-0542D85633FB</gtr:id><gtr:name>Future Health</gtr:name><gtr:address><gtr:line1>10 Faraday Building</gtr:line1><gtr:line2>Nottingham Science &amp; Technology Park</gtr:line2><gtr:line3>University Boulevard</gtr:line3><gtr:postCode>NG7 2QP</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7D8EF432-9AFE-48D2-8D3C-596694B37A38"><gtr:id>7D8EF432-9AFE-48D2-8D3C-596694B37A38</gtr:id><gtr:name>Assoc of British Healthcare Industries</gtr:name><gtr:address><gtr:line1>Industries</gtr:line1><gtr:line2>111 Westminster Bridge Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:line5>London</gtr:line5><gtr:postCode>SE1 7HR</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/45555183-99CB-4B93-BB81-CE9DDF06CF7E"><gtr:id>45555183-99CB-4B93-BB81-CE9DDF06CF7E</gtr:id><gtr:name>Lonza Biologics</gtr:name><gtr:address><gtr:line1>228 Bath Road</gtr:line1><gtr:line4>Slough</gtr:line4><gtr:postCode>SL1 4DX</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FBF03A84-9391-46C1-9938-267050D599CD"><gtr:id>FBF03A84-9391-46C1-9938-267050D599CD</gtr:id><gtr:name>Medilink East Midlands</gtr:name><gtr:address><gtr:line1>BioCity</gtr:line1><gtr:line2>Pennyfoot Street</gtr:line2><gtr:line4>Nottingham</gtr:line4><gtr:postCode>NG1 1GF</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6B4B86BB-DE72-4810-B555-FDBD214DEE64"><gtr:id>6B4B86BB-DE72-4810-B555-FDBD214DEE64</gtr:id><gtr:name>Cell Medica</gtr:name><gtr:address><gtr:line1>27 Fitzroy Square</gtr:line1><gtr:postCode>W1T 6ES</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5A5739A5-B58F-47C1-B425-94267E91DEE1"><gtr:id>5A5739A5-B58F-47C1-B425-94267E91DEE1</gtr:id><gtr:name>Technology Strategy Board</gtr:name><gtr:address><gtr:line1>Block B, Floor 1</gtr:line1><gtr:line2>North Star House</gtr:line2><gtr:line3>North Star Avenue</gtr:line3><gtr:line4>Swindon</gtr:line4><gtr:postCode>SN2 1JF</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/201D4225-A466-48C9-B550-55B945185992"><gtr:id>201D4225-A466-48C9-B550-55B945185992</gtr:id><gtr:name>RepRegen Ltd</gtr:name><gtr:address><gtr:line1>BioIncubator Unit</gtr:line1><gtr:line2>Bessemer Building RSM Level 1</gtr:line2><gtr:line3>Prince Consort Road</gtr:line3><gtr:line5>London</gtr:line5><gtr:postCode>SW7 2BP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2603A6AC-B0EF-4C9D-AA7E-7DD79312ACFA"><gtr:id>2603A6AC-B0EF-4C9D-AA7E-7DD79312ACFA</gtr:id><gtr:name>Critical Pharmaceuticals</gtr:name><gtr:address><gtr:line1>BioCity Nottingham</gtr:line1><gtr:line2>Pennyfoot Street</gtr:line2><gtr:line4>Nottingham</gtr:line4><gtr:postCode>NG1 1GF</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/941C2E74-C576-49DA-9987-CE40EF8A611D"><gtr:id>941C2E74-C576-49DA-9987-CE40EF8A611D</gtr:id><gtr:name>Pfizer</gtr:name><gtr:address><gtr:line1>235 East 42nd Street</gtr:line1><gtr:postCode>10017</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF46D1B5-9EE9-459F-8D6D-68C3987370BD"><gtr:id>EF46D1B5-9EE9-459F-8D6D-68C3987370BD</gtr:id><gtr:name>University Hospitals of Leicester NHS</gtr:name><gtr:address><gtr:line1>Leicester Royal Infirmary</gtr:line1><gtr:line2>Infirmary Square</gtr:line2><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 5WW</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D31C478D-680E-46CA-8A7F-8CD1698914FE"><gtr:id>D31C478D-680E-46CA-8A7F-8CD1698914FE</gtr:id><gtr:name>BioIndustry Association</gtr:name><gtr:address><gtr:line1>7th Floor Southside</gtr:line1><gtr:line2>105 Victoria Street</gtr:line2><gtr:postCode>SW1E 6QT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68641F7E-FA4B-4EF7-96AB-06D9B3F8CB35"><gtr:id>68641F7E-FA4B-4EF7-96AB-06D9B3F8CB35</gtr:id><gtr:name>Regentec Limited</gtr:name><gtr:address><gtr:line1>BioCity Nottingham</gtr:line1><gtr:line2>Pennyfoot Street</gtr:line2><gtr:line4>Nottingham</gtr:line4><gtr:postCode>NG1 1GF</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FBB5D5EE-22A6-43CF-B4B6-685D339A78F4"><gtr:id>FBB5D5EE-22A6-43CF-B4B6-685D339A78F4</gtr:id><gtr:name>TiGenix Ltd</gtr:name><gtr:address><gtr:line1>Byron House</gtr:line1><gtr:line2>Cambridge Business Park</gtr:line2><gtr:line3>Milton Road</gtr:line3><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB4 0WZ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/603B325C-6543-4592-9C93-E00F88F3FD37"><gtr:id>603B325C-6543-4592-9C93-E00F88F3FD37</gtr:id><gtr:name>Smith and Nephew Healthcare Ltd</gtr:name><gtr:address><gtr:line1>Healthcare House</gtr:line1><gtr:line2>Goulton Street</gtr:line2><gtr:line4>Hull</gtr:line4><gtr:postCode>HU3 4DJ</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6CA15047-34B5-45CA-97AD-D971C6DE3841"><gtr:id>6CA15047-34B5-45CA-97AD-D971C6DE3841</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:address><gtr:line1>Ramsgate Road</gtr:line1><gtr:line4>Sandwich</gtr:line4><gtr:line5>Kent</gtr:line5><gtr:postCode>CT13 9NJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4C459D00-5878-4FD8-AAD8-3A0C129CB9D1"><gtr:id>4C459D00-5878-4FD8-AAD8-3A0C129CB9D1</gtr:id><gtr:name>EpiStem Ltd</gtr:name><gtr:address><gtr:line1>EpiStem Ltd</gtr:line1><gtr:line2>Grafton Street</gtr:line2><gtr:line4>Manchester</gtr:line4><gtr:postCode>M13 9XX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EDB67137-AF95-475C-954C-8EA1517069D6"><gtr:id>EDB67137-AF95-475C-954C-8EA1517069D6</gtr:id><gtr:name>Nat Inst for Bio Standards and Control</gtr:name><gtr:address><gtr:line1>Blanche Lane</gtr:line1><gtr:line2>South Mimms</gtr:line2><gtr:line4>Potters Bar</gtr:line4><gtr:line5>Hertfordshire</gtr:line5><gtr:postCode>EN6 3QG</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EA6140A4-02E6-4F2F-BEA0-B0AEA445F086"><gtr:id>EA6140A4-02E6-4F2F-BEA0-B0AEA445F086</gtr:id><gtr:name>Smith and Nephew UK Limited</gtr:name><gtr:address><gtr:line1>York Science Park</gtr:line1><gtr:line2>Heslington</gtr:line2><gtr:postCode>YO10 5DF</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/592A8843-A09A-4EB9-B524-466F79424AB4"><gtr:id>592A8843-A09A-4EB9-B524-466F79424AB4</gtr:id><gtr:name>Unilever UK</gtr:name><gtr:address><gtr:line1>100 Victoria</gtr:line1><gtr:line2>Embankment</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>EC4Y 0DY</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D24E60EE-4C36-4709-BD06-8A0F979DF2E8"><gtr:id>D24E60EE-4C36-4709-BD06-8A0F979DF2E8</gtr:id><gtr:name>Sigma-Aldrich</gtr:name><gtr:address><gtr:line1>3050 Spruce Street</gtr:line1><gtr:postCode>MO 63103</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8FE574A0-96F9-4BFD-9BD8-262BDDFCA9FD"><gtr:id>8FE574A0-96F9-4BFD-9BD8-262BDDFCA9FD</gtr:id><gtr:name>East Midlands Development Agency</gtr:name><gtr:address><gtr:line1>Apex Court</gtr:line1><gtr:line2>City Link</gtr:line2><gtr:line3>City Link</gtr:line3><gtr:line4>Nottingham</gtr:line4><gtr:postCode>NG2 4LA</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8C250FB6-4890-4BF9-9C23-69E6B2E02B95"><gtr:id>8C250FB6-4890-4BF9-9C23-69E6B2E02B95</gtr:id><gtr:name>Wake Forest University</gtr:name><gtr:address><gtr:line1>Wake Forest University</gtr:line1><gtr:line2>1834 Wakeforest Road</gtr:line2><gtr:line4>Winston Salem</gtr:line4><gtr:line5>North Carolina</gtr:line5><gtr:postCode>NC 27106</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DBBA9886-237D-492B-8B64-277AAFE19253"><gtr:id>DBBA9886-237D-492B-8B64-277AAFE19253</gtr:id><gtr:name>NHS Innovations East Midlands</gtr:name><gtr:address><gtr:line1>BioCity Nottingham</gtr:line1><gtr:line2>Pennyfoot Street</gtr:line2><gtr:line4>Nottingham</gtr:line4><gtr:postCode>NG1 1GF</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CED6BE02-600E-416A-9E8F-40AA3A4CE8A0"><gtr:id>CED6BE02-600E-416A-9E8F-40AA3A4CE8A0</gtr:id><gtr:name>McGowan Inst for Regenerative Medicine</gtr:name><gtr:address><gtr:line1>Suite 200</gtr:line1><gtr:line2>100 Technology Drive</gtr:line2><gtr:postCode>PA 15219-3</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7472C1F8-8A21-44A3-82AA-1DA22BA229EC"><gtr:id>7472C1F8-8A21-44A3-82AA-1DA22BA229EC</gtr:id><gtr:name>MedCell</gtr:name><gtr:address><gtr:line1>Minerva Building</gtr:line1><gtr:line2>Babraham Research Campus</gtr:line2><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/133C931D-94DE-45BC-A1C7-69724588BDF5"><gtr:id>133C931D-94DE-45BC-A1C7-69724588BDF5</gtr:id><gtr:name>NHS Technology Adoption Centre</gtr:name><gtr:address><gtr:line1>1st Floor Postgraduate Centre Annexe</gtr:line1><gtr:line2>Manchester Royal Infirmary</gtr:line2><gtr:line3>Oxford Road</gtr:line3><gtr:postCode>M13 9WL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/54441B70-BD32-42E0-B30B-E4516D8A34A3"><gtr:id>54441B70-BD32-42E0-B30B-E4516D8A34A3</gtr:id><gtr:name>British Standards Institution BSI</gtr:name><gtr:address><gtr:line1>389 Chiswick High Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>W4 4AL</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/01187BF8-3312-4A57-BFD2-3A7B8B0725D2"><gtr:id>01187BF8-3312-4A57-BFD2-3A7B8B0725D2</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Somekh</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DCF408FC-18BC-484A-A60C-35003BF9ED81"><gtr:id>DCF408FC-18BC-484A-A60C-35003BF9ED81</gtr:id><gtr:firstName>Yang</gtr:firstName><gtr:surname>Liu</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0161962B-BB09-4E8C-A7E9-570FF7C26938"><gtr:id>0161962B-BB09-4E8C-A7E9-570FF7C26938</gtr:id><gtr:firstName>Jon</gtr:firstName><gtr:surname>Petzing</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A4FAC096-B2E9-405E-B459-FECEBC4CF72B"><gtr:id>A4FAC096-B2E9-405E-B459-FECEBC4CF72B</gtr:id><gtr:firstName>Melissa</gtr:firstName><gtr:surname>Mather</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/225572B3-F87E-4461-B5CB-96F94E53BF6C"><gtr:id>225572B3-F87E-4461-B5CB-96F94E53BF6C</gtr:id><gtr:firstName>Joel</gtr:firstName><gtr:otherNames>Israel</gtr:otherNames><gtr:surname>Segal</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4A2DC047-DB99-4BE7-BE2B-4BD478404BB6"><gtr:id>4A2DC047-DB99-4BE7-BE2B-4BD478404BB6</gtr:id><gtr:firstName>Alicia</gtr:firstName><gtr:surname>El Haj</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DA78ACB5-9A2A-4125-B571-650E8671C3D4"><gtr:id>DA78ACB5-9A2A-4125-B571-650E8671C3D4</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Thomas</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/741648AA-70D5-4DEE-B5A9-864BEDC9878E"><gtr:id>741648AA-70D5-4DEE-B5A9-864BEDC9878E</gtr:id><gtr:firstName>Cameron</gtr:firstName><gtr:surname>Alexander</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/20FEE189-39EF-41CE-9DEB-F845DA0D456C"><gtr:id>20FEE189-39EF-41CE-9DEB-F845DA0D456C</gtr:id><gtr:firstName>Felicity</gtr:firstName><gtr:otherNames>Rosamari</gtr:otherNames><gtr:surname>Rose</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0D887594-55DF-4700-A17C-508595F5727C"><gtr:id>0D887594-55DF-4700-A17C-508595F5727C</gtr:id><gtr:firstName>David John</gtr:firstName><gtr:surname>Williams</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6D93C4B4-6A1A-4858-8A69-03438AAFF1FC"><gtr:id>6D93C4B4-6A1A-4858-8A69-03438AAFF1FC</gtr:id><gtr:firstName>Chris</gtr:firstName><gtr:surname>Denning</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6390AF4F-E65D-46AF-83DB-A6E00A8FFCE0"><gtr:id>6390AF4F-E65D-46AF-83DB-A6E00A8FFCE0</gtr:id><gtr:firstName>Chris</gtr:firstName><gtr:surname>Hewitt</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C8781D80-900D-4EB0-BC88-B885D37E824A"><gtr:id>C8781D80-900D-4EB0-BC88-B885D37E824A</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>Bruce</gtr:otherNames><gtr:surname>Richardson</gtr:surname><gtr:orcidId>0000-0002-7233-3950</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B746E2BB-517C-444F-9F52-7080DCE5F05E"><gtr:id>B746E2BB-517C-444F-9F52-7080DCE5F05E</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Crowe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A1F59322-EEB9-4309-BC9F-67B3582D1A98"><gtr:id>A1F59322-EEB9-4309-BC9F-67B3582D1A98</gtr:id><gtr:firstName>Svetan</gtr:firstName><gtr:otherNames>Marinov</gtr:otherNames><gtr:surname>Ratchev</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C298C70E-4993-4580-8C65-5829182DD005"><gtr:id>C298C70E-4993-4580-8C65-5829182DD005</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:surname>Medcalf</gtr:surname><gtr:orcidId>0000-0001-8173-1961</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4A9AA458-F9A0-43EC-9726-86676F718F98"><gtr:id>4A9AA458-F9A0-43EC-9726-86676F718F98</gtr:id><gtr:firstName>Kevin</gtr:firstName><gtr:surname>Shakesheff</gtr:surname><gtr:orcidId>0000-0003-3236-2439</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5FEE6BEA-296C-4419-BCA6-CE2EF4B5A46B"><gtr:id>5FEE6BEA-296C-4419-BCA6-CE2EF4B5A46B</gtr:id><gtr:firstName>William Eustace Basil</gtr:firstName><gtr:surname>Johnson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FH028277%2F1"><gtr:id>E24B07A4-548A-4DE1-8463-9EFB026AC540</gtr:id><gtr:title>EPSRC Centre for Innovative Manufacturing in Regenerative Medicine</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/H028277/1</gtr:grantReference><gtr:abstractText>Regenerative medicine (RM) is a convergence of conventional pharmaceutical sciences, medical devices and surgical intervention employing novel cell and biomaterial based therapies. RM products replace or regenerate damaged or defective tissues such as skin, bone, and even more complex organs, to restore or establish normal function. They can also be used to improve drug testing and disease modelling. RM is an emerging industry with a unique opportunity to contribute to the health and wealth of the UK. It is a high value science-based manufacturing industry whose products will reduce the economic and social impact of an aging population and increasing chronic disease.The clinical and product opportunities for RM have become clear and a broad portfolio of products have now entered the translational pipeline from the science bench to commercialisation and clinical application. The primary current focus for firms introducing these products is first in man studies; however, success at this stage is followed by a requirement for a rapid expansion of delivery capability - the 'one-to-many' translation process. This demands increasing attention to regulatory pathways, product reimbursement and refinement of the business model, a point emphasised by recent regulatory decisions demanding more clarity in the criteria that define product performance, and regulator initiatives to improve control of manufacturing quality. The IMRC will reduce the attrition of businesses at this critical point in product development through an industry facing portfolio of business driven research activities focussed on these translational challenges. The IMRC will consist of a platform activity and two related research themes. The platform activity will incorporate studies designed to influence public policy, regulation and the value system; to explore highly speculative and high value ideas (particularly clinically driven studies); and manufacturing-led feasibility and pilot studies using state of the art production platforms and control. The research themes will focus on areas identified as particular bottlenecks in RM product translation. The first theme will explore the delivery, manufacturing and supply processes i.e. the end to end production of an RM product. Specifically this theme will explore using novel pharmaceutical technology to control the packaged environment of a living RM product during shipping, and the design of a modular solution for manufacturing different cell based therapies to the required quality in a clinical setting. The second research theme will apply quality by design methods to characterise the quality of highly complex RM products incorporating cells and carrier materials. In particular it will consider optical methods for non-invasive process and product quality control and physicochemical methods for process monitoring.The IMRC will be proactively managed under the direction of a Board and Liaison Group consisting of leading industrialists to ensure that the Centre delivers maximum value to the requirements of the business model and assisting the growth of this emerging industry.</gtr:abstractText><gtr:potentialImpactText>The impact of the research will be in three key areas: improved public health, improved business and national economic performance, and better informed public policy. Public health will be improved through the IMRC's facilitation of new therapies for unmet clinical needs. The focus of RM on chronic diseases and aging related conditions mean that these innovations will affect the population with highest levels of morbidity and therefore have maximum impact on population health. The research will have many levels of economic impact through supporting the growth of a high value industry. Key industrial collaborations will assist UK located large companies and SME's in understanding of the commercial value of their therapies and other enabling technology products, product development, and in developing cost effective manufacturing approaches. Realisation of more products in a shorter timescale will directly support both national and global economic growth but also ultimately contribute to improved public finances through reducing the escalating long term costs associated with aging and chronic disease. The establishment of a UK based centre of enabling technology in RM translation will assist in attracting inward investment to the UK from product developers who are suffering from a global skill deficit. It will create skilled employment opportunities and boost product, technology and knowledge based exports. Policy forming and regulatory bodies will benefit from our industrially informed influencing studies and focus groups. Public policy will be influenced by the preparation and dissemination of evidence documents to key stakeholders and by active participation by IMRC partners in key national and international fora and networks. The NHS are well represented in the IMRC and this involvement will be critical in any UK led clinical adoption of advanced RM therapies. The IMRC approach directly complements the public regulators' mission to drive quality and safety into product development. The clear economic, health and policy impacts will only be realised if the IMRC transforms the product development and manufacturing status of the RM industry. We are in a unique position to achieve this through the internationally competitive lead established by the remedi Grand Challenge and our extensive commercial sector engagement with a track record of focussing academic teams on solving real problems presented through our industrial collaborators. This momentum will ensure early impact from the IMRC. The Liaison Group and Board will ensure continued impact by representing the voice of industrial stakeholders and guiding the research, as well as providing a direct route back to industrial application. The timing of the impact will be three phased. The technological impact to improve product development and manufacturing process will be rapid as the IMRC builds on the momentum and work established with partners under the remedi Grand Challenge. The economic benefit will build over the first few years as technological and methodological development enable industrial partners to meet milestones, reduce risk and therefore attract investment. Health benefits and the additional associated economic benefits of lower morbidity have longer term impact due to regulatory approval and clinical adoption times. We anticipate the IMRC's activities will have visible impact in this area within a decade through traceable contributions to key product successes in this emerging industry.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-02-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2010-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>5874637</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>World Courier</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Engagement Activity - Right Product, Right Patient, Right Time Speakers</gtr:description><gtr:id>B40D836B-AA2B-4A76-847C-CE2F322DC51F</gtr:id><gtr:impact>Transfer of best practice from various sectors to facilitate step-change improvements in the regenerative medicine supply chain. Resulted in publication of StemBook paper 'From production to patient: challenges and approaches for delivering cell therapies' by Nick Medcalf and Karen Coopman.</gtr:impact><gtr:outcomeId>544e49a2396e90.78739721-1</gtr:outcomeId><gtr:partnerContribution>Attendance at the event and speaker slot.</gtr:partnerContribution><gtr:piContribution>Co-organised the event 'Getting the product to the patient - right time, right place and safe to deliver: Challenges and innovation in cold chain, supply logistics and transport' with the Knowledge Transfer Network.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>JRI Orthapaedics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Regen Med Careers Awareness Event Speakers</gtr:description><gtr:id>E602D43D-B52A-486D-AF61-E42E5DBE19DE</gtr:id><gtr:impact>Increase in awareness within early career community of alternative careers in the regenerative medicine sector. Increased confidence of early career researchers in applying for roles outside of the 'normal' route to postdoc/fellowship.</gtr:impact><gtr:outcomeId>544e3337263249.25101979-4</gtr:outcomeId><gtr:partnerContribution>Speaker role and CV clinic mentor (1 day plus prep time). [Cell Therapy Catapult provided 2 CV clinic mentors]</gtr:partnerContribution><gtr:piContribution>Organisation and publicity of the event, 66% subsidy on cost of attendance for early career researchers, payment of speakers' travel costs.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Dragons' Den Sandpit Event Newcastle</gtr:description><gtr:id>49EB89B2-75BE-4AE1-93B2-82F759FAB17B</gtr:id><gtr:impact>Numerous projects created at the event and one project funded with &amp;pound;40,000 (80% fEC value).</gtr:impact><gtr:outcomeId>544e42943ca2a3.55613706-1</gtr:outcomeId><gtr:partnerContribution>Free of charge provision of a meeting room, some local administrative organisation.</gtr:partnerContribution><gtr:piContribution>Organisation of the event, payment for accommodation and catering.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Engagement Activity - Regen Med Careers Awareness Event CV Clinic Mentors</gtr:description><gtr:id>1F620160-5A04-4B04-A781-D044542E1008</gtr:id><gtr:impact>Increase in awareness within early career community of alternative careers in the regenerative medicine sector. Increased confidence of early career researchers in applying for roles outside of the 'normal' route to postdoc/fellowship.</gtr:impact><gtr:outcomeId>544e37dc8be213.92833236-1</gtr:outcomeId><gtr:partnerContribution>CV clinic mentor (1 day plus prep time).</gtr:partnerContribution><gtr:piContribution>Organisation and publicity of the event, 66% subsidy on cost of attendance for early career researchers, payment of speakers' travel costs.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>SynbiCITE</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP050 - SynBiCITE</gtr:description><gtr:id>780BFAD5-5475-4636-9F55-1955700E0887</gtr:id><gtr:impact>Contributed to Fellowship award, raised Loughborough University's profile within Synthetic Biology and facilitated access to state of the art Synthetic Biology research groups</gtr:impact><gtr:outcomeId>544e275745c852.43973404-1</gtr:outcomeId><gtr:partnerContribution>Staff time, in person meetings, Letters of Support for fellowship funding</gtr:partnerContribution><gtr:piContribution>Staff time, in-person meetings, maintaining the partnership and progress updates</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cool Logistics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP040 - Cool Logistics</gtr:description><gtr:id>59B759F4-0606-4C0E-B12A-54B4FF5263C5</gtr:id><gtr:outcomeId>b970713cb970715a-1</gtr:outcomeId><gtr:piContribution>Modelling Thermal Performance of a Cold Chain Transportation System. During this project we developed and validated a computational model capable of describing, analysing and predicting the thermal performance of the Credo cold chain transportation packaging system under diverse loads and ambient conditions.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Reneuron</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP049 - ReNeuron</gtr:description><gtr:id>E0A0DDD8-842F-49B3-A956-141815B132BD</gtr:id><gtr:outcomeId>b966e518b966e536-1</gtr:outcomeId><gtr:piContribution>QbD approach to risk reduction and optimisation of CTX culture and cryopreservation manufacturing processes</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard Stem Cell Institute</gtr:department><gtr:description>Engagement Activity - StemBook</gtr:description><gtr:id>2CE46E0F-667C-4559-A075-CD2F8D056AD2</gtr:id><gtr:impact>New manufacturing chapter for StemBook, providing material for knowledge exchange and training. Numerous papers include EPSRC Centre authors.</gtr:impact><gtr:outcomeId>544e3d375d1ea2.47350043-1</gtr:outcomeId><gtr:partnerContribution>Editorial support for new manufacturing chapter - arranging peer-review of papers and maintenance of online repository.</gtr:partnerContribution><gtr:piContribution>Provided guidance on potential manufacturing content for StemBook, an online peer-reviewed repository aimed at stem cell experts and non-experts. David Williams joined the editorial board. EPSRC Centre members co-authored numerous papers within the new manufacturing chapter created.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mica Biosystems</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP045 - Mica Biosystems</gtr:description><gtr:id>2F50AB36-3C23-483F-A87F-FE79873AF2D3</gtr:id><gtr:outcomeId>b9709694b97096a8-1</gtr:outcomeId><gtr:piContribution>Development of dynamic 3D models for regenerative medicine</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Future Health Technologies</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP003 FHT</gtr:description><gtr:id>5725D13B-6C0B-43D3-BC00-DFAD6E4AD26A</gtr:id><gtr:outcomeId>b97384c6b97384da-1</gtr:outcomeId><gtr:piContribution>Mapping processes</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>PA Consulting</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Summer Student PA Consulting</gtr:description><gtr:id>5E198A7A-82EA-489A-956B-597A43FEDB74</gtr:id><gtr:impact>Progress in the design of a medical device for improving the delivery and effect of stem cell treatments to the knee.</gtr:impact><gtr:outcomeId>544e2db6b87115.68904690-1</gtr:outcomeId><gtr:partnerContribution>PA Consulting funded the student bursary and co-supervised the project. Provided training experience for a future medical doctor.</gtr:partnerContribution><gtr:piContribution>PA Consulting were introduced to Keele University academics through the Head of Engagement, followed by negotiation of the summer project content and how it would be funded.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Dragon's Den Sandpit, Birmingham - organisation</gtr:description><gtr:id>B577A3CA-D27C-4819-A0E3-17E36C3A2810</gtr:id><gtr:impact>One project funded by EPSRC Centre - Electrospin &amp;amp; Electrostim. Additional projects being worked up.</gtr:impact><gtr:outcomeId>54c7ab64cff792.54315229-1</gtr:outcomeId><gtr:partnerContribution>Provision of venue free of charge.</gtr:partnerContribution><gtr:piContribution>Organisation and facilitation of the sandpit event, with funding provided for one project by the EPSRC Centre.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oswestry Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP003 Oswestry Hospital</gtr:description><gtr:id>327AAA75-8CBE-47BB-B1F6-38815E7CC4C9</gtr:id><gtr:outcomeId>b97382dcb97382f0-1</gtr:outcomeId><gtr:piContribution>Developing research opportunities</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Neusentis Pfizer</gtr:department><gtr:description>ECP037 - Neusentis</gtr:description><gtr:id>5534E070-FFB2-4421-9620-0F4C46FA9DE2</gtr:id><gtr:outcomeId>b971f9eeb971fa0c-1</gtr:outcomeId><gtr:piContribution>Optimisation of a Delivery Membrane</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Moorfields Eye Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP005 - Moorfields Eye Hospital</gtr:description><gtr:id>CEC30B06-537A-492E-B9C3-6611CC79E2AA</gtr:id><gtr:outcomeId>b9710f34b9710f52-1</gtr:outcomeId><gtr:piContribution>Label Free Assessment of Live Cell Quality with Total Internal Reflection Microscopy</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Haemostatix</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP029 - Haemostatix</gtr:description><gtr:id>B27316B1-98D9-44E2-B1A1-48328057FDDE</gtr:id><gtr:outcomeId>b9723d64b9723d78-1</gtr:outcomeId><gtr:piContribution>In vitro optimisation and evaluation of a series of flow-able gelatin paste composites for wound healing</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>SRG</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Regen Med Careers Awareness Event SRG</gtr:description><gtr:id>D0E84E92-D76D-4F67-88FE-4B7B9990E89E</gtr:id><gtr:impact>Increase in awareness within early career community of alternative careers in the regenerative medicine sector. Increased confidence of early career researchers in applying for roles outside of the 'normal' route to postdoc/fellowship.</gtr:impact><gtr:outcomeId>544e39699a3996.84115288-1</gtr:outcomeId><gtr:partnerContribution>Training session provider (1 day plus prep time).</gtr:partnerContribution><gtr:piContribution>Organisation and publicity of the event, 66% subsidy on cost of attendance for early career researchers, payment of speakers' travel costs.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Pittsburgh</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>ECP004 - McGowan Institute</gtr:description><gtr:id>EEFF6E19-B0E0-4391-8B2C-235B08594FE7</gtr:id><gtr:outcomeId>b96639bab96639ce-1</gtr:outcomeId><gtr:piContribution>A new 3D delivery platform for regenerative medicine</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nottingham University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP038 - Nottingham University Hospitals NHS Trust</gtr:description><gtr:id>623A12CB-D7C5-4EA1-A9C1-066F08B9F2F2</gtr:id><gtr:outcomeId>b9709158b970916c-1</gtr:outcomeId><gtr:piContribution>Defining and manufacturing a cell therapy product for the generation of bone in spinal surgery applications</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP050 - Dr Ivan Wall</gtr:description><gtr:id>6729E7CB-49E0-41C7-88A1-DF95F41E9758</gtr:id><gtr:impact>Submitted Joint Proposal to Manufacturing the Future competition, multidisciplinary; Synthetic Biology, Regenerative Medicine, Biochemical Engineering and Manufacturing Engineering</gtr:impact><gtr:outcomeId>544e2a118bac02.17681467-1</gtr:outcomeId><gtr:partnerContribution>Staff time, in-person meetings, joint proposal writing and maintaining the partnership</gtr:partnerContribution><gtr:piContribution>Staff time, in-person meetings, joint proposal writing and maintaining the partnership</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Institute for Stem cell Therapy and Exploration of Monogenic diseases (I-Stem)</gtr:department><gtr:description>ECP051 - CECS/I-STEM</gtr:description><gtr:id>A2DFD3B6-5782-46DE-A3C2-B18BCFB0D5F4</gtr:id><gtr:impact>This collaboration has led to the inclusion of Loughborough University in the I-STEM lead Horizon 2020 project</gtr:impact><gtr:outcomeId>544e2bd0c244c7.70614856-1</gtr:outcomeId><gtr:partnerContribution>Cells, protocols for automated and manual expansion, telephone contact with I-STEM research staff</gtr:partnerContribution><gtr:piContribution>Create a working cell bank, perform manual and automated expansion of the hiPSC line, bank these cells and then perform quality metrics to the I-STEM metrics. In addition, these cells will be differentiated to MSCs and the cells will be tested for their quality. I-STEM have developed a protocol for the automated expansion of their hiPSC lines. They want to see whether the protocols are comparable over multiple sites and Loughborough University will be able to present them with this data.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Department for Business, Energy &amp; Industrial Strategy</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UK Science and Innovation Network</gtr:department><gtr:description>Engagement Activity - UK Science and Innovation Network</gtr:description><gtr:id>EFE95211-63EA-47A7-A4A7-D4CDDF043A95</gtr:id><gtr:impact>New manufacturing chapter in StemBook. Publication by EPSRC Centre authors of numerous papers within this chapter. UK-wide national competition resulting in Elizabeth Cheeseman attending Harvard's prestigious internship programme.</gtr:impact><gtr:outcomeId>544e4fd40990e6.32334895-1</gtr:outcomeId><gtr:partnerContribution>Introductions to key colleagues in Boston and the surrounding area. Organisation of the Boston mission.</gtr:partnerContribution><gtr:piContribution>Interaction with UK Science and Innovation Network on a regular basis, resulting in a mission to Boston, development of a new manufacturing chapter for StemBook in collaboration with the Harvard Stem Cell Institute and a UK-wide competition to send an undergraduate student to undertake Harvard's prestigious summer internship programme.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Syngenta</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>ECP002 - Syngenta</gtr:description><gtr:id>3D680A15-5940-47CB-9792-F714212A0CB1</gtr:id><gtr:outcomeId>b9640082b96400a0-1</gtr:outcomeId><gtr:piContribution>Development of a Tissue Engineered 3D in vitro lymph node model. Syngenta have expressed an interest in the development of an in vitro model of human lymph node as it has direct relevance to their industry. Although not providing any financial contribution to the studentship, they are providing academic expertise through attendance at quarterly supervisor meetings.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Unilever</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP002 - Unilever</gtr:description><gtr:id>548FDE8E-9755-49AF-A0CC-99CEBF6560C9</gtr:id><gtr:outcomeId>b97270e0b97270fe-1</gtr:outcomeId><gtr:piContribution>Development of a Tissue Engineered 3D in vitro lymph node model</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wicell Research Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>ECP051 - Wicell Research Institute</gtr:description><gtr:id>A907E63E-FB72-4701-A78B-71277F0B5143</gtr:id><gtr:outcomeId>b9647a3ab9647a58-1</gtr:outcomeId><gtr:piContribution>Process engineering and techniques enabling the automation of GMP cell culture processes</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP030 - Newcastle University</gtr:description><gtr:id>97F73F29-4928-4BB1-AFE2-CC1F2CE28EE0</gtr:id><gtr:outcomeId>b972fdc6b972fde4-1</gtr:outcomeId><gtr:piContribution>Evaluation of Injectable scaffolds for use in accelerated anterior cruciate ligament (ACL) reconstruction</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Synpromics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP050 - Synpromics</gtr:description><gtr:id>E061AE87-C4B4-4EBA-96AD-041055F04F16</gtr:id><gtr:impact>Contributed to successful award of fellowship funding, multidisciplinary collaboration; Synthetic Biology, Stem Cell research, Gene Therapy research, Engineering</gtr:impact><gtr:outcomeId>544e280e0741c8.25352083-1</gtr:outcomeId><gtr:partnerContribution>Staff time, meetings, technology and materials contributions, letters of support for fellowship bid</gtr:partnerContribution><gtr:piContribution>Generation of a collaborative Fellowship project, staff time, in-person meetings, bid writing, maintenance of the collaboration</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tissue Growth Technologies</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>ECP007 - Tissue Growth Technologies</gtr:description><gtr:id>DB846611-F425-4928-AF51-6F0F0D5C806F</gtr:id><gtr:outcomeId>b965dae2b965db00-1</gtr:outcomeId><gtr:piContribution>Development &amp;amp; validation of TGT Hydrostatic Bioreactor for tissue processing and manufacturing in regenerative medicine</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Synthace</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP050 - Synthace</gtr:description><gtr:id>72AE299A-4AFD-4B78-9F0A-FD17F05B5666</gtr:id><gtr:impact>Raising profile of EPSRC Centre among Synthetic Biology Industry leaders, potential for future collaboration</gtr:impact><gtr:outcomeId>544e296e265ab5.12512892-1</gtr:outcomeId><gtr:partnerContribution>Staff time, in person meetings, discussions and scoping for potential collaborative research projects</gtr:partnerContribution><gtr:piContribution>Staff time, in person meetings, discussions and scoping for potential collaborative research projects</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>TAP Biosystems</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP051 - TAP Biosystems</gtr:description><gtr:id>FBCAED50-85C3-45B7-A658-8FF7BF14CC6F</gtr:id><gtr:outcomeId>b9647d5ab9647d6e-1</gtr:outcomeId><gtr:piContribution>Process engineering and techniques enabling the automation of GMP cell culture processes</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Anthony Nolan Cell Therapy Centre</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP003 Anthony Nolan</gtr:description><gtr:id>D915A3CF-5827-4012-A58E-7FA5502FF186</gtr:id><gtr:outcomeId>b9d299a2b9d299c0-1</gtr:outcomeId><gtr:piContribution>Mapping processes</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>TAP Biosystems</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP003 - TAP Biosystems</gtr:description><gtr:id>8C4C8634-0A13-4BDF-B88A-C86B437E4B12</gtr:id><gtr:outcomeId>b9737e5eb9737e72-1</gtr:outcomeId><gtr:piContribution>Near Patient Cell Processing, Phase 1: Enabling manufacturing &amp;amp; supply of cell therapies in hospital settings</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Scottish National Blood Transfusion Service (SNBTS)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Regen Med Careers Awareness Event Speakers</gtr:description><gtr:id>3B9183EE-238F-4C3A-8601-8812FD9A66CE</gtr:id><gtr:impact>Increase in awareness within early career community of alternative careers in the regenerative medicine sector. Increased confidence of early career researchers in applying for roles outside of the 'normal' route to postdoc/fellowship.</gtr:impact><gtr:outcomeId>544e3337263249.25101979-6</gtr:outcomeId><gtr:partnerContribution>Speaker role and CV clinic mentor (1 day plus prep time). [Cell Therapy Catapult provided 2 CV clinic mentors]</gtr:partnerContribution><gtr:piContribution>Organisation and publicity of the event, 66% subsidy on cost of attendance for early career researchers, payment of speakers' travel costs.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nottingham University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Pathology Department</gtr:department><gtr:description>ECP003 QMC</gtr:description><gtr:id>96EAD43A-17B8-465E-9468-15860023917C</gtr:id><gtr:outcomeId>b97383ccb97383e0-1</gtr:outcomeId><gtr:piContribution>Mapping processes</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dana-Farber Cancer Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>ECP003 Dana Farber Cancer Institute</gtr:description><gtr:id>8066EE52-2945-4F0C-9A54-732458B2978E</gtr:id><gtr:impact>Multi-disciplinary spanning medicine, biology and engineering.</gtr:impact><gtr:outcomeId>b9d3680ab9d3681e-1</gtr:outcomeId><gtr:partnerContribution>Access to comprehensive data on biological variation in a key clinical procedure including manufacturing steps.</gtr:partnerContribution><gtr:piContribution>Developing research opportunities</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lonza Group</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Engagement Activity - Regen Med Careers Awareness Event CV Clinic Mentors</gtr:description><gtr:id>05EEF22E-A361-4719-B0F4-24BBD6812AD9</gtr:id><gtr:impact>Increase in awareness within early career community of alternative careers in the regenerative medicine sector. Increased confidence of early career researchers in applying for roles outside of the 'normal' route to postdoc/fellowship.</gtr:impact><gtr:outcomeId>544e37dc8be213.92833236-2</gtr:outcomeId><gtr:partnerContribution>CV clinic mentor (1 day plus prep time).</gtr:partnerContribution><gtr:piContribution>Organisation and publicity of the event, 66% subsidy on cost of attendance for early career researchers, payment of speakers' travel costs.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cell Therapy Catapult</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Right Product, Right Patient, Right Time Speakers</gtr:description><gtr:id>95FFD6A1-7B28-4562-9B4A-9E7B16A981CF</gtr:id><gtr:impact>Transfer of best practice from various sectors to facilitate step-change improvements in the regenerative medicine supply chain. Resulted in publication of StemBook paper 'From production to patient: challenges and approaches for delivering cell therapies' by Nick Medcalf and Karen Coopman.</gtr:impact><gtr:outcomeId>544e49a2396e90.78739721-2</gtr:outcomeId><gtr:partnerContribution>Attendance at the event and speaker slot.</gtr:partnerContribution><gtr:piContribution>Co-organised the event 'Getting the product to the patient - right time, right place and safe to deliver: Challenges and innovation in cold chain, supply logistics and transport' with the Knowledge Transfer Network.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP048 - Glasgow University</gtr:description><gtr:id>4AD2FB26-8FCC-464C-B33F-28A6B2C04BE3</gtr:id><gtr:outcomeId>b9704b62b9704b76-1</gtr:outcomeId><gtr:piContribution>RBC production from hESC in scalable suspension format - Phase 2</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>British Mass Spectrometry Society</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Summer Student British Mass Spectrometry Society</gtr:description><gtr:id>6EDABD79-582D-4EE5-AE0B-3E3CFA52E06D</gtr:id><gtr:impact>Work presented at Mercia Stem Cell Alliance meeting. Training the next generation of doctors.</gtr:impact><gtr:outcomeId>544e30ac724450.46494526-1</gtr:outcomeId><gtr:partnerContribution>Sponsorship of student bursary for summer project.</gtr:partnerContribution><gtr:piContribution>Design and supervision of the project, training the next generation of doctors.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cell Therapy Catapult</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP049 - Cell Therapy Catapult</gtr:description><gtr:id>947C48D6-CD53-46BB-AE8E-A26DEA0AC796</gtr:id><gtr:outcomeId>b966e630b966e644-1</gtr:outcomeId><gtr:piContribution>QbD approach to risk reduction and optimisation of CTX culture and cryopreservation manufacturing processes</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Puridify</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Regen Med Careers Awareness Event Speakers</gtr:description><gtr:id>7FDFA7F9-16AC-4F78-9704-D6558824C617</gtr:id><gtr:impact>Increase in awareness within early career community of alternative careers in the regenerative medicine sector. Increased confidence of early career researchers in applying for roles outside of the 'normal' route to postdoc/fellowship.</gtr:impact><gtr:outcomeId>544e3337263249.25101979-5</gtr:outcomeId><gtr:partnerContribution>Speaker role and CV clinic mentor (1 day plus prep time). [Cell Therapy Catapult provided 2 CV clinic mentors]</gtr:partnerContribution><gtr:piContribution>Organisation and publicity of the event, 66% subsidy on cost of attendance for early career researchers, payment of speakers' travel costs.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Intercytex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Regen Med Careers Awareness Event CV Clinic Mentors</gtr:description><gtr:id>B5EB5A60-E99A-4560-A215-00738EB17F41</gtr:id><gtr:impact>Increase in awareness within early career community of alternative careers in the regenerative medicine sector. Increased confidence of early career researchers in applying for roles outside of the 'normal' route to postdoc/fellowship.</gtr:impact><gtr:outcomeId>544e37dc8be213.92833236-5</gtr:outcomeId><gtr:partnerContribution>CV clinic mentor (1 day plus prep time).</gtr:partnerContribution><gtr:piContribution>Organisation and publicity of the event, 66% subsidy on cost of attendance for early career researchers, payment of speakers' travel costs.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>TAP Biosystems</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP021 - TAP Biosystems</gtr:description><gtr:id>242A05B9-C45D-4A77-B2CE-40B2C10A0641</gtr:id><gtr:outcomeId>b9716f4cb9716f6a-1</gtr:outcomeId><gtr:piContribution>Near Patient Cell Processing, Phase 2: Enabling manufacturing &amp;amp; supply of cell therapies in hospital settings</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>TAP Biosystems</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP001 - TAP Biosystems</gtr:description><gtr:id>A960BA92-A433-47AE-BA64-FF13AC27FE79</gtr:id><gtr:outcomeId>b97381c4b97381e2-1</gtr:outcomeId><gtr:piContribution>Efficient (next generation) Manufacturing Platform for adherent allogeneic cell therapies</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>nanoTherics Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Summer Students x2 nanoTherics</gtr:description><gtr:id>4C2F8A35-3CF1-4109-9049-DEE7CD849B23</gtr:id><gtr:impact>Presentation at INSPIRE student conference. Training of future doctors in research and development and ways of working with industry.</gtr:impact><gtr:outcomeId>544e2eafb5c272.50082788-1</gtr:outcomeId><gtr:partnerContribution>nanoTherics provided support in designing the two projects and provided the medical students with experience of working with an industrial company.</gtr:partnerContribution><gtr:piContribution>nanoTherics introduced to two projects based at Keele for the summer of 2014. Can magnetic hyperthermia safely enhance magnetic nanoparticle labelling of neural stem cells? and Using a novel multifunctional magnetic nanoparticle with a state-of-the-art 'magnetofection' device to enhance gene transfer to neural transplant cells?</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP028 - University of Cambridge</gtr:description><gtr:id>EFA777D3-FA37-4743-8FD9-5A29811402D2</gtr:id><gtr:outcomeId>b9723f62b9723f80-1</gtr:outcomeId><gtr:piContribution>A Novel Method to Develop Electrospun Scaffolds with Tailored Geometries for in vitro models of Skin</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Roslin Cells Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP050 - Roslin Cells</gtr:description><gtr:id>3E00588F-7AD8-47CE-AA58-8C1489820B45</gtr:id><gtr:outcomeId>b9663424b9663442-1</gtr:outcomeId><gtr:piContribution>Exploring the feasibility of Synthetic Biology applications in systematic engineering of cell therapies</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Dragons Den Sandpit Event, Birmingham - Mentoring SA</gtr:description><gtr:id>FE8F9EBB-9F5F-4FA1-8D68-1B5F0D63B466</gtr:id><gtr:impact>One project funded by EPSRC Centre - Electrospin &amp;amp; Electrostim. Additional projects being worked up.</gtr:impact><gtr:outcomeId>54c7aa0272f1d0.14752819-1</gtr:outcomeId><gtr:partnerContribution>Mentoring provided by Dr Sajjad Ahmad</gtr:partnerContribution><gtr:piContribution>Organisation of Dragon's Den Sandpit in Opthalmology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cell Therapy Catapult</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Regen Med Careers Awareness Event Speakers</gtr:description><gtr:id>99C2F99A-23DE-4DA6-B2AE-7771AABCF46A</gtr:id><gtr:impact>Increase in awareness within early career community of alternative careers in the regenerative medicine sector. Increased confidence of early career researchers in applying for roles outside of the 'normal' route to postdoc/fellowship.</gtr:impact><gtr:outcomeId>544e3337263249.25101979-3</gtr:outcomeId><gtr:partnerContribution>Speaker role and CV clinic mentor (1 day plus prep time). [Cell Therapy Catapult provided 2 CV clinic mentors]</gtr:partnerContribution><gtr:piContribution>Organisation and publicity of the event, 66% subsidy on cost of attendance for early career researchers, payment of speakers' travel costs.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Regentec</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP004 - RegenTec</gtr:description><gtr:id>9FFC39F9-2181-4694-8905-1B3F04CEA42B</gtr:id><gtr:outcomeId>b9663528b966353c-1</gtr:outcomeId><gtr:piContribution>A new 3D delivery platform for regenerative medicine</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Medical Technologies IKC</gtr:department><gtr:description>Engagement Activity - Regen Med Careers Awareness Event CV Clinic Mentors</gtr:description><gtr:id>CF321FB8-98FA-4B84-AE2A-2B64F51DD474</gtr:id><gtr:impact>Increase in awareness within early career community of alternative careers in the regenerative medicine sector. Increased confidence of early career researchers in applying for roles outside of the 'normal' route to postdoc/fellowship.</gtr:impact><gtr:outcomeId>544e37dc8be213.92833236-4</gtr:outcomeId><gtr:partnerContribution>CV clinic mentor (1 day plus prep time).</gtr:partnerContribution><gtr:piContribution>Organisation and publicity of the event, 66% subsidy on cost of attendance for early career researchers, payment of speakers' travel costs.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Terumo BCT</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Engagement Activity - Regen Med Careers Awareness Event CV Clinic Mentors</gtr:description><gtr:id>227A09F3-12F9-42B0-A7AB-6EDBC2D1AD8D</gtr:id><gtr:impact>Increase in awareness within early career community of alternative careers in the regenerative medicine sector. Increased confidence of early career researchers in applying for roles outside of the 'normal' route to postdoc/fellowship.</gtr:impact><gtr:outcomeId>544e37dc8be213.92833236-3</gtr:outcomeId><gtr:partnerContribution>CV clinic mentor (1 day plus prep time).</gtr:partnerContribution><gtr:piContribution>Organisation and publicity of the event, 66% subsidy on cost of attendance for early career researchers, payment of speakers' travel costs.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Dragon's Den Sandpit, Birmingham - Clinical Leadership &amp;amp; Mentoring</gtr:description><gtr:id>5A5D1D82-7FEF-42DE-9F82-24F35B0416D6</gtr:id><gtr:impact>One project funded by EPSRC Centre - Electrospin &amp;amp; Electrostim. Additional projects being worked up.</gtr:impact><gtr:outcomeId>54c7aab1c529d5.98668281-1</gtr:outcomeId><gtr:partnerContribution>Clinical leadership provided by Prof Robert Scott and Saaeha Rauz. Mentoring provided by Prof Liam Grover, Prof Ann Logan and Dr Graham Wallace.</gtr:partnerContribution><gtr:piContribution>Organisation of Dragon's Den Sandpit Event in Opthalmology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bath</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Dragons Den Sandpit Event Bath</gtr:description><gtr:id>20830E6C-3659-4B43-9F3B-0D9B47981212</gtr:id><gtr:impact>Numerous projects created at the event and one project funded with &amp;pound;40,000 (80% fEC value).</gtr:impact><gtr:outcomeId>544e3dd5c0ec06.08916470-1</gtr:outcomeId><gtr:partnerContribution>Free of charge provision of a meeting room, some local administrative organisation.</gtr:partnerContribution><gtr:piContribution>Organisation of the event, payment for accommodation and catering.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Orthopaedic Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP023 - Orthopaedic Institute</gtr:description><gtr:id>51B9C7B1-476B-4FA2-899C-B2E39651F244</gtr:id><gtr:outcomeId>b9669aa4b9669ab8-1</gtr:outcomeId><gtr:piContribution>From Science Bench to the Clinical Application: Establishing a stem cell population with consistent therapeutic behaviours ? Kehoe , Richardson, El Haj (KU)</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Neusentis Pfizer</gtr:department><gtr:description>ECP043 - Neusentis</gtr:description><gtr:id>6AB7638E-E8E9-433E-8104-12770342F74A</gtr:id><gtr:outcomeId>b966c4acb966c4ca-1</gtr:outcomeId><gtr:piContribution>Optimisation of a Delivery Membrane - Phase 2</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP044 - Glasgow University</gtr:description><gtr:id>7DE5350B-17D5-4353-B92B-DF3C1D3C8234</gtr:id><gtr:outcomeId>b9715976b9715994-1</gtr:outcomeId><gtr:piContribution>RBC production from hESC</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Waters Corporation</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Waters Corporation Centre of Mass Spectrometry Excellence</gtr:department><gtr:description>Engagement Activity - Summer Student Waters Corporation</gtr:description><gtr:id>830664B9-EDF8-456C-BD3B-0587ED4882B6</gtr:id><gtr:impact>Work presented at a Mercia Stem Cell Alliance meeting. Training of the next generation of doctors.</gtr:impact><gtr:outcomeId>544e2fe114cd00.25907140-1</gtr:outcomeId><gtr:partnerContribution>Project design with Keele academics, co-supervision of medical student for the summer.</gtr:partnerContribution><gtr:piContribution>Project design, supervision of the student, engagement of company.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Grimsby Institute of Further and Higher Education</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Right Product, Right Patient, Right Time Speakers</gtr:description><gtr:id>5E1AD33D-7133-4F27-A961-CFE05D759664</gtr:id><gtr:impact>Transfer of best practice from various sectors to facilitate step-change improvements in the regenerative medicine supply chain. Resulted in publication of StemBook paper 'From production to patient: challenges and approaches for delivering cell therapies' by Nick Medcalf and Karen Coopman.</gtr:impact><gtr:outcomeId>544e49a2396e90.78739721-5</gtr:outcomeId><gtr:partnerContribution>Attendance at the event and speaker slot.</gtr:partnerContribution><gtr:piContribution>Co-organised the event 'Getting the product to the patient - right time, right place and safe to deliver: Challenges and innovation in cold chain, supply logistics and transport' with the Knowledge Transfer Network.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Anthony Nolan Cell Therapy Centre</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP021 - Anthony Nolan</gtr:description><gtr:id>3A3F07C0-1FF9-41A8-AD60-06C96D0E210E</gtr:id><gtr:outcomeId>b97182cab97182e8-1</gtr:outcomeId><gtr:piContribution>Near Patient Cell Processing, Phase 2: Enabling manufacturing &amp;amp; supply of cell therapies in hospital settings</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Cancer Institute</gtr:department><gtr:description>ECP051 - University College London</gtr:description><gtr:id>1D91C0E5-09E5-4AA0-9E6B-93CACE85FCE3</gtr:id><gtr:outcomeId>b9647b52b9647b66-1</gtr:outcomeId><gtr:piContribution>Process engineering and techniques enabling the automation of GMP cell culture processes</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bose</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Bose ElectroForce</gtr:department><gtr:description>ECP020 - Bose</gtr:description><gtr:id>307D738D-1BE6-40F2-92DB-94E172172A04</gtr:id><gtr:outcomeId>b966cef2b966cf06-1</gtr:outcomeId><gtr:piContribution>Control of human mesenchymal stem cell differentiation to a nucleus pulposus phenotype by improving the design of physiologically relevant in vitro conditions</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Smith and Nephew</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP003 - Smith &amp;amp; Nephew</gtr:description><gtr:id>1F844812-0C83-4E2D-BBFD-D7D8F9062F55</gtr:id><gtr:outcomeId>b9737f62b9737f76-1</gtr:outcomeId><gtr:piContribution>Near Patient Cell Processing, Phase 1: Enabling manufacturing &amp;amp; supply of cell therapies in hospital settings</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Dragons Den Sandpit Event London</gtr:description><gtr:id>DE42D557-BFA3-4163-B37A-AD17171B77F1</gtr:id><gtr:impact>Numerous projects created at the event and one project funded with &amp;pound;40,000 (80% fEC value).</gtr:impact><gtr:outcomeId>544e4366ad5c35.87365606-1</gtr:outcomeId><gtr:partnerContribution>Free of charge provision of a meeting room, some local administrative organisation.</gtr:partnerContribution><gtr:piContribution>Organisation of the event, payment for accommodation and catering.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Knowledge Transfer Network</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Right Product, Right Patient, Right Time KTN</gtr:description><gtr:id>CD4536AA-7F3A-41CD-BC24-BF4C5C880337</gtr:id><gtr:impact>StemBook publication resulted from the variety of talks during the event - http://www.stembook.org/node/6149</gtr:impact><gtr:outcomeId>544e48eca52257.85933320-1</gtr:outcomeId><gtr:partnerContribution>Organisational support for the event - registration, logistics on the day. Led on design of the agenda. Considerable input into promotion among the KTN's network.</gtr:partnerContribution><gtr:piContribution>Provided funding and local venue booking support for hosting the 'Right product, right patient, right time' meeting with the KTN at Loughborough University. Provided input to the design of the agenda, promoted the event and attracted the EPSRC's academic and industrial partners.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fondazione Filarete</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>ECP020 - Fondazione Filarete</gtr:description><gtr:id>6B42ACF6-8CB1-46E0-BB50-CF7D10CA0C40</gtr:id><gtr:outcomeId>b966d276b966d28a-1</gtr:outcomeId><gtr:piContribution>Control of human mesenchymal stem cell differentiation to a nucleus pulposus phenotype by improving the design of physiologically relevant in vitro conditions. This collaboration has included a number of secondments to take advantage of training and access to facilities:
PhD Student HH from Loughborough spent three months at Fondzione Filarete 07/10/11 to 13/01/12
PhD Student AF from Loughborough spent three months at Fondazione Filarete 13/05/12 to 04/09/12
PhD Student TS from Fondazione Filarete spent two weeks at Loughborough 12/03/13 to 24/03/13
PhD Student AF from Loughborough spent two months at Fondazione Filarete 17/02/13 to 19/04/13</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Neusentis Pfizer</gtr:department><gtr:description>ECP015 - Neusentis</gtr:description><gtr:id>DEF64C33-DA69-47EC-9AA7-186086F667F4</gtr:id><gtr:outcomeId>b9723e72b9723e86-1</gtr:outcomeId><gtr:piContribution>Quality by Design (QbD) approach to risk reduction and optimisation for a unit operation of cell therapy manufacture</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Smith and Nephew</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Regen Med Careers Awareness Event Speakers</gtr:description><gtr:id>D94D3FDB-8858-4C8E-9EEB-9638F7A13272</gtr:id><gtr:impact>Increase in awareness within early career community of alternative careers in the regenerative medicine sector. Increased confidence of early career researchers in applying for roles outside of the 'normal' route to postdoc/fellowship.</gtr:impact><gtr:outcomeId>544e3337263249.25101979-2</gtr:outcomeId><gtr:partnerContribution>Speaker role and CV clinic mentor (1 day plus prep time). [Cell Therapy Catapult provided 2 CV clinic mentors]</gtr:partnerContribution><gtr:piContribution>Organisation and publicity of the event, 66% subsidy on cost of attendance for early career researchers, payment of speakers' travel costs.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Ophthalmology UCL</gtr:department><gtr:description>ECP003 UCL Institute of Opthamology</gtr:description><gtr:id>1CF0F795-0853-48CA-85DE-C64B69202B0A</gtr:id><gtr:outcomeId>b9738728b973873c-1</gtr:outcomeId><gtr:piContribution>Developing research opportunities and mapping processes</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MCR Media Group</gtr:collaboratingOrganisation><gtr:country>Israel, State of</gtr:country><gtr:description>ECP031 - Cellon</gtr:description><gtr:id>F675988B-053B-40CB-A6F7-4A27FB9CB398</gtr:id><gtr:outcomeId>b97348dab97348ee-1</gtr:outcomeId><gtr:piContribution>SIFT-MS Monitoring of cell growth in Cellon CELL-tainer bioreactor</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP002 - University of Leeds</gtr:description><gtr:id>AC0447BD-9321-40D3-A696-886C38F187FF</gtr:id><gtr:outcomeId>b9d1b9e2b9d1ba00-1</gtr:outcomeId><gtr:piContribution>Development of a Tissue Engineered 3D in vitro lymph node model. In order to enhance the permeability of the scaffolds being used for this project to the cells being used for model development, we used an ultrasound treatment developed and conducted at Leeds University.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ruskinn Technology Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP020 - Ruskinn Technology</gtr:description><gtr:id>38F17BA9-7150-47B9-ABAB-A9B097146BC9</gtr:id><gtr:outcomeId>b966d14ab966d15e-1</gtr:outcomeId><gtr:piContribution>Control of human mesenchymal stem cell differentiation to a nucleus pulposus phenotype by improving the design of physiologically relevant in vitro conditions</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technology Strategy Board (TSB)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP050 - Dr Belinda Clarke</gtr:description><gtr:id>B7514F31-4B0D-4219-8F3E-F1FBB2CA8BCB</gtr:id><gtr:impact>Contributed towards being awarded fellowship funding and towards meeting key Synthetic Biology figureheads (SynBiCITE directors) and industrial partnerships</gtr:impact><gtr:outcomeId>544e28d1bc94e6.99975091-1</gtr:outcomeId><gtr:partnerContribution>Advice, Letter of Support for fellowship bid</gtr:partnerContribution><gtr:piContribution>Staff time, in person meetings and discussions, TSB workshop presentations, hosting at Loughborough to showcase facilities</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Asymptote</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Right Product, Right Patient, Right Time Speakers</gtr:description><gtr:id>E3EE4A60-A2F3-4877-B36D-7A1E70128E19</gtr:id><gtr:impact>Transfer of best practice from various sectors to facilitate step-change improvements in the regenerative medicine supply chain. Resulted in publication of StemBook paper 'From production to patient: challenges and approaches for delivering cell therapies' by Nick Medcalf and Karen Coopman.</gtr:impact><gtr:outcomeId>544e49a2396e90.78739721-4</gtr:outcomeId><gtr:partnerContribution>Attendance at the event and speaker slot.</gtr:partnerContribution><gtr:piContribution>Co-organised the event 'Getting the product to the patient - right time, right place and safe to deliver: Challenges and innovation in cold chain, supply logistics and transport' with the Knowledge Transfer Network.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Regener8</gtr:department><gtr:description>Engagement Activity - Regen Med Careers Awareness Event Regener8</gtr:description><gtr:id>549F709F-616A-4AFB-9647-AAE16049BACD</gtr:id><gtr:impact>Increase in awareness within early career community of alternative careers in the regenerative medicine sector. Increased confidence of early career researchers in applying for roles outside of the 'normal' route to postdoc/fellowship.</gtr:impact><gtr:outcomeId>544e3223963e80.39169939-1</gtr:outcomeId><gtr:partnerContribution>Co-organiser, marketing and speaker contribution.</gtr:partnerContribution><gtr:piContribution>Organisation and publicity of the event, 66% subsidy on cost of attendance for early career researchers, payment of speakers' travel costs.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Loughborough University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP051 - Loughborough University</gtr:description><gtr:id>58078562-D17A-4FF8-8AA0-957BED1DA0C7</gtr:id><gtr:outcomeId>b9647c4cb9647c60-1</gtr:outcomeId><gtr:piContribution>Process engineering and techniques enabling the automation of GMP cell culture processes</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP013 - Pfizer</gtr:description><gtr:id>1E3FF051-6C8E-41BA-8C5B-EFC51FA3F8BA</gtr:id><gtr:outcomeId>b9726726b972673a-1</gtr:outcomeId><gtr:piContribution>Evaluation of Functionalised Membranes for use in Immunisolatory devices for Regenerative Medicine and Cell based therapies</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Cancer Institute</gtr:department><gtr:description>ECP050 - University College London</gtr:description><gtr:id>9503846F-C86E-4B69-8E0F-2440F383F964</gtr:id><gtr:outcomeId>b96631e0b96631f4-1</gtr:outcomeId><gtr:piContribution>Exploring the feasibility of Synthetic Biology applications in systematic engineering of cell therapies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard Stem Cell Institute</gtr:department><gtr:description>Engagement Activity - Harvard Stem Cell Institute Internship Programme</gtr:description><gtr:id>21A84961-ED43-434F-A857-90EF98ED4D4C</gtr:id><gtr:impact>Internship competition winner Elizabeth Cheeseman is planning to apply for a PhD for 2015 entry. Ongoing relationship with Harvard, with joint StemBook activities.</gtr:impact><gtr:outcomeId>544e3c85a53b92.17789064-1</gtr:outcomeId><gtr:partnerContribution>Considerable training of the winner, Elizabeth Cheeseman of Loughborough University, in stem cell techniques, and provision of a development opportunity for her.</gtr:partnerContribution><gtr:piContribution>Organised a nationwide competition for UK undergraduate students to apply for a place at the Harvard Stem Cell Institute summer internship program. Housing and travel costs covered by the EPSRC Centre.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Physical Laboratory</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP005 - National Physical Laboratory</gtr:description><gtr:id>6FF9F10F-9DA4-46CA-8CBB-83EE3D311BB3</gtr:id><gtr:outcomeId>b9733e4eb9733e62-1</gtr:outcomeId><gtr:piContribution>Label Free Assessment of Live Cell Quality with Total Internal Reflection Microscopy</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leicester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Regen Med Careers Awareness Event Speakers</gtr:description><gtr:id>00764D42-5711-42F3-93C9-76FC34DEA7F2</gtr:id><gtr:impact>Increase in awareness within early career community of alternative careers in the regenerative medicine sector. Increased confidence of early career researchers in applying for roles outside of the 'normal' route to postdoc/fellowship.</gtr:impact><gtr:outcomeId>544e3337263249.25101979-1</gtr:outcomeId><gtr:partnerContribution>Speaker role and CV clinic mentor (1 day plus prep time). [Cell Therapy Catapult provided 2 CV clinic mentors]</gtr:partnerContribution><gtr:piContribution>Organisation and publicity of the event, 66% subsidy on cost of attendance for early career researchers, payment of speakers' travel costs.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Reneuron</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP005 - Reneuron</gtr:description><gtr:id>D149067D-7731-4A91-ADE3-94B31B4DE65E</gtr:id><gtr:outcomeId>b971021eb971023c-1</gtr:outcomeId><gtr:piContribution>Label Free Assessment of Live Cell Quality with Total Internal Reflection Microscopy</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Intercytex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Engagement Activity - Right Product, Right Patient, Right Time Speakers</gtr:description><gtr:id>52544F3C-D765-43DA-B247-1DF15B2474EB</gtr:id><gtr:impact>Transfer of best practice from various sectors to facilitate step-change improvements in the regenerative medicine supply chain. Resulted in publication of StemBook paper 'From production to patient: challenges and approaches for delivering cell therapies' by Nick Medcalf and Karen Coopman.</gtr:impact><gtr:outcomeId>544e49a2396e90.78739721-3</gtr:outcomeId><gtr:partnerContribution>Attendance at the event and speaker slot.</gtr:partnerContribution><gtr:piContribution>Co-organised the event 'Getting the product to the patient - right time, right place and safe to deliver: Challenges and innovation in cold chain, supply logistics and transport' with the Knowledge Transfer Network.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lucideon</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP022 - Ceram</gtr:description><gtr:id>12BC83E8-35FD-435F-86BF-A7899F0416E9</gtr:id><gtr:outcomeId>b97360aeb97360c2-1</gtr:outcomeId><gtr:piContribution>Nano-structured zirconias as an enabling material for enhanced ceramic implants</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ruskinn Technology Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP008 - Ruskinn Technology</gtr:description><gtr:id>348F34A4-4806-4732-988C-F2CBCBB0B17B</gtr:id><gtr:outcomeId>b9715426b971543a-1</gtr:outcomeId><gtr:piContribution>Near Patient Processing: HypOxyCool for Improved Autologous Cell Production</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Boltzmann Society</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:department>Ludwig Boltzmann Institute for Experimental and Clinical Traumatology</gtr:department><gtr:description>ECP004 - Ludwig Boltzmann Institute</gtr:description><gtr:id>DB0D7B7B-179C-4E84-8D87-A9B40C425AC8</gtr:id><gtr:outcomeId>b966362cb9663640-1</gtr:outcomeId><gtr:piContribution>A new 3D delivery platform for regenerative medicine</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>LGC Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cell Metrology</gtr:department><gtr:description>ECP051 - LGC</gtr:description><gtr:id>6C51E63E-3D36-46A6-8F29-DBBF14BDCDA5</gtr:id><gtr:impact>Analysis of the cells for differences in the automation protocols</gtr:impact><gtr:outcomeId>544e2c9a4b26f0.36766654-1</gtr:outcomeId><gtr:partnerContribution>Analyse the cells for differences in the automation protocols</gtr:partnerContribution><gtr:piContribution>Provide cells to the research group at LGC</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Regentec</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECP038 - RegenTec</gtr:description><gtr:id>CD802F61-CE63-4ACB-BA65-97A02A13AFE0</gtr:id><gtr:outcomeId>b970904ab970905e-1</gtr:outcomeId><gtr:piContribution>Defining and manufacturing a cell therapy product for the generation of bone in spinal surgery applications</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Athersys Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Near patient cell processing</gtr:description><gtr:id>42DEED4E-BF7B-47B3-A9A4-CA8546FA9EA4</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56d56d6803db82.18513722-1</gtr:outcomeId><gtr:partnerContribution>Athersys provided financial support for cell processing and were running the clinical trial.</gtr:partnerContribution><gtr:piContribution>Our cell therapy facility was utilized for closed cell processing of the Athersys Multistem cell therapy product for application in an ischemic stroke focused clinical trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ruskinn Technology Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Hypoxia cell culture equipment</gtr:description><gtr:id>0EA0EF7B-2A70-4852-9A77-1A03F70E47EE</gtr:id><gtr:impact>A wide range of publications and conference presentations have resulted from this collaborative research.

This was a multidisciplinary project requiring cell therapy and stem cell biology expertise coupled to engineering expertise.</gtr:impact><gtr:outcomeId>56d565d6708959.75067641-1</gtr:outcomeId><gtr:partnerContribution>Baker Ruskinn licensed the technology from Keele and provided the engineering expertise to develop prototype systems to valid the system for cell therapy manufacturing purposes.</gtr:partnerContribution><gtr:piContribution>Keele developed a system for rapid deoxygenation of cell culture media for application in cell therapy manufacturing. This technology was filed for patent in both US and EU systems. The US patent was allowed to drop and the EU patent is still pending.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Engagement Activity - Royal Society Summer Science Exhibition</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C2DC4A0F-E871-460E-995D-74D2C2095E6D</gtr:id><gtr:impact>Team led by Kevin Shakesheff designed and delivered the Biology Builders exhibition during the week-long summer science exhibition.

Engagement of school age learners from across the UK. Engagement of VIPs during evening soiree, including scientific TV personalities.</gtr:impact><gtr:outcomeId>544fae74ca5734.99359438</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.epsrc-regen-med.org/biologybuilders/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ECP007 Bioreactor Course 2013</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>217D70FD-B90C-42D6-999C-78C8D7060E73</gtr:id><gtr:impact>Representation of our industrial partner, Instron, at the bioreactor course and demonstration of their hydrostatic bioreactor system.

Spoke to postgraduate students, colleagues and industry representatives.</gtr:impact><gtr:outcomeId>54622d6241ed64.22351376</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://www.keele.ac.uk/bioreactorcourse/courseoverview/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - TERM Consortium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4AB8F8C9-38E4-4922-B1DC-D1E1D0C7260B</gtr:id><gtr:impact>Invited to present at TERM Consortium annual meeting in Nantes, France, to investigate possibility of UK academics working with the existing consortium to source additional funding to extend the work of the consortium. The consortium did not contain any UK partners. Sophie Dale-Black presented on the regenerative medicine manufacturing expertise across the UK and invited consortium members to contact her for introductions to UK academics.

Introduction to fifteen Europe-wide academic and commercial organisations. Visits to four companies and training sites in Nantes. Follow-up with academic partners ongoing regarding possible Horizon 2020 European funding bids.</gtr:impact><gtr:outcomeId>544fba75667041.70655145</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.epsrc-regen-med.org/outreach/promoting-the-uk-community/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - Big Bang Fair London 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3647F120-3FE8-4176-BB22-D282B254928E</gtr:id><gtr:impact>Approx. 500 school age learners estimated to have visited our stand. Research communicated included cell biology, scaffold creation and scale-up of cell culture.

Follow-up from charity specialising in supporting learners from economically deprived areas. Increase in visitors to our blog www.heartblog.net which was promoted at the event.</gtr:impact><gtr:outcomeId>544fa73aa2c8a3.62056573</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.thebigbangfair.co.uk/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - HEART Outreach Brand</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4B17166A-CAF1-427F-9D32-AA8E594B084A</gtr:id><gtr:impact>The HEART (Healthcare Engineering and Regenerative Therapies) brand has been created jointly by the EPSRC Centre for Innovative Manufacturing in Regenerative Medicine and the EPSRC-MRC Centre for Doctoral Training in Regenerative Medicine. HEART is an umbrella brand covering all public and schools engagement work in the two centres, from social media (Twitter, Tumblr, Facebook, www.heartblog.net blog) to exhibitions (e.g. Big Bang Fair).

HEART team members featured on BBC Breakfast News during the Big Bang Fair 2014 exhibition. Communication skills have been improved among HEART team members through receiving advanced outreach skills training and gaining experience in communicating their science through blog posts. Over 7,000 learners have been engaged through exhibitions and school workshops.</gtr:impact><gtr:outcomeId>5450dddd626988.70287361</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.heartblog.net</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - EATRIS</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>715979A2-DE83-4AEF-A361-51E0814659FC</gtr:id><gtr:impact>Engagement of the EATRIS translational medicine infrastructure, which does not have UK members at present. Attendance of the 2013 ATMP platform meeting - presentation by Sophie Dale-Black on UK-wide regenerative medicine manufacturing activities and expertise. Attendance of the 2014 ATMP platform meeting - presentation by Mark McCall on cost of goods sold and its relationship to regenerative medicine manufacturing.

Visit by EATRIS senior management to EPSRC Centre. Follow-on activities under discussion - e.g. potential white paper, talks at European conferences etc. Visit to EPSRC Centre by Giuseppe Banfi of Galeazzi Institute, Milan, to discuss possible EU bids. Introduction of Giuseppe Banfi to Cell Therapy Catapult.</gtr:impact><gtr:outcomeId>5450ccaaaf7f53.29258892</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.epsrc-regen-med.org/outreach/promoting-the-uk-community/</gtr:url><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - Annual Summit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DB008718-59AE-4E19-BB7C-CD93C4711159</gtr:id><gtr:impact>Annual regenerative medicine manufacturing summit held, bringing together EPSRC Centre members with key collaborators from the clinical, commercial and regulatory areas.

Constructive discussions regarding the focus of EPSRC Centre research projects and initiatives - especially regulatory science, engagement, training and careers awareness.</gtr:impact><gtr:outcomeId>5450ceebcdf9d2.31416511</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - Towards 2020</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FBCDE826-81D0-463D-A8B8-646F5F64661C</gtr:id><gtr:impact>'Regenerative Medicine Manufacturing: Towards 2020' was published in September 2014 as a proposition to existing and new collaborators regarding ways of working with the EPSRC Centre. The publication demonstrated successes from the EPSRC Centre but primarily focused on identifying ways of working with collaborators for the next five years.

Follow-up with commercial collaborators who received the publication, discussions ongoing regarding new collaborative projects.</gtr:impact><gtr:outcomeId>5450df340a3ab2.70320450</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.epsrc-regen-med.org/news/regenerative-medicine-manufacturing-towards-2020/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - Nanomedicine European Technology Platform</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>40D058B0-616A-411D-90AF-A86602CCCDDF</gtr:id><gtr:impact>The EPSRC Centre joined the Nanomedicine European Technology Platform to represent UK academics in regenerative medicine manufacturing. Attended the 2014 annual general meeting.

Contributed to the ETP's map of collaborators to ensure good UK inclusion. Joined working groups in regenerative medicine and training/education. Contributed to strategic research and innovation agenda of the ETP through both working groups.</gtr:impact><gtr:outcomeId>544fbccce92a46.55947739</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.epsrc-regen-med.org/outreach/promoting-the-uk-community/</gtr:url><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - Galeazzi Institute</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0784FDF4-58E0-440F-9A0B-1311C546D61B</gtr:id><gtr:impact>Visit by Giuseppe Banfi to EPSRC Centre, to meet with Loughborough, Nottingham and Keele university representatives.

Discussion of possible collaborative EU funding bids. Reciprocal introductions of EPSRC Centre academics to members of Galeazzi Institute.</gtr:impact><gtr:outcomeId>5450cd1ba6d759.64579977</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.epsrc-regen-med.org/outreach/promoting-the-uk-community/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - UKTI visit to Loughborough University</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>382D7F7F-F404-4556-91F1-4A5C32B0289F</gtr:id><gtr:impact>Visit to Loughborough University by 25 British Embassy and Consulate representatives as part of a UKTI tour of the life sciences work in the UK. Loughborough, Nottingham, Keele, Birmingham and Leeds universities were engaged with the regenerative medicine component of this visit.

Follow-ups with embassies worldwide for further information on regenerative medicine research.</gtr:impact><gtr:outcomeId>544fb5b39e2025.14579122</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - Social Media</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4551DD69-00F9-40E8-9BE5-E027C19A9862</gtr:id><gtr:impact>Social media is used to promote and disseminate the EPSRC Centre's successes to academic, clinical and commercial contacts, and also to the public as a whole. Platforms used include Twitter (@RM_Outreach and @HEARTregenmed), LinkedIn (public feed plus group and company pages), Mailchimp (e-newsletters), Tumblr (HEART outreach).

Engagement of existing partners achieved in a smart way - short, directed messages and longer, aesthetically-designed e-newsletters. Engagement of new partners through public feeds on social media. Followers in excess of 1000 plus public feed immeasurable. Reach of messages enhanced through sharing/retweeting by EPSRC Centre members, the EPSRC itself and key partners such as the Cell Therapy Catapult.</gtr:impact><gtr:outcomeId>5450dcb22ce565.00887920</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.epsrc-regen-med.org/outreach/</gtr:url><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - REMEDIC Consortium</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F1081622-7FCC-495B-BFFE-4EE0DD65F8C5</gtr:id><gtr:impact>Attended workshop organised by the REMEDIC Consortium, to investigate the possibility of UK academics working with the existing consortium to source additional funding to extend the work of the consortium. The consortium did not contain any UK partners. Sophie Dale-Black presented on the regenerative medicine manufacturing expertise across the UK and invited consortium members to contact her for introductions to UK academics.

Introduction to ten Europe-wide academic and commercial organisations. Follow-up with academic partners ongoing regarding possible Horizon 2020 European funding bids.</gtr:impact><gtr:outcomeId>5450dd28e1e128.62521335</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.epsrc-regen-med.org/outreach/promoting-the-uk-community/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ECP050 TSB 1</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>55BB2F01-98F3-4F5B-AD95-8282EAE88FEC</gtr:id><gtr:impact>1st Tools and Services for Synthetic Biology TSB Workshop, Manchester, UK
60 Industrial Enterprise and Academic representatives attended a TSB workshop in Synthetic Biology, I presented key work of the EPSRC Centre which sparked questions and discussion afterwards.

Met two new collaborators with whom I had follow up meetings and discussions regarding collaborative research; 1 developed into a successful fellowship bid.</gtr:impact><gtr:outcomeId>544f85364723a5.58347467</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Bioprinting talk to NC3Rs workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8A989FB2-328A-4EC5-98FD-65BC07EF48A9</gtr:id><gtr:impact>The NC3Rs, Innovate UK and the Knowledge Transfer Network jointly hosted a workshop to advance the development and application of bioprinting approaches for improved efficacy and safety testing of drugs and other chemicals. A significant number of industrialists were present and the clinical translation and regulatory emphasis of the presentation given were of particular interest to the audience and led to some new planned interactions with industry partners.</gtr:impact><gtr:outcomeId>56dd69cc32dcb7.39736229</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>https://www.nc3rs.org.uk/events/bioprinting-for-more-predictive-efficacy-and-safety-testing</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - Bose Video</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EA7E3D76-8564-4FD4-99D5-A94CAADCFA33</gtr:id><gtr:impact>David Williams and Yang Liu interviewed for a Bose ElectroForce video regarding the EPSRC Centre's 'Hydrogels for treatment of intervertebral disc degeneration' project.

Publicity of the 'Hydrogels for treatment of intervertebral disc degeneration' project and demonstration of engagement with Bose ElectroForce as a commercial partner.</gtr:impact><gtr:outcomeId>544fb34c1a7230.08748538</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.epsrc-regen-med.org/news/epsrc-centre-and-dtc-members-appear-in-new-bose-electroforce-video/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Industry Day 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A2FD4BC5-1F85-495C-A4F3-F1C06E64E0F1</gtr:id><gtr:impact>The presentation of CIM output and capability has been made principally through the Industry Days. Usually annual, the most recent of these, a two-day event at Cambridge University (Madingley Hall) in January 2016 enabled researchers to showcase their work and to co-produce a series of research priorities with the delegates via workshops on day two. The output of the meeting has been briefed informally to the EPSRC and will form the basis of a White Paper after the current reporting round.</gtr:impact><gtr:outcomeId>56db0353d1d574.08289370</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Navigating Regulatory Requirements for Redistributed Manufacturing in Healthcare (MRC, London)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>78188448-8DBC-4B05-9B38-95B6E1FEE567</gtr:id><gtr:impact>This workshop in conjunction with the MHRA invited experts from a range of Universities and industrial companies to discuss and review future regulatory requirements for redistributed healthcare manufacturing.</gtr:impact><gtr:outcomeId>58aee5d51444e7.50306540</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - NOMs meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D62E1DDC-783F-4110-B038-B7C674F9C73C</gtr:id><gtr:impact>Organised one-day meeting for National Outreach Managers from EPSRC Centres. Delivered two talks - one on outreach/engagement in regenerative medicine manufacturing and one on using social media tools to perform outreach/engagement.

A number of National Outreach Managers adapted their social media strategies to include elements from our EPSRC Centre.</gtr:impact><gtr:outcomeId>544fb2c3791051.59762270</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ECP050 TSB 2</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>85830249-9F57-404C-90E2-B44F3C7323B3</gtr:id><gtr:impact>2nd Tools and Services for Synthetic Biology TSB Workshop, Cardiff, UK
60 Industrial enterprise and academic research representatives attended a TSB workshop in Synthetic Biology, I presented key work of the EPSRC Centre and the automation and scaling work performed at Loughborough University.

TSB Lead Technologist in Synthetic Biology requested a visit to my host department, the Centre for Biological Engineering at Loughborough University and to meet the EPSRC Centre team based at Loughborough.</gtr:impact><gtr:outcomeId>544f8850e6abb1.10385959</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - HEART Blog</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>89C39278-3102-4908-899D-FF9E9F75E732</gtr:id><gtr:impact>HEART blog (www.heartblog.net) is a collection of posts from 40+ students, researchers and academics who wish to communicate their research in the areas of Healthcare Engineering and Regenerative Therapies to the public, specifically to young learners of ages 11-19. The blog underpins the schools and public engagement work that is carried out by members of the EPSRC Centre for Innovative Manufacturing in Regenerative Medicine and the EPSRC-MRC Centre for Doctoral Training in Regenerative Medicine, with guest posts from the EPSRC Centre for Doctoral Training in Targeted Therapeutics and Formulation Sciences. The HEART blog features two posts a week, at 11am UK time on a Tuesday and a Thursday. During school holidays, this is reduced to one post a week. The blog is created through Tumblr and is cross-posted to the Twitter (@HEARTregenmed) and Facebook (www.facebook.com/heartblog) social media platforms.

The blog has had a total of 2,400 page views to date (Oct 27th 2014), with a returning visitor percentage of 40%. The blog also has an 'ask an expert' function where learners can ask questions of the scientists and engineers, allowing engagement with blog readers. The blog is used to follow-up after visits by researchers to schools to directly engage young learners.</gtr:impact><gtr:outcomeId>5450dea5b3c0e0.59997293</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.heartblog.net</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - Big Bang Fair 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>78E464DF-FD55-493E-995C-6719F56E6070</gtr:id><gtr:impact>Represented the EPSRC, at their invitation, on their stand at an event with a footfall of approx. 75,000. Approx. 5,000 school age learners estimated to have visited our stand. Research communicated included cell biology, scaffold creation and scale-up of cell culture.

Follow-up from teachers for future schools visits. Request from Rutherford Appleton Laboratory for a speaker for their schools engagement programme, Karen Coopman will be presenting in 2015. Increase in visitors to our blog www.heartblog.net which was promoted at the event.</gtr:impact><gtr:outcomeId>544fa5c7233d34.09204037</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.thebigbangfair.co.uk/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit and seminar at Wyss Institute</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9329D827-8A3C-4D67-8801-7926DB8FEBE4</gtr:id><gtr:impact>I was invited to give a talk on &amp;quot;Manufacturing Process Developments for Bioprinting and Tissue Engineering&amp;quot;. The audience of between 50 and 100 people consisted of Clinicians from the Massachusetts General Hospital and the Boston Childrens Hospital, research staff from Harvard, Wyss Institute research staff and a number of postgraduate researchers from Harvard.
The talk focused on two main areas of manufacturing process development to support bioprinting activities and the electrospinning of cell scaffolds and the application of design for manufacture principles to contribute to the clinical translation.
As a result, several discussions took place connected with bioprinting and electrospinning work funded by the EPSRC and potential collaborations are currently being explored.</gtr:impact><gtr:outcomeId>56dd68cc5402c2.68849955</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://wyss.harvard.edu/viewevent/478/manufacturing-process-developments-for-bioprinting-and-tissue-engineering;jsessionid=CEB65635A9901E3DB2BB4D312F3DFF6C.wyss1</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - Dragons Den Sandpit Event - Birmingham</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BF51DE6D-49A0-4B31-8623-02DBB833B181</gtr:id><gtr:impact>Dragons' Den sandpit event, themed on Opthalmology, attended by 26 participants and 9 mentors/clinical leads/facilitators.

One project funded with &amp;pound;50K of EPSRC Centre funding 'Electrospin &amp;amp; Electrostim'. Four other projects deemed fundable by the panel, teams being encouraged to follow-up discussions and submit bids to external funding agencies.</gtr:impact><gtr:outcomeId>54c7ac19a5e0b2.07282111</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ISO TC276 workshop on 'manufacturability'</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>267ECE91-401A-4163-A275-296C8A59F316</gtr:id><gtr:impact>The Centre has a leading role in the regenerative medicine work of ISO Technical Committee 276 (Bioprocessing) working alongside BSi and LGC. In November 2015 a workshop was held at Loughborough at the request of the Japanese delegation and convener (Heki, Tatsuo of FIRM) to examine the topic of 'manufacturability' i.e. that property of well-designed cell processes that can provide out-scalable manufacture. Nick Medcalf is leading this activity which will result in a white Paper in 2016 co-produced by the Japanese, US, UK and South Korean delegates.</gtr:impact><gtr:outcomeId>56d71979c7be82.47426923</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ECP007 Bioreactor Course 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E95B269F-BB3B-44C9-BB84-03479FDE713D</gtr:id><gtr:impact>Oral presentation at the bioreactor course.

Spoke to postgraduate students, academics and representatives from industry.</gtr:impact><gtr:outcomeId>54622a999c53c1.36196905</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://www.keele.ac.uk/bioreactorcourse/home/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - ARMA Training</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8E21EFFB-35FD-416A-BEAA-BF9C4830A0C4</gtr:id><gtr:impact>Head of Engagement invited to give training session on using social media to engage partners which was delivered as part of a collaboration-building training session for research managers and administrators. Average scores of 4.4 out of 5 for format and delivery and 4.2 out of 5 for content and materials.

Audience reported increase in knowledge of social media, and in particular how it can be applied to engaging partners.</gtr:impact><gtr:outcomeId>544fb24e84c7b6.35087798</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - Biomat-IN visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F403AB40-0C78-442E-BC8B-100B9FD091E1</gtr:id><gtr:impact>Visit to Loughborough University by members of the Biomat-IN consortium - laboratory tour plus meeting time with academics.

Follow-up discussions regarding ways of working together for EU funding calls.</gtr:impact><gtr:outcomeId>544fbbefa9f294.24702214</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.epsrc-regen-med.org/outreach/promoting-the-uk-community/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - UKTI proposition</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>30C991D7-A849-4BDE-A1E3-9B0C4AA632F3</gtr:id><gtr:impact>Worked with UKTI to incorporate EPSRC Centre's work into the UKTI regenerative medicine proposition, and to contribute to the representation of the national picture on behalf of the UK national community.

Publication through UKTI website and in-print. Publicity worldwide through a drive for incoming investment into the UK.</gtr:impact><gtr:outcomeId>544fb632484eb7.34822889</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://ukti.bellman.co.uk/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - Biomat-IN consortium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ACBA8AD4-E9F7-4B28-BEB2-A302AD952F03</gtr:id><gtr:impact>Invited to present at Biomat-IN consortium, to investigate possibility of UK regenerative medicine manufacturing academics working with the existing consortium to source additional funding to extend the work of the consortium. Sophie Dale-Black presented on the regenerative medicine manufacturing expertise across the UK and invited consortium members to contact her for introductions to UK academics.

Introduction to fifteen Europe-wide academic and commercial organisations. Follow-up with visit to Loughborough University by consortium members. Follow-up with academic partners ongoing regarding possible Horizon 2020 European funding bids.</gtr:impact><gtr:outcomeId>544fbaf18f0466.64544844</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.epsrc-regen-med.org/outreach/promoting-the-uk-community/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - Regen Med Careers Awareness Event</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>ACDA6244-1572-43AC-94F2-17CB4BAFD63A</gtr:id><gtr:impact>Over 55 students and postdocs from 12 institutions across the UK attended the UK's first careers awareness event in regenerative medicine, which we facilitated in conjunction with Regener8. Speakers and CV clinic mentors arranged from GSK, Lonza, SRG, TerumoBCT, Smith &amp;amp; Nephew, Puridify, Regner8, the Medical Technologies IKC, the University of Leicester, Loughborough University, the Cell Therapy Catapult, Intercytex, JRI Orthopaedics, SRG and the Scottish National Blood Transfusion Service. Review of the event published on EPSRC Centre website and opinion piece published in Orthopaedic Product News.

Increased awareness by early career researchers of roles in the regenerative medicine industry. Should contribute to reduced leakage of skills from the sector. Should reduce oversubscription to fellowship calls as alternatives have been highlighted.</gtr:impact><gtr:outcomeId>544f8cdd388160.73335649</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.epsrc-regen-med.org/news/review-of-the-first-national-regenerative-medicine-careers-event/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Education needs interview (The Telegraph)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C5516912-70CD-4511-A0AD-B3F388BC9ED1</gtr:id><gtr:impact>N Medcalf was interviewed by Helena Pozniak, a journalist at the Daily Telegraph for a feature on future job opportunities in medical technology as part of their &amp;quot;Careers of the Future&amp;quot; supplement. This is to show that it is technology as a growth area and explain why it offers significant opportunities for young people, as well as potential paths into a career in the field.

The release will come out on the 18th March, hence &amp;quot;Not aware of any impact&amp;quot; below.</gtr:impact><gtr:outcomeId>56d71ae867e3c3.15432851</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Medicines Agency consultation</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DE0F9ABC-560D-45E9-96C2-119F688E002A</gtr:id><gtr:impact>The Centre has been active within the European Regulatory area through an initiative with EATRIS. In 2015 a joint meeting was held with the European Medicines Agency at Canary Wharf with the objective of introducing the Centre/EATRIS initiative in distributed manufacturing. an invitation has been extended for Loughborough to put key research questions to the Committee for Advanced Therapeutics in 2016 which could result in cooperative effort to establish a collaborative program of work in EMA priority areas.</gtr:impact><gtr:outcomeId>56d719e1038bd8.46534789</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement Activity - Boston Mission</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>149468D3-333B-4F42-86F4-4579F8FD87E8</gtr:id><gtr:impact>The EPSRC Centre undertook a mission to Boston, USA, in collaboration with the UK Science and Innovation Network at the British Consulate-General, to explore the biomanufacturing activities ongoing in Massachusetts and to develop new relationships for cooperation in cell therapy and regenerative medicine. The mission delegates had the opportunity to meet with many Boston organisations, including the MIT BioMAN Research Program site, the Harvard Stem Cell Institute, the Massachusetts Life Sciences Center and companies Xcellerex and Joule Unlimited.

The mission allowed the promotion of the UK community's capabilities to a highly relevant US audience, sowing the initial seeds for future international collaborations.</gtr:impact><gtr:outcomeId>544fb6b83016c8.64019835</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.epsrc-regen-med.org/outreach/promoting-the-uk-community/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>139000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Impact Acceleration Account</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>2297143C-3539-4607-8625-F63FF8CE67E9</gtr:id><gtr:outcomeId>544e521fd85614.40262632</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>887759</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Fellowships in Manufacturing - Regenerative Medicine Manufacture: A Systems Based Research Platform</gtr:description><gtr:end>2018-11-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/K037099/1</gtr:fundingRef><gtr:id>C3DC76CB-C40D-4B1A-9449-875627A53A0C</gtr:id><gtr:outcomeId>5edc69de5edc69fc</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>402995</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sensor integrated Bioreactors (SIBs)</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Technology Strategy Board (TSB)</gtr:fundingOrg><gtr:fundingRef>101101</gtr:fundingRef><gtr:id>E069FEE5-1C41-4699-92DE-8128EC21073C</gtr:id><gtr:outcomeId>5ee0ab165ee0ab2a</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>91403</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KTA: Supporting the Improvement and Optimisation for Cell Culture for Regenerative Medicine Products Companies</gtr:description><gtr:end>2012-07-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>C8299636-434A-477A-ADDE-AF9B30A8C38F</gtr:id><gtr:outcomeId>5ed986c45ed986d8</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>185000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Stuart Jenkins Fellowship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/I017801/1</gtr:fundingRef><gtr:id>90A13EE5-5988-4F4B-8628-7769202B39DA</gtr:id><gtr:outcomeId>5eda15f85eda160c</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3499345</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UK Regenerative Medicine Platform Hub: Acellular</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>MRC Headoffice</gtr:fundingOrg><gtr:fundingRef>MR/K026682/1</gtr:fundingRef><gtr:id>CD64913D-868A-47A9-B8CF-87BFAE52E51B</gtr:id><gtr:outcomeId>5450ed60a4e4e7.11602616</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2884739</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>E-TERM</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/I017801/1</gtr:fundingRef><gtr:id>D3141541-C4D9-4C89-9C77-237DFDEBE741</gtr:id><gtr:outcomeId>5eda15265eda153a</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>59468</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>High resolution live cell imaging tool for early predication of cell quality and safety</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>University of Nottingham</gtr:fundingOrg><gtr:id>5254E33C-91D8-4901-A042-4A14EAEBB442</gtr:id><gtr:outcomeId>5ee3055a5ee3056e</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>55000</gtr:amountPounds><gtr:country>Iraq, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Fully Funded Studentship - Uni of Kurdistan Hewler</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>University of Kurdistan Hewler</gtr:fundingOrg><gtr:id>5923E0D0-EF76-4AB4-A3F1-ABF09FD7252A</gtr:id><gtr:outcomeId>5ebff3bc5ebff3d0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>98147</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Enduring Challenge Competition (human performance - medical)</gtr:description><gtr:end>2015-11-02</gtr:end><gtr:fundingOrg>Defence Science &amp; Technology Laboratory (DSTL)</gtr:fundingOrg><gtr:fundingRef>DSTLX1000088675</gtr:fundingRef><gtr:id>7A2D96BF-F4BD-47DE-A795-E359F1C89BDC</gtr:id><gtr:outcomeId>544e52dabb7024.55410376</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>452430</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developing generic scaleable and standardised selection methods for human therapeutic cells</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/I017143/1</gtr:fundingRef><gtr:id>00D5E76F-6F11-4034-ABD9-DADFA651F3D5</gtr:id><gtr:outcomeId>5ee50ac65ee50ada</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>308637</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Bar-Coded Biomaterials</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/H005625/1X</gtr:fundingRef><gtr:id>7F9D2B6B-3919-4859-9E7C-C41885C3882B</gtr:id><gtr:outcomeId>5ed94baa5ed94bbe</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>733386</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Self assembling liposome nano-transducers</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/J001953/1</gtr:fundingRef><gtr:id>507C6991-C337-4D01-A482-A6834987DAE2</gtr:id><gtr:outcomeId>5edabe905edabea4</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Construction of a miniaturized human lymph node model as an alternative to the Local Lymph Node Assay</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:id>9EC10110-F67A-46D4-8C57-600EC857C64E</gtr:id><gtr:outcomeId>5ec92c0c5ec92c20</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>402880</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Rational Bioactive Materials Design for Tissue Regeneration</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>262948-2</gtr:fundingRef><gtr:id>9CCAE219-C56B-4CA9-97D0-5D58498D23C9</gtr:id><gtr:outcomeId>5ec5f6725ec5f686</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>12000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Institute of Orthopaedics</gtr:fundingOrg><gtr:fundingRef>RPG 139</gtr:fundingRef><gtr:id>12BE769E-BDCB-483F-9A46-E1572B857174</gtr:id><gtr:outcomeId>544e5473c782f9.84410264</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>65914</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Additional Funds to EPSRC Centre for Innovative Manufacturing in RM</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/H028277/1</gtr:fundingRef><gtr:id>AF757466-A169-4C66-9273-A844BB1514DF</gtr:id><gtr:outcomeId>5ed985c05ed985d4</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>348000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BIODESIGN: Rational Bioactive Materials Design for Tissue Regeneration</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>262948-2</gtr:fundingRef><gtr:id>10F62EC9-AD58-488D-BD1D-87027EF73958</gtr:id><gtr:outcomeId>5ec5f7265ec5f73a</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>98735</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Stem Cells as Therapeutic Agents in Arthritis</gtr:description><gtr:end>2013-11-02</gtr:end><gtr:fundingOrg>The Dowager Countess Eleanor Peel Trust</gtr:fundingOrg><gtr:id>8C29EB09-F1A3-44EC-81AC-560215787DCA</gtr:id><gtr:outcomeId>5ec4bbf45ec4bc08</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50291</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KTA: Supporting the Regulation and Reimbursement of Regenerative Medicine Products in the UK</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>AF1298B1-B995-4609-93DB-C8E5EB5D4D2C</gtr:id><gtr:outcomeId>5ed98ab65ed98ad4</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>21000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>skelGEN</gtr:description><gtr:end>2016-11-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>8107A445-341D-40F2-B0FA-676D9A0C9CA0</gtr:id><gtr:outcomeId>5ec6efd25ec6efe6</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>17488</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A hub for engineering and exploiting the stem cell niche</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>MRC Headoffice</gtr:fundingOrg><gtr:fundingRef>MR/K026666/1</gtr:fundingRef><gtr:id>C77910F9-88B2-4AE8-96D5-FA66559469CC</gtr:id><gtr:outcomeId>5450ee96a37ce1.65834158</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1294482</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Engineering Biological Science-Processes and Systems for Haematopoietic Stem Cell Based Therapy Manufacture</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/K00705X/1</gtr:fundingRef><gtr:id>2B628A9E-519A-4D23-898F-442EFEC478FA</gtr:id><gtr:outcomeId>5edbde4c5edbde60</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Grant from Anne Duchess of Westminster Charity</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>Anne Duchess of Westminster Charity</gtr:fundingOrg><gtr:id>B8818E07-F80F-48B1-97D0-47C1E89EA583</gtr:id><gtr:outcomeId>544e54ff3bafe3.44418128</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>98000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Grant</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>The Dowager Countess Eleanor Peel Trust</gtr:fundingOrg><gtr:id>DBC6E022-51F6-4A79-AB74-26533BBB39CD</gtr:id><gtr:outcomeId>544e53bb790378.41055577</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Redistributed Manufacturing in Healthcare Network - Feasibility Studies</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/M017559/1</gtr:fundingRef><gtr:id>F462F0CC-BB2C-4334-B13D-0EED751769F5</gtr:id><gtr:outcomeId>56d59555a28a89.42246584</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>154000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Equipment purchase of BD Jazz Cell Sorter</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Loughborough University</gtr:fundingOrg><gtr:id>483D9BEC-CEA1-4A7F-8BE7-A5DFF6B73CC6</gtr:id><gtr:outcomeId>5ede89b25ede89c6</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>583461</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Translational Scheme</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>92ED7A79-364C-468F-A354-8F1B0A81E9F4</gtr:id><gtr:outcomeId>544f79b34f22f7.47188487</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>47137</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>The Leverhulme Trust/Royal Academy of Engineering</gtr:department><gtr:description>Research Fellowships Scheme (Marianne Ellis)</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>Royal Academy of Engineering</gtr:fundingOrg><gtr:id>36655F1D-7964-4CB5-908C-14ABA50E4B5C</gtr:id><gtr:outcomeId>58c42661121173.22849054</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Nottingham Catalyst Partnership Fund</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>University of Nottingham</gtr:fundingOrg><gtr:id>2A9BC6CD-C701-4BC0-BEE8-8AEA32A8B2D1</gtr:id><gtr:outcomeId>544fb05a5bbc40.18775418</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>141694</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KTA: Supporting the Establishment and Validation of a Regulated Manufacturing Facility for Contract Research and Manufacturing of Cell Therapies</gtr:description><gtr:end>2012-07-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>5C0A7FDE-03F4-4C38-BAD0-4F913DC17E7E</gtr:id><gtr:outcomeId>5ed98b885ed98b9c</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>535000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Contract Process Development</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Cell Therapy Catapult</gtr:fundingOrg><gtr:id>5C9F7CFB-6103-41A6-BBD6-6CCC19E4E56D</gtr:id><gtr:outcomeId>544f79157f18a1.91419570</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>12000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Defining the mechanisms on anti-inflammatory and chondroprotective effects of MSCs in arthritis</gtr:description><gtr:end>2013-11-02</gtr:end><gtr:fundingOrg>Institute of Orthopaedics</gtr:fundingOrg><gtr:id>0B3AA13C-C8FA-48F7-A44D-197608B8897C</gtr:id><gtr:outcomeId>5ebff8445ebff858</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>131000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Modifications to CBE laboratories to increase capacity</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>Loughborough University</gtr:fundingOrg><gtr:id>930AC3FA-8FC7-45E6-AF1C-BB0A222E1C32</gtr:id><gtr:outcomeId>5ede88ea5ede88fe</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>325501</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Bioprocessing Research for Cellular products</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/I017062/1</gtr:fundingRef><gtr:id>F92A9972-C86E-4B8D-AAFA-136BD9D479B0</gtr:id><gtr:outcomeId>5ee509ae5ee509c2</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>713417</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Arthritis Research UK Tissue Engineering Centre</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:fundingRef>19429</gtr:fundingRef><gtr:id>A90A837A-F584-4FF3-8CAD-7384CFEF28EA</gtr:id><gtr:outcomeId>5ec15cf25ec15cfc</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>534000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC National Centre</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/H028277/1</gtr:fundingRef><gtr:id>92713880-FF81-4142-B43D-BCC9B120C072</gtr:id><gtr:outcomeId>5ed80f245ed80f38</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>922367</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Supporting regenerative medicine and cell therapies</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Technology Strategy Board (TSB)</gtr:fundingOrg><gtr:fundingRef>32065-222136</gtr:fundingRef><gtr:id>771CF786-E363-43B9-A94F-20DAF2FE7FDD</gtr:id><gtr:outcomeId>544f73bc1cedd3.30554404</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Centre's impact on Industry: Quotes from Collaborators giving examples of the Centre's impact on Industry.

The Centre has made significant impact within the Regenerative Medicine Industrial community as evidenced by the following quotes:

From Dr Amr Abid, Head of Strategic Growth &amp;amp; Development, Life Sciences, GE Healthcare:

&amp;quot;GE Healthcare Life Sciences had the opportunity to experience first-hand the uniqueness of the EPSRC Centre for Innovative Manufacturing in Regenerative Medicine at Loughborough University by working on industrial process development for our human cardiomyocytes differentiation from human stem cells. The Centre has combined in one team different capabilities, skills and talent in engineering and biology coming from industry and academia. This unique and rare blend of people, expertise and capabilities has been, and is still, extremely valuable for the project we have been working on.&amp;quot;

From David Newble, CEO, TAP Biosystems:

&amp;quot;I am writing to endorse the collaborative support we have received from the EPSRC Centre for Innovative Manufacturing in Regenerative Medicine. In particular they have highlighted regulatory changes required to remove barriers to establishing cell therapy processing capabilities in hospital environments - a major hurdle for the adoption of certain cell therapies.&amp;quot;

From Guy Parkes, Head of Special Projects, Anthony Nolan:

&amp;quot;The automated process that we use to extract stem cells from an umbilical cord blood collection is one of the major limiting factors in our processing chain. Our work with the team at Loughborough analysing our existing protocols and experimenting with new solutions has allowed us to both understand the limitations of our current processing system with regard to cellular yields and to identify a new method to substantially improve those yields.&amp;quot;

Hermann Hauser, 'Review of the Catapult Network: Recommendations on the future shape, scope and ambition of the programme' November 2014:

&amp;quot;The CTC is able to work with Loughborough's recognised experts in the manufacture and quality control of cells and tissues used in cell therapy, as well as linking with the University's Engineering and Physical Sciences Research Council (EPSRC) Centre for Innovative Manufacturing and its Doctoral Training Centre in Regenerative Medicine.&amp;quot; 

1. Introduction

(The items listed here that are cited under the individual output sections of ResearchFish are included in order to provide a continuous narrative only. The references given in square brackets may be found in the 'Publications' section.)

As one of sixteen EPSRC Centres for Innovative Manufacturing, the EPSRC Centre for Innovative Manufacturing (CIM) in Regenerative Medicine was created in 2010 and was led from Loughborough University in the UK, in partnership with complementary groups at Keele University and The University of Nottingham. Each university brought its own expertise to create a unique partnership combining leadership in regulated manufacturing, tissue engineering and clinical science.

As a National Centre, the EPSRC Centre has had an engagement programme that brought together the UK regenerative medicine manufacturing community to create a distributed centre of excellence.

The EPSRC Centre was closely aligned with the EPSRC-MRC Centre for Doctoral Training in Regenerative Medicine and the E-TERM Landscape Fellowships Programme providing an integrated platform of fundamental and translational research. The EPSRC Centre for Innovative Manufacturing in Regenerative Medicine has worked to equip the industry with manufacturing tools, technologies and platforms by considering the supply chain from end to end. We have utilised a systems approach to draw together the many processes involved in transferring the right therapies to the right patient at the right time.

The CIM builds on synergies between the three main universities. Keele University has provided an especially close connection with clinical application though its work with the RJAH Orthopaedic Hospital at Oswestry. The practical, logistical and clinical insight that this collaboration brings has made it possible to ensure that the CIM innovation and regulatory insights are grounded in the practical realities of the hospital setting. Nottingham has a strong materials background. The work by the group under Prof Kevin Shakesheff in thermoreversible scaffold polymers to allow integration of cell manufacture and administration reflects this. During the last three years the especial emphasis of the Nottingham work has been on integrating cell and polymer bioprinting as described below. The role of Loughborough has been twofold. On the one hand Loughborough has brought the application of automated solutions to cell processing into applications-based research. On the other hand Loughborough has focused on the regulatory context of the manufacturing research, leading to a succession of papers on the business, regulatory and quality assurance challenges and how these might be addressed.

The CIM was originally structured with three major research themes: manufacturing and automation, characterisation and control, and delivery and 3D constructs. These reflected the capability of the Centre partners and the key requirements of industry. The CIM went through its international mid-stage review in April 2013. The review panel for this was chaired by Michael May, President and CEO of the Centre for Commercialization of Regenerative Medicine (CCRM), Toronto, and included international and national academic and industrial members in addition to EPSRC and TSB observers. 
The mid-stage review had a positive outcome with recognition of the role and potential of the Centre nationally and internationally. In summary, the review identified the Centre as 

&amp;quot;..one of a few that understands and addresses cell manufacturing bottlenecks - a critical gap in regenerative medicine commercialization&amp;quot;. Underpinning this, the review identified the following strengths:
? Partnership between three institutions, each bringing unique capabilities: Loughborough, with its industry perspective and focus on process, scale and quality systems; Nottingham, with its academic research focus and depth; and Keele with its clinical capabilities.
? A strong culture of training and programmes in place to deliver highly qualified personnel with unique skill sets.
? Visionary leadership tied to an extensive network of academic and industry contacts.
? Excellent governance and good record keeping, with external Board representation.
? Industry input to provide market pull, balancing the technology push of academia; projects that address &amp;quot;real-life&amp;quot; problems in the field.
? Records indicating a rigorous, stage-gated project approval/review process.
? Initial funding for an ambitious national outreach plan to connect key institutions advancing Regenerative Medicine and Cell Therapy across the UK.&amp;quot;

The review identified several major achievements attributed to the strengths of the Centre:
? The CIM had widened its scope and mandate and maintained strong collaboration among the three institutions.
? The CIM had identified and funded a substantial pipeline of projects in a relatively short period of time.
? The CIM had attracted industry to support projects and commit time to advisory roles and Board positions.
? This had brought scientists with different backgrounds and perspectives together, creating &amp;quot;common language and understanding&amp;quot;, which is critical to success in such a multidisciplinary, emerging field.
? Management had leveraged the Centre to create new opportunities and attract new funding to a core network of investigators.
? The CIM had created links with other key players in the UK regenerative medicine research system (e.g., the Cell and Gene Therapy Catapult).

Recognising the dynamic nature of the UK landscape/innovation system for regenerative medicine and its impact on the Centre, the review panel did, however, advise that to maximize its impact and track towards sustainability, the Centre needed to clarify and reinforce its vision, address succession of its leadership and make key strategic changes to its project portfolio. An action plan in response to these recommendations was successfully delivered within six months (October 2013). As a consequence, the EPSRC Centre's vision and strategic objectives (including outreach strategy) were updated, taking account of changes to the UK funding environment, in particular the Cell and Gene Therapy Catapult (CGTC, then the CTC) and the Joint Research Councils UK Regenerative Medicine Platform (UKRMP). Prof Nick Medcalf became Director of the EPSRC Centre for Innovative Manufacturing in Regenerative Medicine on 1st September 2014, succeeding the founding Director, Prof David Williams OBE. A flagship cross-institution disruptive challenge project started in November 2013. This signalled the next phase of the EPSRC Centre's research, which, by integrating key manufacturing technology themes (personalised 3D bioprinting, product characterisation and closed-loop process control) using a framework based on regulatory science, has successfully addressed significant translational bottlenecks in the industry.

1.1. The original themes

The original three themes during the first review period of the CIM were compiled under the directorship of Prof David J Williams. These themes interacted in terms of their emphasis on control of processes and the role of automated equipment.
Work in manufacturing and automation built upon the achievements of the remedi Grand Challenge but with a strong focus on near-patient cell processing. The projects examined the creation of novel modular process equipment for use in hospitals (with TAP Biosystems and Dana Farber Cancer Institute, Harvard), media-conditioning equipment (with Ruskinn), novel platforms for adherent culture to reduce the cost of goods (resulting in two patents), and culture in hydrostatic conditions (with Tissue Growth Technologies [Henstock 2013]). A strongly emerging theme was the management of biological variation by process design to reduce its effect. This was demonstrated in a clinical setting with the Anthony Nolan Trust [Win Niang 2015], and for human embryonic stem cell culture [Ratcliffe 2013] and cryopreservation [Mitchell 2014]. Work on near-patient processing identified the significant regulatory issues with transferring manufacture to multiple sites and the interaction between manufacturing strategy and regulation. An influential consensus white paper developed with industry shared these issues [Hourd 2014] and led to work in the key areas of quantification of biological variation (with Dana Farber and from the literature [Thurman-Newell 2015]) and the development of techniques and methods of demonstrating process comparability [Archibald 2015]. As part of PhD Candidate Jamie Thurman-Newell's project, a collaboration was struck between the Boston hospital and LU, to investigate the extent of biological variation within clinic and explore potential cell processing issues. This resulted in two on-site visits and the collaborators are now writing a joint paper. This theme has been continued as a main focus of the Loughborough involvement in the UKRMP Pluripotent Stem Cell Platform. Later work has begun to explore the manufacturing problems at the boundary of regenerative medicine and synthetic biology. 

A second aspect of the automation theme was research focussed on the use of statistical models within a Quality-by-Design framework to improve cell processing. The challenges that were addressed included selecting assays that had sufficient throughput and were informative enough to develop meaningful models of cell function. In particular the Centre published exemplars of the use of focussed (via appropriate risk assessment) and linked statistical models to greatly improve reproducibility and quality of high risk process operations such as cryopreservation [Ratcliffe 2013 and Mitchell 2014].

Delivery and 3D constructs was a third area of research and this was developed into a leading activity following the mid-term review. The detail is described below.

1.2. Research themes following the mid-term review
After the mid-term review there were a further three themes, linked by an emphasis on the regulatory challenge that must be addressed before technology can be deployed.
'Regulatory science' was an integrating project, overarching the other three:

&amp;quot;.. the science that will inform and enable robust regulatory decisions by both influencing and informing the regulator and assisting the manufacturer in providing the knowledge base to deliver confidence in these products&amp;quot;. EPSRC Centre Manufacturing Industrial Summit, 2012

As part of its systems approach to the manufacture and translation of Regenerative Medicine, the Centre has built in a strong and strategic regulatory science component across the project portfolio. In the description given here the regulatory-related activity of the CIM is recounted for the whole life of the Centre and not merely the activity following the mid-term review. However, the emphasis on this aspect grew in the second half of the term. In addressing important issues identified in these and other parallel research activities, such as the TSB-funded VALUE project, and by industry stakeholders at the 'EPSRC Centre Manufacturing Industrial Summit' in 2012, new concepts addressing the major challenges for the manufacture and commercialisation of autologous and 3D tissue engineered therapies were developed. Captured in a two key positioning papers this work has contributed directly to the Centre's increased engagement with the UK regulator (MHRA), the European Regulator (EMA) and other stakeholders, including the Harvard Stem Cell Institute and the International Society for Cellular Therapy (notably via input to consultations on EU and US regulatory guidance by its Commercialisation Committee) and has directly influenced national policy with input into the Regenerative Medicine Expert Group (RMEG) (one of the key consequences of the House of Lords Report). 

&amp;quot;building stronger links between the regulators and those who are regulated would be a vital step in overcoming the difficulties of GMP requirements&amp;quot;. House of Lords Science and Technology Committee report on Regenerative Medicine, July 2013

This work continues to influence manufacturing themes in healthcare via input into feasibility studies currently being undertaken by the EPSRC Re-Distributed Manufacturing in Healthcare Network (RiHN), in particular the 3-D Bioprinting and Cell Microfactories feasibility studies.

In parallel with other research activities, for example under the UKRMP Pluripotent Stem Cell Platform (PSCP), the Centre has also driven or been involved in a number of national and international industrial and academic workshops in the regulatory science space (upstream of the CGTC). The most significant of these were the Centre-led Industry translation session at International Society for Cellular Therapy regional meeting (Philadelphia, Sept 2013), the 'Safety &amp;amp; Starting Materials' workshop (Sheffield, 8-9th Jan 2015, and the Comparability &amp;amp; Characterisation' workshop (Cambridge, 14-15th Sept 2015).

Providing valuable insight into issues faced by regenerative medicine businesses, another key role of the Centre has been to provide regulatory support to regenerative medicine SMEs via the creation of a specialised role funded by the EPSRC Knowledge Transfer Account at Loughborough. Examples of companies that have benefited from this work include Organogenesis, TAP Biosystems, Cell Medica, Videregen and Intercytex, with the products ranging from stem cell treatments to wound-healing matrices. Through this role and via membership of standards committee at the British Standards Institute, the Centre has made significant contributions to three regulatory guidance documents relating to the development of cellular medicines (PAS93:2011, PAS83:2012, PAS157:2015). This work has enhanced the regulatory knowledge of the Centre, provided input into teaching materials for the Doctoral Training Centre programme and input into the development and validation of the Cell Therapy Manufacturing Facility of the Loughborough Centre for Biological Engineering.

Throughout its lifetime, the Centre has indirectly influenced [Hourd 2014 and Hourd 2015] regional, national and EU policy, with invited evidentiary input into programmes such as the GO-Science Foresight 'Future of Manufacturing' project, which was presented directly to Vince Cable (Secretary of State for Business, Innovation and Skills) and the Ministerial Industry Strategy Group future strategy for medicines manufacture in the UK. This has been complemented by sustained input into several targeted stakeholder consultation programmes, including consultation on Department of Health's Advisory Committee on the Safety of Blood, Tissues, and Organs (SaBTO) cell therapies guidance; on diagnostics for Stratified Medicine (Catapult); on the Foundation for the Accreditation of Cellular Therapy (FACT) Common Standards guidance and consultation with BSI on the application of Quality by Design (QbD) to cell therapy development and standards for evaluation of materials. In November 2015 the Centre contributed to the development of Good Manufacturing Practice for Advanced Therapy Medicinal Products (European Commission). 

Under the Regulatory Science Work Package were three technical work packages. The first of these was the Closed-loop control activity. The purpose of the project, closely linked to the following 'Sensors' project, has been to examine the impact that management of cell culture using responsive feeding could have on the otherwise open-loop menu-driven culture that is usual for manual T-flask systems. There were two main areas of work in this section of the program. The first involved the modification of bioreactor vessels in order to achieve bleed-feed loops for nutrition management and resulted in manual in-house modification of the disposable vessels in the AMBR bioreactor system to enable progressive medium replacement and adjustment. (The AMBR is a workhorse piece of equipment in the CBE, manufactured by TAP Biosystems.) The second focussed on a worked example of real-time management of medium composition to drive the growth of chondroprogenitor cells. Preliminary studies using bovine cells from primary tissue were conducted. Further work is being continued under the EPSRC Fellowship held by N Medcalf (EP/K037099/1)

The published regulatory guidance from the US and the EU highlights the importance of on-line and at-line bioprocess monitoring and control. Currently there exist fundamental engineering science challenges that limit the state-of-the-art process analytical technologies to address this need. Specificity of signal and avoidance of fouling of sensors are amongst the biggest of these challenges. To address these challenges, in the 'Sensors' project we explored a novel nonlinear acoustic detection technology for rapid receptor-based detection of biological cells and proteins. This was implemented on a 14.3 MHz quartz crystal resonator, which was driven at relatively high oscillation amplitude and acceleration (~million g). The resulting inertial loading on the attached bioparticles was observed to dissociate non-specific binding from the sensor surface, reducing fouling. The use of aptamers as bioreceptors further improved the specificity of detection. The entirely electronic detection technology implemented on a microfluidic cartridge is modular and favours easy integration with the cell reactor for online biological monitoring. The current research, extending beyond the life of the CIM, is focusing on studying the heat transfer and fluid mechanical problems for thermal stability, and fast and efficacious capture of bioparticles. This project has recently received funding from BioProNET, a BBSRC supported network, to work with the Centre for Process Innovation (CPI), a Catapult Centre, to feasibility test the technology with industry-relevant biomolecules and conditions.

The Bioprinting/customised products work package (Joel Segal) has focussed on potential future clinical translation of the bioprinting process for personalised/customised combination products. Throughout the project, there has been substantial and regular clinical review (surgeon and prostheticist) which has provided essential inputs about establishing product specifications, defining critical parameters and the testing and verification required. This meant that the design of the product has been optimised for clinical need. A strongly emerging theme was the lack of a current regulatory framework for these product scenarios. This has led directly to a feasibility study project supported by the Redistributed Manufacturing in Healthcare Network (EPSRC - EP/M017559/1)

Key achievements are:-
? Development of a process to 3D-print tissue engineering nose constructs based on medical scans.
? Creation of a bespoke insulated enclosure to control the bioprinting environment (air temperature and cooling air flow rate).
? Development of an effective printing process for polycaprolactone and hydrogel (temperature settings, print extrusion rate, etc.).
? Study and understanding of the effect of hydrogel formulation on printing fidelity and cell viability.
? An optimal scaffold design was agreed with the surgeon and created using 3D modelling software - The scaffold needed to be as thin as possible but porous enough to enable a suturing needle to pass through without excessive force. Slots were included to house cartilage plates.
? Produced software to allow finer control of the 3D print path and printing parameters for test samples than off-the-shelf software: The program enabled a novel print path concept to be utilised for control of surface porosity. The effect of surface porosity was quantified for compressive modulus, suturing forces, cell seeding and cell proliferation [Ruiz-Cantu 2016]. Software was developed to generate printer control code for a full 3D nose model. It enables fine control over the porosity:
? Several different print configurations were utilised and two polymer types to achieve a range of scaffolds. Feedback from the surgeon suggested the scaffolds were ideal for this application.

The work has also been presented at several conferences including Biofabrication 2015, TCES 2015 and TERMIS 2015. 

2. Impact channels

(International impacts, both academic and industrial, are included in section 3.) The presentation of CIM output and capability has been made principally through the Industry Days. Usually annual, the most recent of these, a two-day event at Cambridge University (Madingley Hall) in January 2016 enabled researchers to showcase their work and to co-produce a series of research priorities with the delegates via workshops on day two. The output of the meeting has been briefed informally to the EPSRC and will form the basis of a White Paper after the current reporting round. 

The CIM has directly and indirectly benefited industry (manufacturers and equipment providers), academia, trade organisations and regulatory and standards bodies as noted above. The industrial influence has been upon translation and practice.

The Cell and Gene Therapy Catapult was established during the middle period of the EPSRC Centre funding period. There was a natural alignment between the Centre and the Catapult with the former able to supply emerging technologies, equipment and specialist services to the latter. The Centre signed a memorandum of understanding with the CGTC early in its operation, and subsequently a framework agreement to facilitate rapid deployment of packages of work. This collaborative relationship continues as part of the Centre's sustainability and forms a pipeline through which the Centre ensures that its research is positioned slightly upstream of the CGTC, providing tools, techniques and insights to operation (e.g. the work on distributed manufacture, which aligns with the CGTC theme of 'seamless freight'). The significant amount of industry work, especially by Rob Thomas' group, is partly a result of this close working relationship.

The previous CEO of TAP Biosystems (now Sartorius), David Newble, commissioned a study with the CIM to evaluate the impact of the lack of a centrifugation step in the TAP cell therapy automated cell culture platform, CompacT SelecT&amp;reg;. This study (valued by TAP at &amp;pound;103k) was incorporated in the EPSRC Centre project EP051 in June 2013. Results of the testing with various cell types have been reported by the EPSRC Centre and by TAP in their marketing brochures [Archibald 2015, Archibald 2016, French 2015]. Since the first purchase of the CompacT SelecT&amp;reg; platform by the Centre for Biological Engineering there have been many publications on the benefits of automation of cell culture and has resulted in increased sales of the machine around the world, helping to establish it as a platform technology. The EPSRC Centre also contributed to an international effort for enabling consistency in stem cell derived products leading to the experimental design of the project.

As part of PhD candidate Jamie Thurman-Newell's project, collaboration was initiated between the pharmaceutical giant GSK and LU. The aim of this collaboration was to examine how to address the processing and variation issues within cell therapy. This continued over a three year period and resulted in useful feedback that informed both industrial and academic direction. This concluded in a seminar given to the GSK Cell and Gene Therapy team

Prior to the Centre the team had worked with ReNeuron to develop an automated process for manufacture of their lead clinical cell line, CTX, currently in Phase I/II trials for stroke therapy. The Centre went on to collaborate with ReNeuron to define a robust upstream process for production of CTX cells that would enable delivery at phase III clinical trial and market scale. This relationship continues to grow with a pipeline of work planned to support ReNeuron's large scale clinical manufacture. 

Baker Ruskinn played a pivotal role in two CIM projects in addition to contributing to the Mid-term Review. Projects which befitted directly from Baker Ruskinn participation were the Hypoxycool project and the Invertebral disc engineering project. Baker Ruskinn have now licensed the Hypoxycool IP from Keele University and have subsequently developed a commercially-available product. The intervertebral disc project stimulated a technology redesign within Baker Ruskinn such that their hypoxia workstation can now incorporate flexibility to accommodate bioreactor products.

Asymptote is a globally-significant specialist company delivering cryogenic equipment to the industry. The CIM has built an excellent relationship with Asymptote and this has resulted in a successful bid for InnovateUK funding to develop a bioartificial liver device.

The Centre and UCL have worked hard to sustain a strategic relationship. This is evidenced by a number of joint proposals and more particularly by the Joint UCL-Loughborough bid for the Cell Therapy Catapult. This made it to the final interview stage as one of three candidates. More recently the 2014 Loughborough-UCL bid for an EPSRC Manufacturing Hub (Medcalf and Velayudhan) passed the EOI stage.

The work of remedi and more recently the CIM has supported and given context to the doctoral training activity. A successful start to the DTC programme led to the award of an E-TERM (Engineering Tissue Engineering and Regenerative Medicine) EPSRC Landscape Programme, bringing together for the first time the six University DTC teams (Loughborough, Nottingham, Keele, Leeds, Sheffield and York). This programme provided an opportunity to combine the research strengths of the six institutions to deliver a strategic collaborative programme of cross-disciplinary research, and to further develop a cohort of future multidisciplinary research leaders. Twelve Early Career Fellows have been appointed to date, located at Sheffield, York, Keele, Nottingham and Loughborough universities, of which eight have now completed their individual research programmes. 

The CIM has assisted Innogen with their recent surveys and report to BSi relating to Standards and Regulations for advanced therapeutics. The work at Innogen and at the CIM is complementary in the area of viable business models for the sector and currently Joyce Tait, Geoff Banda and Nick Medcalf are planning a collaborative workshop with industry and clinicians on this topic for later in 2016.

The relationship between the Centre and the MHRA has been very strong and we will continue to nurture this pathway to impact. John Wilkinson (Director of Devices, MHRA) is using the CIM 3D bioprinting paper within MRHA as a benchmark for ways of working to inform regulation in this area. Ian Rees (MHRA Inspectorate) is a regular correspondent in meetings informal and formal and has contributed valuable insights to the research.

The Centre occupies an important position in the emerging standards and guidance via BSi. On the international stage the Centre has a leading role in the regenerative medicine work of ISO Technical Committee 276 (Bioprocessing), working alongside BSi and LGC. In November 2015 a workshop was held at Loughborough at the request of the Japanese delegation and convener (Heki, Tatsuo of FIRM) to examine the topic of 'manufacturability' i.e. that property of well-designed cell processes that can provide out-scalable manufacture. Nick Medcalf is leading this activity which will result in a white Paper in 2016 co-produced by the Japanese, US, UK and South Korean delegates.

Keele University (El Haj) has been an important contributor to EMA initiatives such as the 2012 Workshop on Focus Groups: a model for fruitful interaction between the CAT and its interested parties. The Centre has also been active within the European Regulatory area through an initiative with EATRIS. In 2015 a joint meeting was held with the European Medicines Agency at Canary Wharf with the objective of introducing the Centre/EATRIS initiative in distributed manufacturing. An invitation has been extended by the EMA for Loughborough to put key research questions to the Committee for Advanced Therapeutics in 2016 which could result in cooperative effort to establish a collaborative program of work in EMA priority areas.

The CIM provided written and oral evidence to the 2012 - 2013 House of Lords Science and Technology Committee Inquiry into Regenerative Medicine. The oral evidence was focussed on manufacturing and was sought from a panel made up of David Newble of TAP Biosystems, Keith Thompson CEO of the CGTC and David J Williams of Loughborough [HoL 2013].

The House of Lords Inquiry led to the formation of the Regenerative Medicine Expert Group in order to address the key issues identified. David Williams was on the expert group. The Centre made particular contributions to the Regulation and Licencing Subgroup (via Williams, Medcalf and Chandra) in particular using evidence of the complexity of near-patient processing issues to signal regulatory issues [RMEG 2014].

The joint Innovate-MRC Biomedical Catalyst has been the major national intervention to support medical technology innovation in industry and was put in place as a consequence of the downturn. David Williams served as a member of its Major Awards Committee.

The Centre has occupied a strategic role in the international research and policy community in regenerative medicine. The items below are illustrative. One of the most significant translational centres internationally is CCRM (the Canadian Centre for Regenerative Medicine). The Centre has cultivated and continues to cultivate a strategic relationship with CCRM. Significantly Michael May, the CCRM CEO, led the mid-term review. The Centre and CCRM have collaborated in particular by means of DTC/CDT student secondment and co-publishing especially on adoption issues [Rose 2012].

The CIM has focussed on ISCT (The International Society for Cell Therapy) as a key international target for both dissemination and influencing. Activities with ISCT have included regular attendance at US and International ISCT conferences, the use of the Society Journal, Cytotherapy, as the destination for policy influencing &amp;quot;white&amp;quot; papers, and by actively contributing to the work of the Society's Commercialisation Committee (Williams). 

As part of building a strategic relationship with the Boston Area, a number of discussions have been held with the MIT Centre for Biomedical Innovation. These culminated in the invitation of three Centre researchers (Williams, Thurman-Newell, McCall) to give presentations (including a keynote) at the 2015 Biomanufacturing Summit. Discussions are proceeding with MIT on areas for future collaboration. Importantly MIT are shaping their own research activity to focus on analytical techniques taking account of the UK capabilities in processing developed in the Centre. There is a significant interest in manufacturing strategy and the enablers for the distribution of manufacturing. 

Through the Centre Outreach program there is an ongoing relationship between the Centre and the Harvard Stem Cell Institute. Arianna Rech, a Chemical Engineering undergraduate student from Loughborough, was awarded an internship at the Wyss Institute at Harvard University (Don Ingber's Laboratory) to assist with development of 'Bone Marrow on a Chip'. The purpose is to provide a test platform for understanding disease and the effects of radiation on bone health.

A study led from Keele (Forsyth, El Haj) gave a high impact demonstration of near patient cell processing. The study mapped and observed the transfer of a leading edge regenerative medicine product from the industrial development setting into delivery application within a UK hospital. Working in collaboration with key stakeholders, the NHS, the Stroke Research Network, and a significant regenerative medicine industry partner (the American company Athersys), the researchers evaluated the ease of transition of a cell-based product into a UK hospital setting. The product was targeted for the treatment of an acute neurological disorder.
The primary outcome of the evaluation was that the UK hospital setting can successfully integrate manufactured cell-based regenerative medicine products into the healthcare delivery platform. There are, however, substantial baseline requirements for this to be met. These include the onsite localisation of GMP grade clean rooms (with Class A handling), 24/7 readiness and coordinated lines of communication from patient to processor.

The French AFM-Telethon and the Soci&amp;eacute;t&amp;eacute;s de Projets Industriels equity fund headed by the Banque publique d'investissement are investing in the creation of the largest European centre for the development and manufacturing of gene and cell therapies with a planned size of 13,000 m2 in Evry, France. To reach industrial scale, the facility will be equipped with the latest automation equipment including platforms for the expansion of stem cells. The EPSRC Centre has been collaborating with I-Stem, France in the EP051 automation project. Researchers from the EPSRC Centre (Chandra, Williams) are currently working with the I-Stem to specify the automation platform(s) and use their experience for validation to produce therapeutics.

One of the European major centres for the automation of cell and tissue processing is FhG-IBMT. This organisation is also investing in the Babraham Science Park. Loughborough is working in collaboration with FhG-IBMT via the UKRMP PSCP Partnership Project on automated cell culture comparability, an opportunity that has arisen through the positional work in the CIM on automation.

In addition to the ISO work detailed above the Centre has applied funding from the Sasakawa Foundation to enable two researchers (Hao Zhang and Tom Heathman) to make trips to Japan to build links with relevant research groups in Osaka, Kyoto, Tokyo and Tsukuba.

The CIM has established strong links with SIMTech (Singapore) via the researcher May Win-Naing and this important near-patient cell processing link will continue to play an important role in the future.

3. Outreach

The CIM has played an important role in providing trainees for the future, in raising public awareness and in providing for regulatory development for the sector.

The CIM has provided two fully funded undergraduate internships at Harvard Stem Cell Institute, strengthening the relationship between UK and US institutions. Following their experiences, the first candidate is undertaking a PhD and the second secured funding to return to HSCI and will apply for a PhD on their return.

The CIM supported training of four undergraduate medical students to take part in the INSPIRE programme at Keele University. It combined the CIM's target areas of commercial engagement, training of the next generating and raising awareness of careers in regenerative medicine sector.
To promote the CIM's activities, a monthly/bi-monthly newsletter was distributed to more than 500 subscribers including industrial contacts, lead academics and researchers. The CIM institutions will continue to communicate with the established database to inform stakeholders of future projects and events. Through the CIM, the Healthcare Engineering and Regenerative Therapies (HEART) programme has been formed to bring regenerative medicine, science and engineering to learners of all ages. The CIM and HEART group has been invited to exhibit at more than 10 events over the past two years, to communicate the centre's research to members of the public. Notable events include Big Bang Fayre, Birmingham &amp;amp; London, Cheltenham Science Festival, Cheltenham and Imagineering, Coventry. A HEART blog has been established, aimed at school age readers, which delivers accessible research to learners, in addition to providing suitable classroom material for teachers. The blog attracts 100+ views per day with up to 92% being new users. In addition to the larger exhibitions, the team have also run tailored workshops in schools. The HEART team is comprised of CIM researchers, DTC/CDT researchers and E-TERM fellows. Continuity of research communication will be maintained through the two latter groups.

A total of four projects have been funded at approximately &amp;pound;40k each as a result of thematic sandpit events held by the CIM. Researchers at the universities at Bath (Modular manufacturing of bone), Newcastle (Wave-based panning for pancreatic islets), Birmingham (ElectroStim optic nerve scaffolds) and UCL (Magnetic patterning of cells for hollow organ tissue engineering) have conducted focused projects awarded on a competitively-funded basis.

A significant component of the outreach activity was to support the development of promising early career researchers outside the core partners. Four researchers were particularly identified: Liam Grover (Birmingham), Marianne Ellis (Bath), Lucy Foley (Formerly of Newcastle), and Ivan Wall (UCL). These were encouraged to form a network and to &amp;quot;raise their game&amp;quot; by exposure to the Boston innovation system in a one week visit. The relationships have been sustained and grown particularly in the cases of Grover and Wall. The network was actively encouraged to participate in the Sandpit activities as above.

One of the core challenges for any centre of excellence is to decide how it manages the interface with Europe and EU Funding as this can be resource hungry with comparatively little return. A strategic decision was therefore made to interact via a translational organisation, EATRIS, and to have a particular focus on regulatory issues and to leverage the EATRIS relationship with the EMA (European Medicines Agency) as noted above. This is ongoing. 

4. IP generation

A major focus of the CIM has been the securing of intellectual property through patents and through know-how. The patents are listed elsewhere in ResearchFish and range over equipment, instruments and materials.

5. Leverage 

Selected Leveraged Projects in addition to those described already include:

UK Regenerative Medicine Platform: Confirming that EPSRC Centre partners are major players in UK regenerative medicine research, Centre academics are involved in three of the five Hubs. This includes directing the Acellular (smart material) Hub which provides approaches for therapeutic delivery (Kevin Shakesheff, University of Nottingham) and contribution from an EPSRC Centre member within the core team (Alicia El Haj, Keele University). The Stem Cell Niche Hub is supported by EPSRC Centre member (El Haj). The Cell Behaviour, Differentiation and Manufacturing Hub - Pluripotent Stem Cell Platform (PSPC) includes EPSRC Centre members within its core team (David Williams, Robert Thomas, Nick Medcalf, Loughborough University).

As part of a DARPA-funded consortium led by Celgene Cellular Therapeutics, in close partnership with TAP Biosystems, EPSRC Centre members have cultured haematopoietic progenitor cells derived from umbilical cord through an expansion and erythroid lineage commitment process to test and engage in process development programmes. This project led to two additional complementary investments. The first was an EPSRC Early Career Fellowship for Rob Thomas. The second utilised funding from the EPSRC Centre and the Wellcome Trust to collaborate with an existing Wellcome Trust-funded consortium seeking to produce red blood cells in the laboratory. The consortium comprises The University of Bristol, The University of Edinburgh, The University of Glasgow, NHS Blood and Transplant, the Scottish National Blood Transfusion Service, the Irish Blood Transfusion Service and Roslin Cells. 

The TSB Regenerative Medicine Value Systems and Business Models project: 'Navigating the Uncertainties' was designed to address the entire value system of regenerative medicine by taking a perspective encompassing four key uncertainties: Technological - Product, Process and Supply; Regulatory - Status and Application; Reimbursement - Public and Private and Financial - Business and Investment models. This research has been cited in the 'The case for public support of innovation: At the sector, technology and challenge area levels' report published by the UK Government's Department of Business, Innovation and Skills (2014). 

6. Continuity

The CIM has been the location for effective career progression and continuity in research.

Melissa Mather, a key researcher at Nottingham, was made Professor of BioMedical Imaging at Keele University in recognition of her work on medical imaging.

During the period of the Centre Rob Thomas was awarded an early career Fellowship to develop processes and technologies for haematopoietic cell products. (He has also been awarded a Readership in Manufacturing for Cell-Based Therapies.) In conjunction with a Wellcome Trust award to develop manufacturing processes for first in man clinical studies with red blood cells this enabled a group to be established working on process control and characterisation for a specific and high value set of near market products. This work continues to evolve with new process development approaches and further products such as platelets and immunotherapies.

Nick Medcalf transferred from the Smith &amp;amp; Nephew Research Centre, York, in 2013 as an EPSRC Manufacturing Fellow and took up the post of CIM Director in 2014 from Dave Williams. Nick brings a strong systems focus to the research work and is also now representing industry readiness training for the CDT offering.

A number of research assistants and associates and DTC students involved in CIM projects have now secured lectureships: Liz Ratcliffe and Mark McCall (Loughborough), Lisa White (Nottingham) and Arum Saeed (UEA). Significantly the scale and visibility of the activity has also drawn in internationally recognised translational researchers to UK academic positions in particular Alexandra Stolzing, now a Senior Lecturer in Loughborough, from FhG-IZM, Leipzig.

A characteristic of the Centre has been its commercial orientation. The research program and the ethos resulted in three enterprise fellowships. Dr Alex Lyness is an Enterprise Fellow at Loughborough University and funded via EPSRC IAA awarded by the LU Enterprise Office. His work is focused on identifying the needs and requirements of enabling technologies to deliver the cell-based therapies to patients in the clinic. In his role Alex is developing his research in the field of cell delivery into a device ready for IP protection by the end of the Fellowship and has also conducted work for the Cell Therapy Catapult, where he is the Technical Lead on project to develop an intradermal delivery device to deliver a cell-based therapy. 

Mark McCall held the first EPSRC Impact Acceleration Account funded Enterprise Fellowship at Loughborough University working on commercially exploitable projects with both UK based SME's and multinationals. The fellowship focused on novel approaches to cost reduction in bioprocess manufacturing and development through process improvement and technology innovation. During the first 20 months of the 24-month fellowship Mark took a novel scaled expansion bioreactor technology from an early demonstration system to a medium-scale operational prototype, which led to extensive due diligence with a leading developer of bioprocess tools and platforms. He also supervised complex technical and process development activities for commercial clients including multiples processes and products intended for clinical use within the next two years. 

Elizabeth Ratcliffe, a researcher within the CIM, was awarded an EPSRC Impact Acceleration Enterprise Fellowship (&amp;pound;140k): 'Developing Synthetic Biology strengthened tools for Gene Therapy translation'. This was a competitive 16 month Enterprise Fellowship in Synthetic Biology breaking new ground for Loughborough University, working on challenge-led translational science and technology development in collaboration with Dr Michael Roberts, CSO and founder of Synpromics Ltd. (a leading Synthetic Biology platform technology company) and Professor Michael Linden, Professor of Virology, University College London / Pfizer. The project involves developing synthetic biology-strengthened cells and viral vectors for gene therapy research and combining this with scalable automated manufacturing methods and process development methods for HEK293T cell expansion and transfection to make informed advancements in the bioprocess development and scaling of gene therapy manufacture. 

7. New directions

The CIM, its predecessor remedi, and the related grant portfolios including the DTC and CDT have resulted in the development of an internationally distinctive capability in regenerative medicine manufacturing with a hub at Loughborough. Importantly this has been consolidated and is now sustained by a large group of permanent academic staff funded via new national and university initiatives in particular HEFEC Catalyst funding and Vice Chancellor's Lectureships and with EPSRC Fellowship support.

The market research that was conducted in order to make the two bids for EPSRC Future Manufacturing hubs has provided the Centre with clear directions for future research. These concentrate around the subject of control, systems engineering and improved methods for ensuring reproducibility of processes, site-to-site and between teams. Some of this work is now being developed in the UKRMP project. The remainder will be re-examined and used to form the basis of single-theme applications for funding with co-production from our industry collaborators.
The subject of systems analysis and technology gaps comes together in the current work on re-distributed manufacturing. By means of work at the management level for the network and in the feasibility studies for microfactories and bioprinting the CIM will exert leadership in influence over future research directions for the EPSRC and the ESRC. Recommendations are due by the end of 2016.

A strategically-important spin-off study from the CIM in the regulatory/systems area has been the study of the implementation of 'Optimed-ID', an automated medicines dispensing platform at Leicester General Hospital. The system is being assessed for its impact on medicines costs across the four renal wards by removing losses in-system and improving ordering precision. LU has reported on the system to the committee chaired by lord Carter of Coles and also to the Department of Health. The work is expected to generate opportunities for integrating fresh-preserved medicines in this rapid and fully-traceable supply chain system. 

It has become increasingly clear as the CIM has evolved that there is a requirement to get closer to clinical adopters in particular to determine product quality requirements and that Defence Medicine has a history of being a first mover innovator adopter in transformative medical approaches and technologies. These combined with the success of the Loughborough involvement in the DARPA Blood project and the recent &amp;pound;300M investment in the Defence and National Rehabilitation Centre at Stanford Hall has led to an increased focus on defence medical requirements at Loughborough. David Williams is university academic lead on Defence Medicine. 

8. Operational learning and management organisation

The Centre was led from Loughborough University by Prof David William as Director and PI for the research and supported by a Deputy Director (Dr Rob Thomas) and a Programme Manager (Dr Paul Hourd) in partnership with complementary groups at Keele University and The University of Nottingham.

Having some degree of external governance and oversight of the Centre is an integral part of EPSRC's requirements, a Board was appointed as the primary vehicle for delivering that governance and ensuring that output from the Centre was of high quality and met the deliverables outlined in the proposal. The Board, chaired by Richard Archer (an industrialist), comprised the most senior and experienced members of the Executive and four 'non-executive' members, appointed by the major collaborators in addition to an EPSRC representative. An Executive Committee was also appointed to manage the operational aspects of the programme, which incorporated a research portfolio management process to provide visible budget, resource and new proposal review as well as the phase-gated project management of selected major research projects. This Executive Committee comprised the major academic theme/project leaders from Loughborough, Keele and Nottingham, including the Programme Manager. Both the Board and the Executive Committee met formally four times per year. Minutes of the meetings were recorded and issued within 1 week of the meeting with all actions traceable to completion or closure. A confidential Register of Interests was maintained to ensure that potential conflicts were transparent to and recognised by the Board. 

Applied to individual elements and across the whole programme, this structure provided a robust (and academically atypical) management approach, which together with strong leadership from the Chairman and Director, was very important to ensuring good governance and the delivery of high value Centre outcomes. 

9. CDT interface

Several DTC/CDT students, including Peter Archibald and Mark McCall, have contributed to CIM projects. Furthermore, the CIM and the DTC/CDT in Regenerative Medicine have worked closely together on a number of initiatives including joint outreach campaigns. For example, the HEART blog started by Sophie Dale-Black, Head of Engagement at the CIM, is now run by a CDT student. Involvement with the DTC/CDT has also highlighted a gap between the amount of multi-disciplinary training provided for PhD students working in this sector and that which we provide for our RAs. This shortfall is something PIs within the CIM, through their own RAs and by influencing the Universities and research councils are continuing to address.

It is important to recognise the support that remedi and the CIM have received from the EPSRC. The Loughborough team under the leadership of Prof David Williams has managed, in a competitive research environment, to secure and leverage investments and support for the CDT Interface. This vital strategic support has enabled the Loughborough/Keele/Nottingham research teams to co-ordinate activity from the CDT, the CIM, ETERM and the Fellowships to give research synergy and to establish critical mass for the research portfolio. 

10. CGTC interface

The presence of the Cell and Gene Therapy Catapult in the UK research system has given a powerful boost to the UK advanced therapeutics translational capability. The influence of the CGTC upon the CIM has been largely positive and we must be careful to manage the unique position of the CGTC in terms of the impact that it has upon the role and profile of the Centre. The CIM Management has been aware that with the new CGTC facility in London and the production site being built in Stevenage there is now a perception amongst grant reviewers that the UK has all the investment that it currently needs in the subject of regenerative medicine manufacturing research. There is, however, still a role for the creation of enabling technology upstream of the CGTC and this is recognised by that organisation. 

11. Summary

The CIM has built on the achievements of its forerunner, remedi, and continues to play a leading role in the UK regenerative medicine research system that will endure beyond its term of funding through the excellence of its published science, a rich people pipeline, policy influence and leveraged funding activity.

12. Additional information in 2017

The activity of the CIM in automated manufacturing of cell therapies, as reported by, in particular, Dr Amit Chandra, Prof. David Williams, Dr Robert Thomas, Dr Peter Mitchell and Dr Peter Archibald, attracted the attention of I-STEM (Evry, France) and, as a consequence of the close support that has been given by Dr Amit Chandra to I-STEM over the last twelce months, Dr Chandra departed the Loughborough Laboratories in December 2016 to take up the post of Business Development Manager at I-STEM. This important appointment at the Banque de la Republique-funded labs in France demonstrates the importance of the CIM in providing industry-relevant research and capability to major international ventures.</gtr:description><gtr:firstYearOfImpact>2013</gtr:firstYearOfImpact><gtr:id>54E03707-F4DC-41B0-9673-37781DF17898</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>m-5445712549.095706de258c6e</gtr:outcomeId><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The invention provides polymer particles that are obtainable by a method selected from emulsion methods, diffusion methods and evaporation methods carried out in the presence of surface-engineering surfactant which is one or more polymer that displays a lower critical solution temperature, in aqueous media, that is between 10 to 90&amp;deg; C., this polymer being the polymerisation product of one or more monomer selected from polymerisable alkyleneglycol acrylate monomers and polymerisable alkyleneglycol methacrylate monomers. The polymer particles can be used in controlled release applications, such as flavour release applications, fragrance release applications and biomedical applications. The invention also provides a cell support matrix comprising the polymer particles.</gtr:description><gtr:grantRef>EP/H028277/1</gtr:grantRef><gtr:id>97FCE261-3E29-4834-9FC5-42EB0B66876C</gtr:id><gtr:impact>The invention is used for controlling cell behaviour in regenerative medicine applications. The thermally-switchable behaviour opens up options for managing cell deposition for a variety of uses in advanced therapeutics.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>56df43b36a5245.19643488</gtr:outcomeId><gtr:patentId> US8940336</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Polymer particles prepared from polymerisable alkylene glycol (meth) acrylate monomers</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A method and apparatus to deoxygenate cell culture media to defined set-points.</gtr:description><gtr:grantRef>EP/H028277/1</gtr:grantRef><gtr:id>425E5916-808C-45C6-826C-563D01163FC7</gtr:id><gtr:impact>The intellectual property has formed the basis of a commercial instrument manufacturing and sales campaign by Baker Ruskinn. This brings an income stream to Keele under a fixed royalty arrangement. Further technological developments are being made as line extensions and as separate innovations. These items are, however, still confidential. Sales are satisfactory for a device of this size and sophistication.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>56717b55302070.08563159</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>Methods and apparatuses relating to cell culture media</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A methodology describing culture of pluripotent stem cells on defined naked nanofibers. The innovation builds on the hypoxia control that is enabled by the technology developed for Baker Ruskinn (see ''Methods and apparatuses relating to cell culture media').

In the year 2016-2017 the innovating university (Keele, Prof. Nicholas R Forsyth) has conducted negotiations with potential partners for wider commercialisation. While a satisfactory deal has not yet been made attempts are continuing. Candidate partners include overseas businesses.</gtr:description><gtr:grantRef>EP/H028277/1</gtr:grantRef><gtr:id>CD3CD4BF-1417-4B8B-B821-0C6F7806C3D3</gtr:id><gtr:impact>The technology provides a culture environment that can be used by researchers to enable biomimetic 3D culture of pluripotent cells.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56717c1ee90862.10598305</gtr:outcomeId><gtr:patentId>US 9,005,607B2</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Stem Cell Culture Method</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>An injectable, agent delivery system comprising a composition comprising: (i) an injectable scaffold material comprising discrete particles, which are capable of interacting to form a scaffold; and (ii) a carrier comprising an agent for delivery. The product can have a pharmaceutical use or use in cosmetic surgery; in particular it can be used in tissue regeneration or reconstruction. The agent for delivery may be a therapeutically, prophylactically or diagnostically active substance.</gtr:description><gtr:grantRef>EP/H028277/1</gtr:grantRef><gtr:id>FB47C945-2DCE-466A-9855-33156A2FFB37</gtr:id><gtr:impact>The patent forms the basis of activity for Locate Therapeutics. The technology is a platform from which formulated derivatives can be made.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>56df4476061f60.46145386</gtr:outcomeId><gtr:patentId>WO2015019109-A1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Injectable agent delivery system useful in pharmaceutical or cosmetic surgery and for treating neurodegeneration disorders, contains agent for sustained delivery located within discrete particles and injectable scaffold material</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Scaffold production for regenerative medicine.</gtr:description><gtr:grantRef>EP/H028277/1</gtr:grantRef><gtr:id>46D9DD63-D3FE-49AE-96FF-F700179456AD</gtr:id><gtr:impact>IP for this technology was licensed to Locate Therapeutics Ltd. The company has secured a 2 year Wellcome Trust award to develop for scale up of cell manufacturing.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>m-2706125558.08026847667526a</gtr:outcomeId><gtr:patentId>GB1212595.1</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Responsive Magnetic Particulate Dispersion for Ex-vivo Cellular Expansion on 2D and 3D Cell Culture and Cell Recovery via Magnetic Separation</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>The EPSRC Centre for Innovative Manufacturing in Regenerative Medicine is one of the primary national interventions supporting the growth of the UK regenerative medicine industry. Its role is to define, deliver and disseminate world-leading, high impact, fundamental and translational manufacturing research building upon its original funding from the EPSRC. Significant additional funding (approximately nine times the original grant received) has been secured from diverse sources. EPSRC Centre members participate significantly in hubs and projects funded by the UK Regenerative Medicine Platform. The recent re-funding of our Centre for Doctoral Training by both EPSRC and the MRC sustains our training pipeline for over 100 PhD students.</gtr:description><gtr:exploitationPathways>The EPSRC Centre for Innovative Manufacturing (CIM) in Regenerative Medicine has come to a conclusion at the end of February 2016. The portfolio of projects that are managed by the participants at Keele, Nottingham and Loughborough continues to evolve and to enlarge. The engagement with the regulatory authorities and with the international community has increased during 2015 with initiative undertaken with the European Medicines Agency and the international Standards Organisation that will outlive the CIM. Opportunities have been identified to work in new collaborations in the USA (via MIT), France (through I-STEM), Italy (with IBSL) and Japan (through Sasakawa Foundation initiatives). Two unsuccessful bids have been made for Future Manufacturing hubs and the content of these will be re-developed for focused research projects with the industrial and academic partners concerned. As noted last year engagement goes from strength to strength through the development of new consortia-led projects, the promotion of the UK academic community in Europe and the communication of regenerative medicine science and engineering to school-age learners and their teachers. The wider EPSRC Centre has a focus on people development through EPSRC-funded Early Career, Career Acceleration and Manufacturing Fellowships. Support for early career researchers is provided through fellowships from a variety of funders, including the EPSRC-funded Engineering, Tissue Engineering and Regenerative Medicine (ETERM) Fellowship Programme and host university programmes. The research funded by the EPSRC Centre during the second half of its term was focused on the cross-institution challenge project where key manufacturing technology themes are integrated using a framework based on regulatory science to facilitate translation. We are now working actively with the Cell Therapy Catapult on industry projects and partnering strategically on research and translational projects. The work here has led to new initiatives in the area of distributed manufacturing. The relationship with the Cell and Gene Therapy Manufacturing Centre has been strengthened. Work on policy and standards and to inform regulation continues with contributions to the work of the Department of Health Regenerative Medicine Expert Group and international standards groups. Regenerative medicine manufacturing remains a key focus nationally and internationally. We are planning for success against this opportunity-rich background. We seek the ongoing support of community members, as both advocates for the importance of EPSRC funding for manufacturing research and in particular as collaborators in research that enables the new industry of regenerative medicine to grow and deliver increasing healthcare benefits. To this end the CIM has worked on policy influence as well as research output and the findings underscore the importance of a systems-level approach to manufacturing research for these advanced products. Without a thorough understanding of how to make regenerative medicines safely, economically and in sufficient quantity, these therapies will never reach their full potential.</gtr:exploitationPathways><gtr:id>33FD7792-4C57-4EF1-9AAA-A169D28DD9B3</gtr:id><gtr:outcomeId>r-2517557323.46098677717bd8</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology,Other</gtr:sector></gtr:sectors><gtr:url>http://www.epsrc-regen-med.org/</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>House of Lords Inquiry</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>191F219C-C396-46AE-8346-27094931EFAE</gtr:id><gtr:impact>David Williams gave oral evidence to the House of Lords Science and Technology Committee for their Inquiry into regenerative medicine focussing on both clinical and economic impacts. EPSRC Centre's research and impact noted in paragraph 96 of the report, including a reference to testing and validation of a project with Instron TGT investigating a prototype hydrostatic pressure growth chamber. David Williams has joined the Regenerative Medicine Expert Group that was formed after the publication of the House of Lords report. This is focussed on improvements in clinical services.</gtr:impact><gtr:outcomeId>5452170d620a53.30745075</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type><gtr:url>http://www.publications.parliament.uk/pa/ld201314/ldselect/ldsctech/23/23.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Regenerative Medicine Expert Group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3043B2BE-4DC2-4B90-8A26-51DCB4B87163</gtr:id><gtr:outcomeId>56d71caf8f66c8.79751910</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type><gtr:url>https://www.nice.org.uk/Media/Default/About/what-we-do/Research-and-development/regenerative-medicines.pdf</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>MSCs that differentiate towards cartilage formation are potentially associated with the higher performing cell population in our pre-clinical model. This information could be used as design input to a further study to test/validate these relationships.</gtr:description><gtr:id>DE56D51A-D419-44BB-9865-6A590F514491</gtr:id><gtr:impact>Our pre-clinical model over a short time period allows assessment of input and output variables to be measured and assessed linked to manufacturing expertise to define cell parameters for quality markers.</gtr:impact><gtr:outcomeId>544fb8bd55e008.07666519</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ECP023 Characteristics of Cells</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have discovered a novel technique that could measure this osteogenic potential from a small marrow sample. The same technique can subsequently separate and enrich the population of highly osteogenic cells from the full cell population.</gtr:description><gtr:id>CC2AA6A9-8CCF-4081-90B5-59EAB85694DA</gtr:id><gtr:impact>Patentability of the technique is currently being evaluated.</gtr:impact><gtr:outcomeId>56d71d65c64068.79748897</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Identification of Subpopulations within Mesenchymal Stem Cell Cultures</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Shunxi Stem Cell Engineering Ltd</gtr:companyName><gtr:description>Shunxi Stem cell engineering ltd was established in the Institute of Life Science, Swansea University, to develop low-cost bench-top bioreactors.
The start-up received KESS grant from Wales government, is for industry-academic collaboration to fund one master student working on automated bioreactor and microcarriers for therapeutical cell manufacturing.
 
The work in Swansea is mainly to test the bioreactor with different cell types and microcarriers.
 
Dr Hao Zhang, a PDRA from the CIM, is leading a team of 8 engineers to develop the bioreactor from scratch, with own medium supply and mixing, air supply, and temperature control hardware and software in China.</gtr:description><gtr:id>2093E14E-BF07-4DC3-B86A-D8B278859800</gtr:id><gtr:impact>The company has not been in business long enough to have a significant impact in the UK.</gtr:impact><gtr:outcomeId>56db04f623a314.91078838</gtr:outcomeId><gtr:url>https://beta.companieshouse.gov.uk/company/08978787/officers</gtr:url><gtr:yearCompanyFormed>2014</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>FFD1F27E-CC20-4CE6-AB78-FFC6ACED4052</gtr:id><gtr:title>A study of enzymatic activity in cell cultures via the analysis of volatile biomarkers.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/285b663e8ab9845a6c87aa3f92a83133"><gtr:id>285b663e8ab9845a6c87aa3f92a83133</gtr:id><gtr:otherNames>Chippendale TW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn><gtr:outcomeId>5457830866ede3.48403900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E80251BF-6ABF-44EE-AE2C-45828BF814E3</gtr:id><gtr:title>Orthopaedic applications of nanoparticle-based stem cell therapies.</gtr:title><gtr:parentPublicationTitle>Stem cell research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c79de8502a4b9875d14960582232e77e"><gtr:id>c79de8502a4b9875d14960582232e77e</gtr:id><gtr:otherNames>Wimpenny I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1757-6512</gtr:issn><gtr:outcomeId>doi_53d07c07c0e261f6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6D2B8FF-8FAD-46A7-BFEB-60866915B1D9</gtr:id><gtr:title>Poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) supports adhesion and migration of mesenchymal stem cells and tenocytes.</gtr:title><gtr:parentPublicationTitle>World journal of stem cells</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b9470cc0106c59220bf86058d32a7a3"><gtr:id>7b9470cc0106c59220bf86058d32a7a3</gtr:id><gtr:otherNames>Lomas AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1948-0210</gtr:issn><gtr:outcomeId>doi_53d08908981efefc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E173E1D-3C83-4006-8E51-CCA2DDA5D797</gtr:id><gtr:title>Three-dimensional culture and bioreactors for cellular therapies.</gtr:title><gtr:parentPublicationTitle>Cytotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/643e3c28f1e84844aad06f3aaaca89a9"><gtr:id>643e3c28f1e84844aad06f3aaaca89a9</gtr:id><gtr:otherNames>Naing MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1465-3249</gtr:issn><gtr:outcomeId>doi_53d085085c1be755</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82E7FBCC-2B41-481B-9735-0EB91B2B7292</gtr:id><gtr:title>Cytoplasmic RNA in undifferentiated neural stem cells: a potential label-free Raman spectral marker for assessing the undifferentiated status.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85b593bc3ce4a9e7da56b9503dae00f8"><gtr:id>85b593bc3ce4a9e7da56b9503dae00f8</gtr:id><gtr:otherNames>Ghita A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn><gtr:outcomeId>545783088abd02.87578967</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>190F1D7C-67AA-4E22-BB44-931AAAFDC351</gtr:id><gtr:title>The application of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) scaffolds for tendon repair in the rat model.</gtr:title><gtr:parentPublicationTitle>Biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eefa5008cf0d46e5e6e94bab3cf1de6b"><gtr:id>eefa5008cf0d46e5e6e94bab3cf1de6b</gtr:id><gtr:otherNames>Webb WR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0142-9612</gtr:issn><gtr:outcomeId>doi_53cfe6fe6c2b96ae</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B428AE61-C1C0-4F57-BF66-984CD933EAF4</gtr:id><gtr:title>A novel automated bioreactor for scalable process optimisation of haematopoietic stem cell culture.</gtr:title><gtr:parentPublicationTitle>Journal of biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdef2f16fd50c3faa8211957474c733d"><gtr:id>cdef2f16fd50c3faa8211957474c733d</gtr:id><gtr:otherNames>Ratcliffe E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-1656</gtr:issn><gtr:outcomeId>545783a75e3207.52898917</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86BA3CF5-574F-448A-83BC-840C46F7579E</gtr:id><gtr:title>Volatile biomarkers emitted by cell cultures: headspace analysis using selected ion flow tube mass spectrometry, SIFT-MS.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa6704204001e15ff18c6a7483acaaba"><gtr:id>aa6704204001e15ff18c6a7483acaaba</gtr:id><gtr:otherNames>Thomas Chippendale (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>r_239535361963ec1b90</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F349F2B3-BAD7-4BA2-A748-5BF33331B3C7</gtr:id><gtr:title>Activin-Directed Differentiation of Human Embryonic Stem Cells Differentially Modulates Alveolar Epithelial Wound Repair via Paracrine Mechanism</gtr:title><gtr:parentPublicationTitle>Stem Cell Discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3fb54ff7e1d6e87179f71d4ae69a4b8"><gtr:id>a3fb54ff7e1d6e87179f71d4ae69a4b8</gtr:id><gtr:otherNames>Akram K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5457677d5dc809.25618838</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47A22C98-2BC9-432A-8EE6-6BA8EE1B2C72</gtr:id><gtr:title>Supercritical CO2 fluid-foaming of polymers to increase porosity: a method to improve the mechanical and biocompatibility characteristics for use as a potential alternative to allografts in impaction bone grafting?</gtr:title><gtr:parentPublicationTitle>Acta biomaterialia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b65afd2ddd29d31ccad1aeea7393f23c"><gtr:id>b65afd2ddd29d31ccad1aeea7393f23c</gtr:id><gtr:otherNames>Tayton E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1742-7061</gtr:issn><gtr:outcomeId>doi_53cfe2fe21838ace</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EB0B9E1-01BF-44BB-A917-D96CF63D3C23</gtr:id><gtr:title>The factory of the future - A study for the Department of Business, Innovation and Skills</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/456578cc8daed2b183638d6980818676"><gtr:id>456578cc8daed2b183638d6980818676</gtr:id><gtr:otherNames>Ridgway, K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>545794c3a64a76.98776416</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2067C19F-52B6-45F1-AFB5-E03921146853</gtr:id><gtr:title>A Tailor-Made Synthetic Polymer for Cell Encapsulation: Design Rationale, Synthesis, Chemical-Physics and Biological Characterizations.</gtr:title><gtr:parentPublicationTitle>Macromolecular bioscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4418fcf8436fbb7bb8c7fd66070660e7"><gtr:id>4418fcf8436fbb7bb8c7fd66070660e7</gtr:id><gtr:otherNames>Gerges I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1616-5187</gtr:issn><gtr:outcomeId>58bd98f4a9f4e5.31808943</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2E8C8F5-06DD-4901-B6EE-89B4860BA616</gtr:id><gtr:title>Computational Modelling Of Mechanical Behavior Of Biological Tissues For Biomedical Applications</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8a46f3752fd4026773cf1b531707cbf"><gtr:id>b8a46f3752fd4026773cf1b531707cbf</gtr:id><gtr:otherNames>Li S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58bd97fd5d2a31.10413973</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13601BEC-637D-45B0-9931-DF44E440A9EF</gtr:id><gtr:title>Automated image analysis with the potential for process quality control applications in stem cell maintenance and differentiation.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0e6f2f52b3aecc428327496834decf9"><gtr:id>f0e6f2f52b3aecc428327496834decf9</gtr:id><gtr:otherNames>Smith D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>585d4aca1b0fc1.78445473</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43F1C8E9-AE76-4856-BE8A-6D195D76E1D9</gtr:id><gtr:title>A chemokine self-presentation mechanism involving formation of endothelial surface microstructures.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d407031a8d8242ed7bb14e155a570abd"><gtr:id>d407031a8d8242ed7bb14e155a570abd</gtr:id><gtr:otherNames>Whittall C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>doi_53d08908906931cf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E0B8C99-2099-4BF8-B38E-BCAB235672E7</gtr:id><gtr:title>Multiparameter flow cytometry for the characterisation of extracellular markers on human mesenchymal stem cells.</gtr:title><gtr:parentPublicationTitle>Biotechnology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b72ee7fa5cffa46951b87bbea236715"><gtr:id>1b72ee7fa5cffa46951b87bbea236715</gtr:id><gtr:otherNames>Chan AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0141-5492</gtr:issn><gtr:outcomeId>545768e0075474.07562390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D506929E-57CC-4FDF-93B8-C32DD8C00EE4</gtr:id><gtr:title>WP002/ECP039/0113: Exploring the feasibility of a new regulatory paradigm for the manufacture of autologous cell therapies: Appendices</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7244c0ef5a5f7ea09468c30f820f7235"><gtr:id>7244c0ef5a5f7ea09468c30f820f7235</gtr:id><gtr:otherNames>Anne Laure Humbert (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>r_58227621786410dfe8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F8463FD-0401-4500-8F9F-1B1BCD015672</gtr:id><gtr:title>Scale-up of human mesenchymal stem cell culture: current technologies and future challenges</gtr:title><gtr:parentPublicationTitle>Current Opinion in Chemical Engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58db9073de15bf4b748d6f436c9f9481"><gtr:id>58db9073de15bf4b748d6f436c9f9481</gtr:id><gtr:otherNames>Rafiq Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5457810d891755.18620417</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79A2F69C-5A64-42EB-93EB-7398B9AACBD6</gtr:id><gtr:title>WP001/ECP039/0113: Exploring the feasibility of a new regulatory paradigm for the manufacture of autologous cell therapies</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e425c2b2f3a8282077524a8ca05a9af2"><gtr:id>e425c2b2f3a8282077524a8ca05a9af2</gtr:id><gtr:otherNames>Carey Jewitt  (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>r_4913447076641197b2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1F1BFCF-786E-4645-965F-8AC32D3E2F86</gtr:id><gtr:title>3D Culture and Differentiation of Human Mesenchymal Stem Cells towards Nucleus Pulposus in a Physiologically Informed Bioreactor</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ebef2330a2d97880739e069e4d9b303"><gtr:id>0ebef2330a2d97880739e069e4d9b303</gtr:id><gtr:otherNames>Deepak Kumar (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>m_188566710813ddcabc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43696691-8A7B-4D95-9D74-A830A70BDDEB</gtr:id><gtr:title>Controlled production of poly (3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHx) nanoparticles for targeted and sustained drug delivery.</gtr:title><gtr:parentPublicationTitle>Journal of pharmaceutical sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26f3fe6e11fcea410106d9f93a48c1c1"><gtr:id>26f3fe6e11fcea410106d9f93a48c1c1</gtr:id><gtr:otherNames>Heathman TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3549</gtr:issn><gtr:outcomeId>5671769dbb1f33.83365517</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6ABE272B-E255-4115-A2E8-0FCC6C7DC2D4</gtr:id><gtr:title>Correlating mesenchymal stem cell delivery with pain in an OA rat model</gtr:title><gtr:parentPublicationTitle>JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d36d139df9d6bf8024ea6b680daecdc1"><gtr:id>d36d139df9d6bf8024ea6b680daecdc1</gtr:id><gtr:otherNames>Markides, H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5450f38d9c2f34.83111709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5ACECBA-6066-479F-A0FC-AFAB2D2E29B7</gtr:id><gtr:title>Rapid micropatterning of cell lines and human pluripotent stem cells on elastomeric membranes.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87660c95d65a3011d13d00df19cbec1f"><gtr:id>87660c95d65a3011d13d00df19cbec1f</gtr:id><gtr:otherNames>Paik I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>545783a7384fa0.23765994</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FA939BF-37EF-48B9-A839-61DEB3B70644</gtr:id><gtr:title>The sensitivity of human mesenchymal stem cells to vibration and cold storage conditions representative of cold transportation.</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society, Interface</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06cda75f04ab4970969cf6e4ff26bf3f"><gtr:id>06cda75f04ab4970969cf6e4ff26bf3f</gtr:id><gtr:otherNames>Nikolaev NI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1742-5662</gtr:issn><gtr:outcomeId>doi_53d0490491938f57</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F77F4D25-AFAF-424A-926B-75DA625BC846</gtr:id><gtr:title>Careers in the developing regenerative medicine sector</gtr:title><gtr:parentPublicationTitle>Orthopaedic Product News</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d8d6b19e48041a1c2497871fb90fded"><gtr:id>3d8d6b19e48041a1c2497871fb90fded</gtr:id><gtr:otherNames>Dale-Black, SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5457956d209f69.38593599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1D9749D-F253-4123-A536-3FAD1D73EB6C</gtr:id><gtr:title>Receptor-targeted, magneto-mechanical stimulation of osteogenic differentiation of human bone marrow-derived mesenchymal stem cells.</gtr:title><gtr:parentPublicationTitle>International journal of molecular sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb214bc4b33611401131be1feceb9998"><gtr:id>bb214bc4b33611401131be1feceb9998</gtr:id><gtr:otherNames>Hu B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1422-0067</gtr:issn><gtr:outcomeId>54577f0fa7c3b1.71290271</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1CABDFD-AE85-46F3-9B62-19D404B3933E</gtr:id><gtr:title>Regenerative medicine, a unique opportunity to transform our national health and wealth, needs capability in manufacturing and supply</gtr:title><gtr:parentPublicationTitle>Innovation in Healthcare</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37a88721afa1729bd9b45069f7bd9927"><gtr:id>37a88721afa1729bd9b45069f7bd9927</gtr:id><gtr:otherNames>Williams, DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>54578748efcc30.99922148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9729DABA-F459-44DF-8351-A34133F78C75</gtr:id><gtr:title>BMP2 repression and optimized culture conditions promote human bone marrow-derived mesenchymal stem cell isolation.</gtr:title><gtr:parentPublicationTitle>Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0729658ae07d098609af2d6a82ff0e2"><gtr:id>e0729658ae07d098609af2d6a82ff0e2</gtr:id><gtr:otherNames>Kay AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1746-0751</gtr:issn><gtr:outcomeId>5671769de36366.54178948</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBA3B346-37D1-4444-89A1-9C1413F89B0E</gtr:id><gtr:title>Intra-articular injection of mesenchymal stem cells leads to reduced inflammation in antigen-induced arthritis</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b6f347545562d5149e5e7773638fcf5"><gtr:id>0b6f347545562d5149e5e7773638fcf5</gtr:id><gtr:otherNames>Oksana Kehoe (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>m_380114491413f4e0da</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A29DEEE2-14D5-4BE8-B19E-C241E04C3E20</gtr:id><gtr:title>Time-optimized X-ray micro-CT imaging of polymer based scaffolds.</gtr:title><gtr:parentPublicationTitle>Journal of biomedical materials research. Part B, Applied biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e75875e0d1e39d0b4da6f00437fcca4b"><gtr:id>e75875e0d1e39d0b4da6f00437fcca4b</gtr:id><gtr:otherNames>Morris DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1552-4973</gtr:issn><gtr:outcomeId>545783a7146202.61681987</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCD2F501-8A8B-4839-8EF8-3D0B221E61ED</gtr:id><gtr:title>Delivery of definable number of drug or growth factor loaded poly(DL-lactic acid-co-glycolic acid) microparticles within human embryonic stem cell derived aggregates.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a25eb9f68ddfd13f9ec2e57186bc628"><gtr:id>9a25eb9f68ddfd13f9ec2e57186bc628</gtr:id><gtr:otherNames>Qutachi O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>5457810d3c9579.03392043</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE6777E2-041C-443E-9BB1-0611EBC189E6</gtr:id><gtr:title>Dynamics of anterior-posterior axis formation in the developing mouse embryo.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25b5aef746d62dd276930a93f78b27f9"><gtr:id>25b5aef746d62dd276930a93f78b27f9</gtr:id><gtr:otherNames>Morris SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>doi_53d02702743aa8f7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B68D08F3-1F3F-4917-BF20-66254E38D980</gtr:id><gtr:title>Ultrasonic monitoring of drug loaded Pluronic F127 micellular hydrogel phase behaviour.</gtr:title><gtr:parentPublicationTitle>Materials science &amp; engineering. C, Materials for biological applications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d2610eee4e4764a247c4c3a70c0e800"><gtr:id>5d2610eee4e4764a247c4c3a70c0e800</gtr:id><gtr:otherNames>Farrugia M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0928-4931</gtr:issn><gtr:outcomeId>545769d5e6ec11.97213924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>075BA8E7-9AF3-481F-8C9A-CEC376FFFC22</gtr:id><gtr:title>5-hydroxymethyl-cytosine enrichment of non-committed cells is not a universal feature of vertebrate development.</gtr:title><gtr:parentPublicationTitle>Epigenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/554888849f9058347fc5093fe6a0ca4f"><gtr:id>554888849f9058347fc5093fe6a0ca4f</gtr:id><gtr:otherNames>Almeida RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1559-2294</gtr:issn><gtr:outcomeId>doi_53d089089475ff38</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>637FE1F4-4123-4610-9FDD-EEFAE17A5ABD</gtr:id><gtr:title>PAS 93:2011 Characterization of human cells for clinical applications. Guide</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f9847632a7a16e6e8fb94a11843c6b1"><gtr:id>4f9847632a7a16e6e8fb94a11843c6b1</gtr:id><gtr:otherNames>Wilma Clark (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>r_8576525083cac136fa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87204020-2DC8-4444-9772-866862550A47</gtr:id><gtr:title>Mesenchymal stem cell therapy and lung diseases.</gtr:title><gtr:parentPublicationTitle>Advances in biochemical engineering/biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db49f699859ed4d605345f035519c99f"><gtr:id>db49f699859ed4d605345f035519c99f</gtr:id><gtr:otherNames>Akram KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>978-3-642-37943-7</gtr:isbn><gtr:issn>0724-6145</gtr:issn><gtr:outcomeId>doi_53cfcbfcb0a8d479</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9864312-1888-4413-BD5F-710C4AD320F0</gtr:id><gtr:title>Combined hydrogels that switch human pluripotent stem cells from self-renewal to differentiation.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/774adde14d69c12426f5b7e4aac46b56"><gtr:id>774adde14d69c12426f5b7e4aac46b56</gtr:id><gtr:otherNames>Dixon JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>545100df540a64.02193201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F324708D-A04E-483F-B333-83C425BAAAF0</gtr:id><gtr:title>Mesenchymal stem-cell-based therapy for the older patient</gtr:title><gtr:parentPublicationTitle>Aging Health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05c3b06f20443a088cb9bd853468a8b3"><gtr:id>05c3b06f20443a088cb9bd853468a8b3</gtr:id><gtr:otherNames>Griffiths S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>doi_53d0850851ca106d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9D52E0D-0C20-4608-8757-3F034441F374</gtr:id><gtr:title>In situ measurement of magnetization relaxation of internalized nanoparticles in live cells.</gtr:title><gtr:parentPublicationTitle>ACS nano</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14fc478188e6a5585ec060f9d2e45309"><gtr:id>14fc478188e6a5585ec060f9d2e45309</gtr:id><gtr:otherNames>Soukup D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1936-0851</gtr:issn><gtr:outcomeId>doi_55f977977b25d04e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3825FAEA-C1A3-4152-BC2A-3C0A52517FA5</gtr:id><gtr:title>Engineering cells to grow tissue</gtr:title><gtr:parentPublicationTitle>Ingenia Magazine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e704d2fa185a308e93879b0c88b6a632"><gtr:id>e704d2fa185a308e93879b0c88b6a632</gtr:id><gtr:otherNames>Alicia El Haj (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>r_807434818463c3fe44</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF4C13B9-D1A9-4C46-83B7-4A6C0F02882A</gtr:id><gtr:title>Regulatory challenges for the manufacture and scale-out of autologous cell therapies</gtr:title><gtr:parentPublicationTitle>StemBook</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7c4f9681563a6bcf0127293184d4c3e"><gtr:id>f7c4f9681563a6bcf0127293184d4c3e</gtr:id><gtr:otherNames>Hourd P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54576a8a5e0090.52556446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>363A8327-5C9C-4C1A-A631-68271CFF6934</gtr:id><gtr:title>A novel technique for the production of electrospun scaffolds with tailored three-dimensional micro-patterns employing additive manufacturing.</gtr:title><gtr:parentPublicationTitle>Biofabrication</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8527de9dedc85516490f787397461bc9"><gtr:id>8527de9dedc85516490f787397461bc9</gtr:id><gtr:otherNames>Rogers CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1758-5082</gtr:issn><gtr:outcomeId>5451008dcaee83.71365062</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8873DE8-CB05-4868-AB27-270D2DB9DEAB</gtr:id><gtr:title>Hydrogels for lung tissue engineering: Biomechanical properties of thin collagen-elastin constructs.</gtr:title><gtr:parentPublicationTitle>Journal of the mechanical behavior of biomedical materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb9dabbec539a0989786388a49aa45ea"><gtr:id>fb9dabbec539a0989786388a49aa45ea</gtr:id><gtr:otherNames>Dunphy SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1878-0180</gtr:issn><gtr:outcomeId>5671769d932868.58825150</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC499222-6C76-4352-B968-E36C330089ED</gtr:id><gtr:title>Control of smooth muscle a-actin (SMA) up-regulation in HBMSCs using remote magnetic particle mechano-activation.</gtr:title><gtr:parentPublicationTitle>Nanomedicine : nanotechnology, biology, and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb214bc4b33611401131be1feceb9998"><gtr:id>bb214bc4b33611401131be1feceb9998</gtr:id><gtr:otherNames>Hu B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1549-9634</gtr:issn><gtr:outcomeId>54576a8aa8a271.97578918</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D4B72F2-9BE9-43EF-A78A-B200620CCC1E</gtr:id><gtr:title>Synthetic biology applications in systems engineering of cell therapy</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3adbf2b3a3d8ce08bd1b78215b08610"><gtr:id>a3adbf2b3a3d8ce08bd1b78215b08610</gtr:id><gtr:otherNames>Ratcliffe, E</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>5450f0981474e8.45987079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85A1E52A-3453-4F9D-9D72-8A2B7FCD43C3</gtr:id><gtr:title>Self-renewal of human embryonic stem cells on defined synthetic electrospun nanofibers.</gtr:title><gtr:parentPublicationTitle>Biomedical materials (Bristol, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a011372df831db18e844680c3913e8fd"><gtr:id>a011372df831db18e844680c3913e8fd</gtr:id><gtr:otherNames>Kumar D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1748-6041</gtr:issn><gtr:outcomeId>5671769e6d2755.78888326</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE2D5A35-4944-48A8-A5C5-DF89AD09B36F</gtr:id><gtr:title>Induced pluripotent stem cells: production and utility</gtr:title><gtr:parentPublicationTitle>Biomedical Scientist</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3adbf2b3a3d8ce08bd1b78215b08610"><gtr:id>a3adbf2b3a3d8ce08bd1b78215b08610</gtr:id><gtr:otherNames>Ratcliffe, E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5450efc4a004e3.92667260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A4165FC-3FF2-4702-90E1-D6F5EA1D9119</gtr:id><gtr:title>Automated adherent human cell culture (mesenchymal stem cells).</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec7682933d5d8a2433bc162e9bb0e1fc"><gtr:id>ec7682933d5d8a2433bc162e9bb0e1fc</gtr:id><gtr:otherNames>Thomas R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>978-1-61779-366-0</gtr:isbn><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>5457852b2692a9.47158423</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DC404CC-F547-4345-9DE5-6F0499214619</gtr:id><gtr:title>Stem Cell Delivery With Polymer Hydrogel for Treatment of Intervertebral Disc Degeneration: From 3D Culture to Design of the Delivery Device for Minimally Invasive Therapy.</gtr:title><gtr:parentPublicationTitle>Cell transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a011372df831db18e844680c3913e8fd"><gtr:id>a011372df831db18e844680c3913e8fd</gtr:id><gtr:otherNames>Kumar D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0963-6897</gtr:issn><gtr:outcomeId>58c021c4a1a8a5.07457862</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>660AFA71-E21B-4D4A-9BB4-391881D622C9</gtr:id><gtr:title>Pluripotent and Multipotent Stem Cells Display Distinct Hypoxic miRNA Expression Profiles.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e52312441274dbd5976f846c0e4c85d"><gtr:id>4e52312441274dbd5976f846c0e4c85d</gtr:id><gtr:otherNames>Agrawal R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c021c4e34760.71372500</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25A01ACA-AC5F-4CEF-BDFE-BE0052E72F95</gtr:id><gtr:title>Expression of the Two Pore Domain Potassium Channel TREK-1 in Human Intervertebral Disc Cells</gtr:title><gtr:parentPublicationTitle>Current Stem Cell Research &amp; Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa4f74f53bb7d95f85e452140087cce0"><gtr:id>fa4f74f53bb7d95f85e452140087cce0</gtr:id><gtr:otherNames>Sharma P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>doi_53d084084fc25102</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DAA3961-45D5-4F45-A84F-1BE37E24A9B3</gtr:id><gtr:title>Chemical and Topographical Effects on Cell Differentiation and Matrix Elasticity in a Corneal Stromal Layer Model</gtr:title><gtr:parentPublicationTitle>Advanced Functional Materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fa67ef462f1c2f32c599b852900c665"><gtr:id>7fa67ef462f1c2f32c599b852900c665</gtr:id><gtr:otherNames>Wilson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>doi_53cfbffbf84598af</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80BF13EA-7C5B-457B-A8AF-A1F0FF1AC425</gtr:id><gtr:title>Growth factors and tendon healing.</gtr:title><gtr:parentPublicationTitle>Medicine and sport science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5d524fdf1ebf1a9d195b758c13510a2"><gtr:id>a5d524fdf1ebf1a9d195b758c13510a2</gtr:id><gtr:otherNames>Oliva F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0076-6070</gtr:issn><gtr:outcomeId>pm_53cc03cc03c0f34ca</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9429EC18-4545-42E5-8440-AD12225BB617</gtr:id><gtr:title>Sustained PDGF-BB release from PHBHHx loaded nanoparticles in 3D hydrogel/stem cell model.</gtr:title><gtr:parentPublicationTitle>Journal of biomedical materials research. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/683b1ce92405c524ac4c9d9e03be1173"><gtr:id>683b1ce92405c524ac4c9d9e03be1173</gtr:id><gtr:otherNames>Dong CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1549-3296</gtr:issn><gtr:outcomeId>5671769d166f89.15944744</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10DF8157-BFDC-4C7F-9F25-A92A481A6CFC</gtr:id><gtr:title>WP003/ECP039/0313: Manufacturing models permitting roll-out/scale out of clinically-led autologous cell therapies: Regulatory and scientific challenges for Comparability</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdc90a29f8082453d2ba0489c2a548d4"><gtr:id>cdc90a29f8082453d2ba0489c2a548d4</gtr:id><gtr:otherNames>Pauline Rea-Dickins (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>r_430522727164119fb4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DD7C039-0D6C-4F00-B8EB-201C85DCD0CE</gtr:id><gtr:title>Intra-articular injection of mesenchymal stem cells leads to reduced inflammation and cartilage damage in murine antigen-induced arthritis.</gtr:title><gtr:parentPublicationTitle>Journal of translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64d7d53999bcd852c710b3091d573a0b"><gtr:id>64d7d53999bcd852c710b3091d573a0b</gtr:id><gtr:otherNames>Kehoe O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1479-5876</gtr:issn><gtr:outcomeId>5450f4ad6c1412.82673773</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7234EE9C-3CE4-4E7F-BF01-E58CCCBFB253</gtr:id><gtr:title>Responsive materials</gtr:title><gtr:parentPublicationTitle>MRS Bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24e1eaa1aecb09f8f9fb77833cb666e7"><gtr:id>24e1eaa1aecb09f8f9fb77833cb666e7</gtr:id><gtr:otherNames>Alexander C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>545785b33b3443.98776010</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44197EB4-E427-49D6-A878-5958978E21BA</gtr:id><gtr:title>Investigation of cell proliferation and alkaline phosphatase activity on powder and solid materials</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a65e84172e908a27fb544839e54ef80"><gtr:id>4a65e84172e908a27fb544839e54ef80</gtr:id><gtr:otherNames>Ian Wimpenny (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>r_854605551163de6a4a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C18E499E-1AF2-4F2B-A8C0-AC695C7217E1</gtr:id><gtr:title>Whole body tracking of superparamagnetic iron oxide nanoparticle-labelled cells--a rheumatoid arthritis mouse model.</gtr:title><gtr:parentPublicationTitle>Stem cell research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81508399548ebd0582dbdbc42d52f065"><gtr:id>81508399548ebd0582dbdbc42d52f065</gtr:id><gtr:otherNames>Markides H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1757-6512</gtr:issn><gtr:outcomeId>54577fa6b505a5.04132499</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DE0670E-13AC-4DC0-939D-4B8AF5D499ED</gtr:id><gtr:title>Pore geometry regulates early stage human bone marrow cell tissue formation and organisation.</gtr:title><gtr:parentPublicationTitle>Annals of biomedical engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf5414e02e21280d5983bd06583df980"><gtr:id>bf5414e02e21280d5983bd06583df980</gtr:id><gtr:otherNames>Knychala J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0090-6964</gtr:issn><gtr:outcomeId>58a5ab6dcbe9b1.07373783</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FBBA2BF-F9B0-41C6-A928-496770B9E29F</gtr:id><gtr:title>A quantitative approach for understanding small-scale human mesenchymal stem cell culture - implications for large-scale bioprocess development.</gtr:title><gtr:parentPublicationTitle>Biotechnology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ef9ca338c86bf075398ae34005a7645"><gtr:id>2ef9ca338c86bf075398ae34005a7645</gtr:id><gtr:otherNames>Rafiq QA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1860-6768</gtr:issn><gtr:outcomeId>5457810db0d522.76858746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3242022C-C1D0-4708-9D7E-2A405923A178</gtr:id><gtr:title>The use of bioreactors as in vitro models in pharmaceutical research.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6a536db9c741e027ee0098c7482e4b5"><gtr:id>f6a536db9c741e027ee0098c7482e4b5</gtr:id><gtr:otherNames>Ginai M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>54576f15b7df19.77505647</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8E263DC-9E14-41C3-84E9-C0A1400C099B</gtr:id><gtr:title>Vibrational spectroscopy in stem cell characterisation: is there a niche?</gtr:title><gtr:parentPublicationTitle>Trends in biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1114614a2e75fe4b4aa618948b954ec4"><gtr:id>1114614a2e75fe4b4aa618948b954ec4</gtr:id><gtr:otherNames>Sul?-Suso J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-7799</gtr:issn><gtr:outcomeId>5671769d3d1718.09822701</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFBE62B9-A4CD-4E36-A620-FCA59445BF64</gtr:id><gtr:title>From production to patient: challenges and approaches for delivering cell therapies</gtr:title><gtr:parentPublicationTitle>StemBook</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6131c8ddc3839090cbab70c77c6f2e8f"><gtr:id>6131c8ddc3839090cbab70c77c6f2e8f</gtr:id><gtr:otherNames>Coopman K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545768e02d4fe1.93237873</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91BCAEB9-89EB-4809-B5B9-0A2FE9AFD8B5</gtr:id><gtr:title>Hollow colloidosomes prepared using accelerated solvent evaporation.</gtr:title><gtr:parentPublicationTitle>Langmuir : the ACS journal of surfaces and colloids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7ece703f5be4052d3e27bc3cf5e7ca9"><gtr:id>f7ece703f5be4052d3e27bc3cf5e7ca9</gtr:id><gtr:otherNames>Shahidan NN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0743-7463</gtr:issn><gtr:outcomeId>545781d8a987a4.09652374</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7EE37FB-8907-42A4-BECD-A3D7F41438DD</gtr:id><gtr:title>Label free assessment of live cell quality with total internal reflection microscopy</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9287ff8dda6beade1a5eb3828b52a23"><gtr:id>a9287ff8dda6beade1a5eb3828b52a23</gtr:id><gtr:otherNames>Mather M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:isbn>978-1-4673-0452-8</gtr:isbn><gtr:outcomeId>doi_53d057057c200e9e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE5E5E44-59C3-41FB-B467-D0BB72D1BFA7</gtr:id><gtr:title>Supercritical CO2: A Clean and Low Temperature Approach to Blending PDLLA and PEG</gtr:title><gtr:parentPublicationTitle>Advanced Functional Materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d70dc7bb49a750d51b5f50e44caa910f"><gtr:id>d70dc7bb49a750d51b5f50e44caa910f</gtr:id><gtr:otherNames>Kelly C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>doi_53cfbffbf7fc246e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8526B502-932A-4768-B806-F5D91F5DDD27</gtr:id><gtr:title>Attitudes of the UK ear, nose and throat clinical community to the future potential use of stem cell therapies to treat deafness.</gtr:title><gtr:parentPublicationTitle>Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/813c906a7d9b235c781b7ad220fdbba9"><gtr:id>813c906a7d9b235c781b7ad220fdbba9</gtr:id><gtr:otherNames>Ali KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1746-0751</gtr:issn><gtr:outcomeId>54578308426eb3.00805097</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E4C154D-81E3-4882-BBB9-6EB54651FD58</gtr:id><gtr:title>Comparative biology of mammalian telomeres: hypotheses on ancestral states and the roles of telomeres in longevity determination.</gtr:title><gtr:parentPublicationTitle>Aging cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a88f4d5057f2e396dd37af1ab5975db"><gtr:id>1a88f4d5057f2e396dd37af1ab5975db</gtr:id><gtr:otherNames>Gomes NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1474-9718</gtr:issn><gtr:outcomeId>doi_53d068068bfc7d8e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5BCA9ED-CE3C-4988-A70E-70B771B73B6E</gtr:id><gtr:title>Investigation of cell proliferation and alkaline phosphatase activity on Hydroxyapatite/PEEK powders</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cce306c03de281b6f7b77398e1f9a4b"><gtr:id>7cce306c03de281b6f7b77398e1f9a4b</gtr:id><gtr:otherNames>Michael Rotherham (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>r_855962386363de691e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14D0B865-5CC2-4DA9-9A87-80B131956C56</gtr:id><gtr:title>Gelatin embedding for the preparation of thermoreversible or delicate scaffolds for histological analysis.</gtr:title><gtr:parentPublicationTitle>Biomedical materials (Bristol, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3051f822eb2d77c6cca4e9e926e092cb"><gtr:id>3051f822eb2d77c6cca4e9e926e092cb</gtr:id><gtr:otherNames>Hruschka V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1748-6041</gtr:issn><gtr:outcomeId>doi_53d04404488966ea</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F06A8ED-02A0-40D8-9906-CF11BCD64132</gtr:id><gtr:title>Tenogenic Differentiation of Human Embryonic Stem Cells.</gtr:title><gtr:parentPublicationTitle>Tissue engineering. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9c951d3d1ad4a004ddba29db6e53ba6"><gtr:id>e9c951d3d1ad4a004ddba29db6e53ba6</gtr:id><gtr:otherNames>Dale TP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1937-3341</gtr:issn><gtr:outcomeId>5a8311986be1b6.73054744</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>564976C4-EC2C-46EC-8724-0FF513DBACF6</gtr:id><gtr:title>Gene expression of single human mesenchymal stem cell in response to fluid shear.</gtr:title><gtr:parentPublicationTitle>Journal of tissue engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bde23452702f3d087e5f35cb87dd0e1"><gtr:id>1bde23452702f3d087e5f35cb87dd0e1</gtr:id><gtr:otherNames>Zhang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2041-7314</gtr:issn><gtr:outcomeId>doi_53d07a07a929d4a7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B256CF16-AB39-4871-B558-BCCC8D8570D4</gtr:id><gtr:title>The effect of physiologic oxygen levels on GABAergic neuronal differentiation from mouse embryonic stem cells</gtr:title><gtr:parentPublicationTitle>Stem cell Studies</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f57bbef6310ea0c574205ca98c4a2295"><gtr:id>f57bbef6310ea0c574205ca98c4a2295</gtr:id><gtr:otherNames>E Shin (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>r_9080690776035dd95a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1905D3F8-BD71-4233-8363-4F2C51D1C865</gtr:id><gtr:title>A 3D bioprinting exemplar of the consequences of the regulatory requirements on customized processes.</gtr:title><gtr:parentPublicationTitle>Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7c4f9681563a6bcf0127293184d4c3e"><gtr:id>f7c4f9681563a6bcf0127293184d4c3e</gtr:id><gtr:otherNames>Hourd P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1746-0751</gtr:issn><gtr:outcomeId>56d593a2b5dc76.25427539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>570CB9B1-DFDE-4529-AC6D-FD66348F74AF</gtr:id><gtr:title>Hydrogels derived from demineralized and decellularized bone extracellular matrix.</gtr:title><gtr:parentPublicationTitle>Acta biomaterialia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02ace3b9f98bfbeadfcb10420926714e"><gtr:id>02ace3b9f98bfbeadfcb10420926714e</gtr:id><gtr:otherNames>Sawkins MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1742-7061</gtr:issn><gtr:outcomeId>545781d884ab85.68271006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C555776E-32E1-4904-9456-E480C4885072</gtr:id><gtr:title>Fabrication and characterization of 3D complex hydroxyapatite scaffolds with hierarchical porosity of different features for optimal bioactive performance</gtr:title><gtr:parentPublicationTitle>Ceramics International</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbfbba64e0bed5a5bd0e165199be7334"><gtr:id>bbfbba64e0bed5a5bd0e165199be7334</gtr:id><gtr:otherNames>Chen Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58bd963cbd6ad3.15192390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAAA289D-07D6-4E65-B571-4104549754ED</gtr:id><gtr:title>Club cells inhibit alveolar epithelial wound repair via TRAIL-dependent apoptosis.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db49f699859ed4d605345f035519c99f"><gtr:id>db49f699859ed4d605345f035519c99f</gtr:id><gtr:otherNames>Akram KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>doi_53d07b07b2d40e56</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C261A679-23F2-4BCE-8B49-D59E68A9B406</gtr:id><gtr:title>The osteogenic response of mesenchymal stem cells to an injectable PLGA bone regeneration system.</gtr:title><gtr:parentPublicationTitle>Biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52251301a10c87dcdd8cca446f0c7189"><gtr:id>52251301a10c87dcdd8cca446f0c7189</gtr:id><gtr:otherNames>Curran JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0142-9612</gtr:issn><gtr:outcomeId>545103c99b78e3.68686499</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1DF4818-29E8-4E9A-8F54-538BAE47DDB3</gtr:id><gtr:title>Current understanding and challenges in bioprocessing of stem cell-based therapies for regenerative medicine.</gtr:title><gtr:parentPublicationTitle>British medical bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdef2f16fd50c3faa8211957474c733d"><gtr:id>cdef2f16fd50c3faa8211957474c733d</gtr:id><gtr:otherNames>Ratcliffe E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1420</gtr:issn><gtr:outcomeId>doi_53d046046260ed28</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B9A3491-994E-474E-B2F6-7543E8CB8A3D</gtr:id><gtr:title>Gelation of microsphere dispersions using a thermally-responsive graft polymer.</gtr:title><gtr:parentPublicationTitle>Journal of colloid and interface science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7ece703f5be4052d3e27bc3cf5e7ca9"><gtr:id>f7ece703f5be4052d3e27bc3cf5e7ca9</gtr:id><gtr:otherNames>Shahidan NN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9797</gtr:issn><gtr:outcomeId>doi_53cff8ff8e9a1f69</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37A32C99-6052-46AA-993A-CFFDB2264A68</gtr:id><gtr:title>Application of response surface methodology to maximize the productivity of scalable automated human embryonic stem cell manufacture.</gtr:title><gtr:parentPublicationTitle>Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdef2f16fd50c3faa8211957474c733d"><gtr:id>cdef2f16fd50c3faa8211957474c733d</gtr:id><gtr:otherNames>Ratcliffe E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1746-0751</gtr:issn><gtr:outcomeId>doi_53d08508527098eb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A603D1D-6762-4C8C-A948-9FA03464285E</gtr:id><gtr:title>Methionine sulfoxide reductase A as a marker for isolating subpopulations of stem and progenitor cells used in regenerative medicine.</gtr:title><gtr:parentPublicationTitle>Medical hypotheses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb214bc4b33611401131be1feceb9998"><gtr:id>bb214bc4b33611401131be1feceb9998</gtr:id><gtr:otherNames>Hu B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0306-9877</gtr:issn><gtr:outcomeId>54577f0f7a0d23.73459387</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22440254-F40C-4E1E-82F0-1620775D357E</gtr:id><gtr:title>Translating cell-based regenerative medicines from research to successful products: challenges and solutions.</gtr:title><gtr:parentPublicationTitle>Tissue engineering. Part B, Reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4aad245a752494faf4852585e04783f5"><gtr:id>4aad245a752494faf4852585e04783f5</gtr:id><gtr:otherNames>Bayon Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1937-3368</gtr:issn><gtr:outcomeId>5457681579e744.07869263</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8636478-B1FA-4656-B665-25427FCA8178</gtr:id><gtr:title>Visualizing medium and biodistribution in complex cell culture bioreactors using in vivo imaging.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdef2f16fd50c3faa8211957474c733d"><gtr:id>cdef2f16fd50c3faa8211957474c733d</gtr:id><gtr:otherNames>Ratcliffe E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>54576c8f439dd2.21715063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6790D13F-E130-47DF-B757-BAB2BB207430</gtr:id><gtr:title>Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability.</gtr:title><gtr:parentPublicationTitle>Cytotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7c4f9681563a6bcf0127293184d4c3e"><gtr:id>f7c4f9681563a6bcf0127293184d4c3e</gtr:id><gtr:otherNames>Hourd P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1465-3249</gtr:issn><gtr:outcomeId>54576a8a848103.04110247</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CCD0894-7F35-4D52-93A0-636973F44D7F</gtr:id><gtr:title>A potentially scalable method for the harvesting of hMSCs from microcarriers</gtr:title><gtr:parentPublicationTitle>Biochemical Engineering Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd1d26448de7ac90e59532cd8506f6cd"><gtr:id>dd1d26448de7ac90e59532cd8506f6cd</gtr:id><gtr:otherNames>Nienow A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54576c8ee9e678.38281380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3A248F9-8009-4CDD-BB24-8F536CE200BB</gtr:id><gtr:title>Large-scale expansion and exploitation of pluripotent stem cells for regenerative medicine purposes: beyond the T flask.</gtr:title><gtr:parentPublicationTitle>Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6725bce4f491d3366a09aef206fd1b8"><gtr:id>d6725bce4f491d3366a09aef206fd1b8</gtr:id><gtr:otherNames>Want AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1746-0751</gtr:issn><gtr:outcomeId>5457841f06f510.13562317</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>343673E5-6D01-45C4-B319-9DA428629289</gtr:id><gtr:title>Improving umbilical cord blood processing to increase total nucleated cell count yield and reduce cord input wastage by managing the consequences of input variation.</gtr:title><gtr:parentPublicationTitle>Cytotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/643e3c28f1e84844aad06f3aaaca89a9"><gtr:id>643e3c28f1e84844aad06f3aaaca89a9</gtr:id><gtr:otherNames>Naing MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1465-3249</gtr:issn><gtr:outcomeId>54524429cd7af5.58175894</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2678C880-2F01-460E-82CC-141DCCBDD7C2</gtr:id><gtr:title>Mesenchymal stem cell isolation from human umbilical cord tissue: understanding and minimizing variability in cell yield for process optimization.</gtr:title><gtr:parentPublicationTitle>Biopreservation and biobanking</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72296fb7bdc9997e707dad0321d7c775"><gtr:id>72296fb7bdc9997e707dad0321d7c775</gtr:id><gtr:otherNames>Iftimia-Mander A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1947-5543</gtr:issn><gtr:outcomeId>54577f0fce0b91.07318393</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C208324-E3A5-4A0E-9956-4BEF63B681BA</gtr:id><gtr:title>Dynamic 3D culture: models of chondrogenesis and endochondral ossification.</gtr:title><gtr:parentPublicationTitle>Birth defects research. Part C, Embryo today : reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/791f8126da838abb19b756fbc3a8c9c8"><gtr:id>791f8126da838abb19b756fbc3a8c9c8</gtr:id><gtr:otherNames>Foster NC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1542-975X</gtr:issn><gtr:outcomeId>58bed9389e4084.73732414</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20071D1E-31D9-42EA-9A23-5A62BB4872D0</gtr:id><gtr:title>Counting cell number in situ by quantification of dimethyl sulphide in culture headspace.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/285b663e8ab9845a6c87aa3f92a83133"><gtr:id>285b663e8ab9845a6c87aa3f92a83133</gtr:id><gtr:otherNames>Chippendale TW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn><gtr:outcomeId>5450f554578847.37053994</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6443A0BD-F0F6-4FFF-A827-744097FA097E</gtr:id><gtr:title>Comparison of osteogenic differentiation of embryonic stem cells and primary osteoblasts revealed by responses to IL-1?, TNF-a, and IFN-?.</gtr:title><gtr:parentPublicationTitle>Stem cells and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/128c57db0f0beabbad1b45ae67cfd5b2"><gtr:id>128c57db0f0beabbad1b45ae67cfd5b2</gtr:id><gtr:otherNames>Sidney LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1547-3287</gtr:issn><gtr:outcomeId>54576d6ed3e1b1.95529275</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>812A2211-D16F-491C-9B54-335CC777603C</gtr:id><gtr:title>Investigation of cell proliferation and alkaline phosphatase activity on Glass beads</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cce306c03de281b6f7b77398e1f9a4b"><gtr:id>7cce306c03de281b6f7b77398e1f9a4b</gtr:id><gtr:otherNames>Michael Rotherham (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>r_808402141963de67ca</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06A27748-D26E-4E9A-A5C9-C34AC141BFF7</gtr:id><gtr:title>Corneal stromal cell plasticity: in vitro regulation of cell phenotype through cell-cell interactions in a three-dimensional model.</gtr:title><gtr:parentPublicationTitle>Tissue engineering. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ea8c72639436b3b4cb51f7d009086b3"><gtr:id>5ea8c72639436b3b4cb51f7d009086b3</gtr:id><gtr:otherNames>Wilson SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1937-3341</gtr:issn><gtr:outcomeId>5457826829c8b7.36649233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AA774D1-CCFD-4A05-817F-6F48DC1D4035</gtr:id><gtr:title>Thermoresponsive magnetic colloidal gels via surface-initiated polymerisation from functional microparticles</gtr:title><gtr:parentPublicationTitle>Journal of Materials Chemistry B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/551e624efffe9aab90a3a754ef3d9cf1"><gtr:id>551e624efffe9aab90a3a754ef3d9cf1</gtr:id><gtr:otherNames>Braim S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>585d7cc7511b10.88808288</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0861F2A-36D0-4231-BEFD-34665D95C38B</gtr:id><gtr:title>A complete system for producing autologous cells for use in regenerative medicine</gtr:title><gtr:parentPublicationTitle>Innovation in Healthcare</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37a88721afa1729bd9b45069f7bd9927"><gtr:id>37a88721afa1729bd9b45069f7bd9927</gtr:id><gtr:otherNames>Williams, DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>545787d98e1057.14278701</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF7B5146-5BDC-48C5-9AC1-B7BF14A30B81</gtr:id><gtr:title>Development of a porous poly(DL-lactic acid-co-glycolic acid)-based scaffold for mastoid air-cell regeneration.</gtr:title><gtr:parentPublicationTitle>The Laryngoscope</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e909749e8ea586ccc209315a28827a7"><gtr:id>9e909749e8ea586ccc209315a28827a7</gtr:id><gtr:otherNames>Gould TW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0023-852X</gtr:issn><gtr:outcomeId>5451037c979e55.48937872</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>094F1D9D-4505-461C-8821-11AEE1376113</gtr:id><gtr:title>The Effect of a Type I Photoinitiator on Cure Kinetics and Cell Toxicity in Projection-Microstereolithography</gtr:title><gtr:parentPublicationTitle>Procedia CIRP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f44f9d0aa9a504bafbb1b37056046b30"><gtr:id>f44f9d0aa9a504bafbb1b37056046b30</gtr:id><gtr:otherNames>Bail R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>56d59247ddaf03.39912830</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D20E31F9-D814-4BE3-91CA-392CF18F2001</gtr:id><gtr:title>The interplay between tissue growth and scaffold degradation in engineered tissue constructs.</gtr:title><gtr:parentPublicationTitle>Journal of mathematical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94c479927bba167c11651e10dfabe45c"><gtr:id>94c479927bba167c11651e10dfabe45c</gtr:id><gtr:otherNames>O'Dea RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0303-6812</gtr:issn><gtr:outcomeId>54578035bf4191.90806365</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6526BDF6-113D-4400-97F2-CA2F807EBDC8</gtr:id><gtr:title>Materials for stem cell factories of the future.</gtr:title><gtr:parentPublicationTitle>Nature materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71778760bcfbaedc02a6e2939f7135ca"><gtr:id>71778760bcfbaedc02a6e2939f7135ca</gtr:id><gtr:otherNames>Celiz AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1476-1122</gtr:issn><gtr:outcomeId>545768dfd63544.33459874</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13FD22A5-F0F3-4E2B-BF2D-11E87E61978F</gtr:id><gtr:title>Overcoming manufacturing and scale-up challenges.</gtr:title><gtr:parentPublicationTitle>Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82c371c9fb92bf839b51d71308f14bfe"><gtr:id>82c371c9fb92bf839b51d71308f14bfe</gtr:id><gtr:otherNames>Williams DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1746-0751</gtr:issn><gtr:outcomeId>doi_53d08508525ed87a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDF7DB18-31CA-49D7-90D5-93866C59BAD9</gtr:id><gtr:title>Three-dimensional hypoxic culture of human mesenchymal stem cells encapsulated in a photocurable, biodegradable polymer hydrogel: a potential injectable cellular product for nucleus pulposus regeneration.</gtr:title><gtr:parentPublicationTitle>Acta biomaterialia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a011372df831db18e844680c3913e8fd"><gtr:id>a011372df831db18e844680c3913e8fd</gtr:id><gtr:otherNames>Kumar D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-7061</gtr:issn><gtr:outcomeId>5671769d68b9a1.45419277</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7313D294-0A94-49A6-8F8E-B639AA63636F</gtr:id><gtr:title>Scale-down studies for assessing the impact of different stress parameters on growth and product quality during animal cell culture</gtr:title><gtr:parentPublicationTitle>Chemical Engineering Research and Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd1d26448de7ac90e59532cd8506f6cd"><gtr:id>dd1d26448de7ac90e59532cd8506f6cd</gtr:id><gtr:otherNames>Nienow A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>545780359a1365.66293619</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9BDE63D-6D57-4306-802D-A01D3AB52CA4</gtr:id><gtr:title>The implementation of novel collaborative structures for the identification and resolution of barriers to pluripotent stem cell translation.</gtr:title><gtr:parentPublicationTitle>Stem cells and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/663614ea4ef8d88d1621a26470ecb340"><gtr:id>663614ea4ef8d88d1621a26470ecb340</gtr:id><gtr:otherNames>Brindley DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1547-3287</gtr:issn><gtr:outcomeId>54576e5d410c75.12784378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8A2EF76-9B24-4A88-9509-AE5D1BAEDD6E</gtr:id><gtr:title>Thermally triggered assembly of cationic graft copolymers containing 2-(2-methoxyethoxy)ethyl methacrylate side chains.</gtr:title><gtr:parentPublicationTitle>Langmuir : the ACS journal of surfaces and colloids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7ece703f5be4052d3e27bc3cf5e7ca9"><gtr:id>f7ece703f5be4052d3e27bc3cf5e7ca9</gtr:id><gtr:otherNames>Shahidan NN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0743-7463</gtr:issn><gtr:outcomeId>5457852af13586.54572604</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3F27589-0043-43CC-ABE5-0CA737E3CF3A</gtr:id><gtr:title>Interconnectivity analysis of supercritical CO2-foamed scaffolds.</gtr:title><gtr:parentPublicationTitle>Computer methods and programs in biomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ebce92f9568bd5026977a0e4e94b42a"><gtr:id>0ebce92f9568bd5026977a0e4e94b42a</gtr:id><gtr:otherNames>Lemon G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0169-2607</gtr:issn><gtr:outcomeId>doi_53cfe9fe991eada6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67D0BEBC-3CB4-4EC2-9121-1074AC722FE8</gtr:id><gtr:title>Investigating the feasibility of scale up and automation of human induced pluripotent stem cells cultured in aggregates in feeder free conditions.</gtr:title><gtr:parentPublicationTitle>Journal of biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e2e5d805263a390d924ccc3b6b5ebf9"><gtr:id>7e2e5d805263a390d924ccc3b6b5ebf9</gtr:id><gtr:otherNames>Soares FA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-1656</gtr:issn><gtr:outcomeId>54576d6f0531d7.56246009</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9307FA3-EF28-4C84-82EF-E525AD2BF944</gtr:id><gtr:title>Engineering an in-vitro model of rodent cartilage.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8527de9dedc85516490f787397461bc9"><gtr:id>8527de9dedc85516490f787397461bc9</gtr:id><gtr:otherNames>Rogers CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3573</gtr:issn><gtr:outcomeId>doi_53d06b06be0be64b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B2ED40D-6691-4537-B359-CD3D1CD198E6</gtr:id><gtr:title>Cyclic hydrostatic pressure stimulates enhanced bone development in the foetal chick femur in vitro.</gtr:title><gtr:parentPublicationTitle>Bone</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70e576116ff8c82072eff475ad8f0b8f"><gtr:id>70e576116ff8c82072eff475ad8f0b8f</gtr:id><gtr:otherNames>Henstock JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1873-2763</gtr:issn><gtr:outcomeId>54576f162abba3.03089101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>890D980C-8F19-4D9C-BF85-8973B6D19031</gtr:id><gtr:title>Enzyme-passage free culture of mouse embryonic stem cells on thermo-responsive polymer surfaces</gtr:title><gtr:parentPublicationTitle>Journal of Materials Chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f58a0cce691e4531a34444aa77fa1355"><gtr:id>f58a0cce691e4531a34444aa77fa1355</gtr:id><gtr:otherNames>Dey S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>doi_53d02d02d60f2bce</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>638843C0-9C53-4B25-82FC-333F8A53B800</gtr:id><gtr:title>Changes in the stiffness of human mesenchymal stem cells with the progress of cell death as measured by atomic force microscopy.</gtr:title><gtr:parentPublicationTitle>Journal of biomechanics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06cda75f04ab4970969cf6e4ff26bf3f"><gtr:id>06cda75f04ab4970969cf6e4ff26bf3f</gtr:id><gtr:otherNames>Nikolaev NI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9290</gtr:issn><gtr:outcomeId>54576c8f200b91.13977017</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDB34A8C-E069-45A5-8D78-3DE097052CB8</gtr:id><gtr:title>Amphipathic polymer-mediated uptake of trehalose for dimethyl sulfoxide-free human cell cryopreservation.</gtr:title><gtr:parentPublicationTitle>Cryobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/258d2368f0a63e438b4e5aeb125787b6"><gtr:id>258d2368f0a63e438b4e5aeb125787b6</gtr:id><gtr:otherNames>Sharp DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0011-2240</gtr:issn><gtr:outcomeId>545781d8d18d76.08020837</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>226C3B42-F9A7-4E73-83D4-F128F77596E6</gtr:id><gtr:title>Online monitoring of mechanical properties of three-dimensional tissue engineered constructs for quality assessment</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d9a22632142d680922f196083537899"><gtr:id>7d9a22632142d680922f196083537899</gtr:id><gtr:otherNames>Reinwald, Y</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>56dd7ec3b379f2.22068038</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5034A859-4439-48F3-8480-837B455F319A</gtr:id><gtr:title>Programmable polymer-DNA hydrogels with dual input and multiscale responses</gtr:title><gtr:parentPublicationTitle>Biomater. Sci.</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b947d5820c85c200f7e5f93ad360c4a"><gtr:id>9b947d5820c85c200f7e5f93ad360c4a</gtr:id><gtr:otherNames>Sicilia G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54576d6eabab34.69594530</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5497AD5A-90C3-4658-874E-19206C79ACD3</gtr:id><gtr:title>Interconnectivity and permeability of supercritical fluid-foamed scaffolds and the effect of their structural properties on cell distribution</gtr:title><gtr:parentPublicationTitle>Polymer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19426bea88f4b86031a639fbe77e2e68"><gtr:id>19426bea88f4b86031a639fbe77e2e68</gtr:id><gtr:otherNames>Reinwald Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54510148027c49.11557951</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F13152D-862C-412A-8CF5-79EA4B23D529</gtr:id><gtr:title>A quality-by-design approach to risk reduction and optimization for human embryonic stem cell cryopreservation processes.</gtr:title><gtr:parentPublicationTitle>Tissue engineering. Part C, Methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1011123e536a5160cb9e1922b75c421b"><gtr:id>1011123e536a5160cb9e1922b75c421b</gtr:id><gtr:otherNames>Mitchell PD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1937-3384</gtr:issn><gtr:outcomeId>54576beb959537.91984708</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD5DDD67-C358-4B3D-8BD4-EE616DF18DFB</gtr:id><gtr:title>Fluorescent labeling of chitosan for use in non-invasive monitoring of degradation in tissue engineering.</gtr:title><gtr:parentPublicationTitle>Journal of tissue engineering and regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae8e1a9e077c5e799412810e5004e7a0"><gtr:id>ae8e1a9e077c5e799412810e5004e7a0</gtr:id><gtr:otherNames>Cunha-Reis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6254</gtr:issn><gtr:outcomeId>54576e5d972692.75200781</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADE31421-3058-4EED-AAEE-969F311F4064</gtr:id><gtr:title>aV ?5 and CD44 are oxygen-regulated human embryonic stem cell attachment factors.</gtr:title><gtr:parentPublicationTitle>BioMed research international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a011372df831db18e844680c3913e8fd"><gtr:id>a011372df831db18e844680c3913e8fd</gtr:id><gtr:otherNames>Kumar D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5671769cbd2e78.39992152</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51330555-AE40-4B32-9C6A-0284F85716E5</gtr:id><gtr:title>WP006/ECP050/0713: Current state of the art in mammalian synthetic biology applications and implications for ATMP bioprocessing</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4fed2517811ab5f37a9ed09f36e87fa8"><gtr:id>4fed2517811ab5f37a9ed09f36e87fa8</gtr:id><gtr:otherNames>John Mohan (Co-author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>r_80628340496410f492</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2570C5B-B927-45E1-A884-5E2E84FCFB70</gtr:id><gtr:title>Evaluation of the growth environment of a hydrostatic force bioreactor for preconditioning of tissue-engineered constructs.</gtr:title><gtr:parentPublicationTitle>Tissue engineering. Part C, Methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19426bea88f4b86031a639fbe77e2e68"><gtr:id>19426bea88f4b86031a639fbe77e2e68</gtr:id><gtr:otherNames>Reinwald Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1937-3384</gtr:issn><gtr:outcomeId>5450f5023e3263.59770360</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BCAE00C-AB84-4A58-8EEF-12A08D13DD1B</gtr:id><gtr:title>The effect of oxygen tension on human articular chondrocyte matrix synthesis: integration of experimental and computational approaches.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8a46f3752fd4026773cf1b531707cbf"><gtr:id>b8a46f3752fd4026773cf1b531707cbf</gtr:id><gtr:otherNames>Li S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>54c7a85fe8a302.87747067</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6821EC18-5CA9-49AC-9F5D-0B6080884C7A</gtr:id><gtr:title>Regenerative medicine, resource and regulation: lessons learned from the remedi project.</gtr:title><gtr:parentPublicationTitle>Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e07612494b74e9ec262bf0bb43b2aaf8"><gtr:id>e07612494b74e9ec262bf0bb43b2aaf8</gtr:id><gtr:otherNames>Ginty PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1746-0751</gtr:issn><gtr:outcomeId>doi_53d08508523a2830</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FB1BEA7-92E6-477F-91C9-DFCE4D422DEA</gtr:id><gtr:title>Post-processing of polymer foam tissue scaffolds with high power ultrasound: a route to increased pore interconnectivity, pore size and fluid transport.</gtr:title><gtr:parentPublicationTitle>Materials science &amp; engineering. C, Materials for biological applications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27938da68418517808e37a03b2b6b38e"><gtr:id>27938da68418517808e37a03b2b6b38e</gtr:id><gtr:otherNames>Watson NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0928-4931</gtr:issn><gtr:outcomeId>doi_53d001001ef27451</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5336AC03-F7E9-4602-AFF5-515DA85569A7</gtr:id><gtr:title>Culture of human mesenchymal stem cells on microcarriers in a 5 l stirred-tank bioreactor.</gtr:title><gtr:parentPublicationTitle>Biotechnology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ef9ca338c86bf075398ae34005a7645"><gtr:id>2ef9ca338c86bf075398ae34005a7645</gtr:id><gtr:otherNames>Rafiq QA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0141-5492</gtr:issn><gtr:outcomeId>5457810d646148.38140112</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>456DF3FA-8F59-4A61-AAE1-76817C3888FB</gtr:id><gtr:title>PAS 83:2012 Developing human cells for clinical applications in the European Union and the United States of America. Guide</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8871f8cde6a084dd73612e825196a22"><gtr:id>c8871f8cde6a084dd73612e825196a22</gtr:id><gtr:otherNames>Benjamin Bedwell (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>r_7086645081cac105fe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5313BFF9-B070-4367-AA6F-9E2B45258CB1</gtr:id><gtr:title>Monitoring Diameter and Roundness Errors in Projection-Microstereolithography of Biomedical Tooling and Scaffolds</gtr:title><gtr:parentPublicationTitle>Procedia CIRP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f44f9d0aa9a504bafbb1b37056046b30"><gtr:id>f44f9d0aa9a504bafbb1b37056046b30</gtr:id><gtr:otherNames>Bail R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>56d59276114cc1.89993383</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAF90BB2-D5BE-4B93-BB85-A1ECA2C7407F</gtr:id><gtr:title>Multiparameter flow cytometry for the characterization of human embryonic stem cells.</gtr:title><gtr:parentPublicationTitle>Biotechnology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78947591342defcc4fa1802e12d241d3"><gtr:id>78947591342defcc4fa1802e12d241d3</gtr:id><gtr:otherNames>Brosnan K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0141-5492</gtr:issn><gtr:outcomeId>54576e5d6eac43.80047078</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E34B9820-A2A8-43A4-907B-9265F11815BD</gtr:id><gtr:title>Poly (3-hydroxybutyrate-co-3-hydroxyhexanoate)/collagen hybrid scaffolds for tissue engineering applications.</gtr:title><gtr:parentPublicationTitle>Tissue engineering. Part C, Methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b9470cc0106c59220bf86058d32a7a3"><gtr:id>7b9470cc0106c59220bf86058d32a7a3</gtr:id><gtr:otherNames>Lomas AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1937-3384</gtr:issn><gtr:outcomeId>doi_53d045045540688f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07D3674C-652E-4C91-BE5E-02D1D85A0214</gtr:id><gtr:title>Current status and perspectives on stem cell-based therapies undergoing clinical trials for regenerative medicine: case studies.</gtr:title><gtr:parentPublicationTitle>British medical bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdef2f16fd50c3faa8211957474c733d"><gtr:id>cdef2f16fd50c3faa8211957474c733d</gtr:id><gtr:otherNames>Ratcliffe E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1420</gtr:issn><gtr:outcomeId>5457810de5bb07.20225431</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9472D3B8-1C7B-4DED-BCE2-10C7635B03FE</gtr:id><gtr:title>Biocompatibility and enhanced osteogenic differentiation of human mesenchymal stem cells in response to surface engineered poly(D,L-lactic-co-glycolic acid) microparticles.</gtr:title><gtr:parentPublicationTitle>Journal of biomedical materials research. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8527de9dedc85516490f787397461bc9"><gtr:id>8527de9dedc85516490f787397461bc9</gtr:id><gtr:otherNames>Rogers CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1549-3296</gtr:issn><gtr:outcomeId>5450f58d2c9315.60858330</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFCD4591-521D-4D87-82B0-9C26D44711A2</gtr:id><gtr:title>Characterisation of the surface structure of 3D printed scaffolds for cell infiltration and surgical suturing.</gtr:title><gtr:parentPublicationTitle>Biofabrication</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82ff84e0466e79f6ba1f4176b9707278"><gtr:id>82ff84e0466e79f6ba1f4176b9707278</gtr:id><gtr:otherNames>Ruiz-Cantu L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1758-5082</gtr:issn><gtr:outcomeId>56deace245a5a8.05571930</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49D9039B-5ADC-4C63-9118-674686996D37</gtr:id><gtr:title>Porous Copolymers of e-Caprolactone as Scaffolds for Tissue Engineering</gtr:title><gtr:parentPublicationTitle>Macromolecules</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11d693375489efc7957bcdc508f2f0d7"><gtr:id>11d693375489efc7957bcdc508f2f0d7</gtr:id><gtr:otherNames>Tang M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>545781d9048dd8.04630613</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10606AF3-6C57-44B8-BFC5-7EED37292D72</gtr:id><gtr:title>Characterisation of mesenchymal stem cell populations used for treatment of rheumatoid arthritis in a murine antigen-induced model</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b6f347545562d5149e5e7773638fcf5"><gtr:id>0b6f347545562d5149e5e7773638fcf5</gtr:id><gtr:otherNames>Oksana Kehoe (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>m_167100684613f4dfb8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A00C8721-CE90-4534-9150-E2145F9234B5</gtr:id><gtr:title>The physical characterisation of a microscale parallel bioreactor platform with an industrial CHO cell line expressing an IgG4</gtr:title><gtr:parentPublicationTitle>Biochemical Engineering Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd1d26448de7ac90e59532cd8506f6cd"><gtr:id>dd1d26448de7ac90e59532cd8506f6cd</gtr:id><gtr:otherNames>Nienow A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>54578035708ec7.06294569</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FC45CC0-78C7-409E-9111-26314CA61094</gtr:id><gtr:title>Gelatin-Based Materials in Ocular Tissue Engineering.</gtr:title><gtr:parentPublicationTitle>Materials (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e4ca3972bc06973dfcbe8c0e9c8bc20"><gtr:id>5e4ca3972bc06973dfcbe8c0e9c8bc20</gtr:id><gtr:otherNames>Rose JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1996-1944</gtr:issn><gtr:outcomeId>54576d6e842544.73449667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1424DFBA-C66D-46F1-BE53-E852C05D4A32</gtr:id><gtr:title>Induced Pluripotent Stem Cells: production and utility in Regenerative Medicine and other applications</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc60eecd401574cf2c7bdcdb3836a6e8"><gtr:id>dc60eecd401574cf2c7bdcdb3836a6e8</gtr:id><gtr:otherNames>Elizabeth Ratcliffe (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>r_102950843763e0220e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70757F84-E08D-47B4-B2E3-2AC5D1794536</gtr:id><gtr:title>Production of erythrocytes from directly isolated or Delta1 Notch ligand expanded CD34+ hematopoietic progenitor cells: process characterization, monitoring and implications for manufacture.</gtr:title><gtr:parentPublicationTitle>Cytotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0616acc97bb1799fd7408e4a49204e6d"><gtr:id>0616acc97bb1799fd7408e4a49204e6d</gtr:id><gtr:otherNames>Glen KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1465-3249</gtr:issn><gtr:outcomeId>54576f15e016a3.58073757</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD8A70C9-A735-4E00-A245-3459AB54DF22</gtr:id><gtr:title>Identification of different subsets of lung cells using Raman microspectroscopy and whole cell nucleus isolation.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e65de04258a560198a9cd0e27d50aeda"><gtr:id>e65de04258a560198a9cd0e27d50aeda</gtr:id><gtr:otherNames>Pijanka JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn><gtr:outcomeId>doi_53d030030057dd54</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0E82644-F384-48B4-84C3-B4FC42AEBA01</gtr:id><gtr:title>Developing Cell Therapies: Enabling cost prediction by value systems modeling to manage developmental risk.</gtr:title><gtr:parentPublicationTitle>Journal of Commercial Biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1d9adbc885935fa31deb885e890612d"><gtr:id>b1d9adbc885935fa31deb885e890612d</gtr:id><gtr:otherNames>McCall M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>54577fa6dcc883.59281290</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60E557D3-1A38-4B54-94B7-330EC8941EE5</gtr:id><gtr:title>Comprehensive Biotechnology: Volume 5 Medical Biotechnology and Healthcare</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd579c58bf41ce529131bd5e630e79dd"><gtr:id>dd579c58bf41ce529131bd5e630e79dd</gtr:id><gtr:otherNames>Chippendale, TWE; Coopman, K; Rafiq, Q; El Haj, AJ; Hewitt, CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:isbn>9780444533524</gtr:isbn><gtr:outcomeId>54578f009d3ae8.92501720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CBA2991-0B8B-4750-ACB5-A4F39B5E5B28</gtr:id><gtr:title>Idiopathic pulmonary fibrosis: immunohistochemical analysis provides fresh insights into lung tissue remodelling with implications for novel prognostic markers.</gtr:title><gtr:parentPublicationTitle>International journal of clinical and experimental pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7813f08db76b6ee48df5de62373f79cf"><gtr:id>7813f08db76b6ee48df5de62373f79cf</gtr:id><gtr:otherNames>Lomas NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1936-2625</gtr:issn><gtr:outcomeId>54635088512ab5.95284451</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40336D5B-2BC3-4643-B285-6842311F80F4</gtr:id><gtr:title>The UK relative to other single payer-dominated healthcare markets for regenerative medicine therapies.</gtr:title><gtr:parentPublicationTitle>Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e4ca3972bc06973dfcbe8c0e9c8bc20"><gtr:id>5e4ca3972bc06973dfcbe8c0e9c8bc20</gtr:id><gtr:otherNames>Rose JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1746-0751</gtr:issn><gtr:outcomeId>doi_53d085085244c628</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>592B2D31-2A23-47CB-9231-3E0B05BC25E7</gtr:id><gtr:title>Immortalisation with hTERT Impacts on Sulphated Glycosaminoglycan Secretion and Immunophenotype in a Variable and Cell Specific Manner.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9c951d3d1ad4a004ddba29db6e53ba6"><gtr:id>e9c951d3d1ad4a004ddba29db6e53ba6</gtr:id><gtr:otherNames>Dale TP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5671769e467d10.36287522</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2730A6CB-0BB2-4FFC-9C25-6C2712E4548C</gtr:id><gtr:title>Design and Validation of a Physiologically-Adapted Bioreactor for Tissue Engineering of the Nucleus Pulposus</gtr:title><gtr:parentPublicationTitle>Processes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/060a6d8109a0cbef5715f4598a0855d0"><gtr:id>060a6d8109a0cbef5715f4598a0855d0</gtr:id><gtr:otherNames>Naing M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>54577fa710d130.27350986</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6B2C91F-94FF-41F0-BBF1-B4A56329069E</gtr:id><gtr:title>Chemically diverse polymer microarrays and high throughput surface characterisation: a method for discovery of materials for stem cell culture&amp;acirc;?&amp;nbsp;Electronic supplementary information (ESI) available. See DOI: 10.1039/c4bm00054dClick here for additional data file.</gtr:title><gtr:parentPublicationTitle>Biomaterials science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71778760bcfbaedc02a6e2939f7135ca"><gtr:id>71778760bcfbaedc02a6e2939f7135ca</gtr:id><gtr:otherNames>Celiz AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2047-4830</gtr:issn><gtr:outcomeId>542d7006aea590.17362410</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9A0E37F-55C8-4C63-B47D-E04D06CCA151</gtr:id><gtr:title>Is Chemokine Receptor CCR9 Required for Synovitis in Rheumatoid Arthritis? Deficiency of CCR9 in a Murine Model of Antigen-Induced Arthritis</gtr:title><gtr:parentPublicationTitle>Open Journal of Rheumatology and Autoimmune Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16c7e35dfc7d5c2123bf94d0f51255be"><gtr:id>16c7e35dfc7d5c2123bf94d0f51255be</gtr:id><gtr:otherNames>Cartwright A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>doi_53d089089801530e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B7CEFC1-10E6-428D-A579-19752CDD384B</gtr:id><gtr:title>Expansion of human mesenchymal stem cells on microcarriers.</gtr:title><gtr:parentPublicationTitle>Biotechnology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05e5864130b563782a8b36b264dc4c5f"><gtr:id>05e5864130b563782a8b36b264dc4c5f</gtr:id><gtr:otherNames>Hewitt CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0141-5492</gtr:issn><gtr:outcomeId>545784afb0cf12.60323081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A75D716-4692-40BE-81A1-BA25570418A0</gtr:id><gtr:title>Precision manufacturing for clinical-quality regenerative medicines.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions. Series A, Mathematical, physical, and engineering sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82c371c9fb92bf839b51d71308f14bfe"><gtr:id>82c371c9fb92bf839b51d71308f14bfe</gtr:id><gtr:otherNames>Williams DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1364-503X</gtr:issn><gtr:outcomeId>doi_53d04b04b2c40ef6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA9CB589-6A96-493F-A631-3F0B0987874A</gtr:id><gtr:title>Mesenchymal stem cells promote alveolar epithelial cell wound repair in vitro through distinct migratory and paracrine mechanisms.</gtr:title><gtr:parentPublicationTitle>Respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db49f699859ed4d605345f035519c99f"><gtr:id>db49f699859ed4d605345f035519c99f</gtr:id><gtr:otherNames>Akram KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1465-9921</gtr:issn><gtr:outcomeId>doi_53d07b07b2e3265a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>487FBCA3-7729-4798-9E1C-9F2F4E2316CD</gtr:id><gtr:title>Chemistry of Polymer and Ceramic-Based Injectable Scaffolds and Their Applications in Regenerative Medicine</gtr:title><gtr:parentPublicationTitle>Chemistry of Materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d95ada89ffab5c902d7d87f68bb786f"><gtr:id>0d95ada89ffab5c902d7d87f68bb786f</gtr:id><gtr:otherNames>Rahman C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>doi_53d014014eb0abd2</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/H028277/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>5E9AA4EC-49E3-4D6A-B545-79DA07CE39E0</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Management &amp; Business Studies</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>FA25733D-A456-4A1B-9D5C-7119577368D9</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Manufacturing</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>2E2E80C2-8D14-44CE-A971-37A9ACC4B244</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Manufact. Enterprise Ops&amp; Mgmt</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>ABBD3B7F-5022-4513-82D6-5414B965FAB3</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Manufacturing Machine &amp; Plant</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>195B48B4-2BC5-4DEB-BA1A-323A90D8730D</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Tissue engineering</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>